{
    "questions": [
        {
            "id": "5a75eb6483b0d9ea66000004",
            "body": "What is Blount's disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19370370",
                "http://www.ncbi.nlm.nih.gov/pubmed/12077670",
                "http://www.ncbi.nlm.nih.gov/pubmed/15481748",
                "http://www.ncbi.nlm.nih.gov/pubmed/8657465",
                "http://www.ncbi.nlm.nih.gov/pubmed/27583129",
                "http://www.ncbi.nlm.nih.gov/pubmed/25932193",
                "http://www.ncbi.nlm.nih.gov/pubmed/7670990",
                "http://www.ncbi.nlm.nih.gov/pubmed/20609637",
                "http://www.ncbi.nlm.nih.gov/pubmed/880738",
                "http://www.ncbi.nlm.nih.gov/pubmed/9702674"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19370370",
                    "text": "BACKGROUND Blount's disease is a multi-planar deformity affecting the pediatric population which leads to varus alignment of the lower extremities.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 147,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12077670",
                    "text": "This report is the first known case of SCFE associated with infantile Blount's disease.",
                    "offsetInBeginSection": 328,
                    "offsetInEndSection": 415,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15481748",
                    "text": "Blount's disease or congenital tibia vara is a clinical entity characterized by tibia bowing, tibia torsion, and beaking of the medial tibia metaphysis on plain radiograph.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 172,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8657465",
                    "text": "In view of the spontaneous recovery of all investigated patients, it must be doubted whether a diagnosis of infantile tibia vara can be made in early infancy, and whether infantile Blount's disease is a diagnosis in its own right.",
                    "offsetInBeginSection": 672,
                    "offsetInEndSection": 902,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27583129",
                    "text": "Blount's disease is a progressive form of genu varum due to asymmetrical inhibition of the postero medial portion of the proximal tibial epiphysis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 147,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25932193",
                    "text": "Blount's disease is an uncommon disorder of postero-medial proximal tibial physis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 82,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7670990",
                    "text": "We postulate the hypothesis of the etiopathogenesis of the infantile type of Blount's disease as a disease related to a dysplastic linkage between epiphysis and metaphysis.",
                    "offsetInBeginSection": 95,
                    "offsetInEndSection": 267,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20609637",
                    "text": "INTRODUCTION In stage\u00a01 of all currently accepted classifications for infantile tibia vara, the diagnosis is difficult between physiological bowing and true Blount's disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/880738",
                    "text": "A family is described with infantile Blount's disease (tibia vara) following an autosomal dominant mode of inheritance.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/880738",
                    "text": "It is speculated that infantile Blount's disease may be inherited as an autosomal dominant condition with variable penetrance, and that genetic factors have been noted only infrequently, as parents may have improved with age or have been affected only mildly.",
                    "offsetInBeginSection": 267,
                    "offsetInEndSection": 526,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6a2dcab750ff4455000023",
            "body": "Which are the constitutive parts of a Genomic Regulatory Block (GRB)?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17387144",
                "http://www.ncbi.nlm.nih.gov/pubmed/19374772",
                "http://www.ncbi.nlm.nih.gov/pubmed/22962458",
                "http://www.ncbi.nlm.nih.gov/pubmed/22666536",
                "http://www.ncbi.nlm.nih.gov/pubmed/21619633",
                "http://www.ncbi.nlm.nih.gov/pubmed/17989259",
                "http://www.ncbi.nlm.nih.gov/pubmed/22234889",
                "http://www.ncbi.nlm.nih.gov/pubmed/18047696",
                "http://www.ncbi.nlm.nih.gov/pubmed/16675487",
                "http://www.ncbi.nlm.nih.gov/pubmed/19969543"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17387144",
                    "text": "We termed these chromosomal segments genomic regulatory blocks (GRBs).",
                    "offsetInBeginSection": 916,
                    "offsetInEndSection": 986,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19374772",
                    "text": "BACKGROUND Genomic regulatory blocks (GRBs) are chromosomal regions spanned by highly conserved non-coding elements (HCNEs), most of which serve as regulatory inputs of one target gene in the region.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 199,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22666536",
                    "text": "The Sonic Hedgehog (Shh) genomic regulatory block (GRB) is one of the best functionally characterized examples, with several discrete enhancers reported within its introns, vast upstream gene-free region and neighboring genes (Lmbr1 and Rnf32).",
                    "offsetInBeginSection": 192,
                    "offsetInEndSection": 436,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21619633",
                    "text": "They are therefore functionally related to a number of key protein coding developmental genes, that form genomic regulatory blocks (GRBs) with arrays of highly conserved non-coding elements (HCNEs) functioning as long-range enhancers that collaboratively regulate the expression of their target genes.",
                    "offsetInBeginSection": 256,
                    "offsetInEndSection": 557,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21619633",
                    "text": "Furthermore these predictions include miRNAs of the miR-9 family, which are the only experimentally verified GRB target miRNAs.",
                    "offsetInBeginSection": 1937,
                    "offsetInEndSection": 2064,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17989259",
                    "text": "These arrays span key developmental regulatory genes, forming genomic regulatory blocks (GRBs).",
                    "offsetInBeginSection": 286,
                    "offsetInEndSection": 381,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22234889",
                    "text": "Developmental genes are regulated by complex, distantly located cis-regulatory modules (CRMs), often forming genomic regulatory blocks (GRBs) that are conserved among vertebrates and among insects.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 197,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16675487",
                    "text": "Proteomics and immunoadsorption studies identified the suppressive proteins secreted by clone MT-5B as granzyme B (GrB) and perforin (PFN).",
                    "offsetInBeginSection": 510,
                    "offsetInEndSection": 649,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16675487",
                    "text": "Removal of GrB or PFN from the culture supernatant (SN) of MT-5B cells or pre-incubation of MT-5B cells with ethyleneglycol-bis(aminoethylether)-tetraacetic acid which blocks PFN activity reduced the immunosuppressive effect in vitro.",
                    "offsetInBeginSection": 701,
                    "offsetInEndSection": 935,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16675487",
                    "text": "We have established a novel CD4 and CD8 double-positive CD25+ T regulatory (Treg) clone, MT-5B, from lymph nodes of type 1 diabetes prone non-obese diabetic (NOD) mice immunized with CFA.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 187,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a735cdc3b9d13c708000004",
            "body": "In November 2017,  in what phase  was  the clinical trial for the drug SYL040012?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24025752",
                "http://www.ncbi.nlm.nih.gov/pubmed/28389707",
                "http://www.ncbi.nlm.nih.gov/pubmed/16037862",
                "http://www.ncbi.nlm.nih.gov/pubmed/29067343",
                "http://www.ncbi.nlm.nih.gov/pubmed/17621880",
                "http://www.ncbi.nlm.nih.gov/pubmed/12020052",
                "http://www.ncbi.nlm.nih.gov/pubmed/25454208",
                "http://www.ncbi.nlm.nih.gov/pubmed/11249584",
                "http://www.ncbi.nlm.nih.gov/pubmed/28671135",
                "http://www.ncbi.nlm.nih.gov/pubmed/28493171"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752",
                    "text": "The objective of this study was to evaluate ocular tolerance, safety, and effect on intraocular pressure (IOP) of a topically administered small interfering RNA; SYL040012, on healthy volunteers.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 195,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28389707",
                    "text": "The siRNAs in focus are PF-04523655, TKM-080301, Atu027, SYL040012, SYL1001, siG12D-LODER (phase 2), QPI-1002, QPI-1007, and patisiran (phase 3).",
                    "offsetInBeginSection": 582,
                    "offsetInEndSection": 727,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29067343",
                    "text": "METHODS We assessed the agents in the AD pipeline as documented in clinicaltrials.gov for phase I, phase II, and phase III, accessed 1/5/2017.",
                    "offsetInBeginSection": 163,
                    "offsetInEndSection": 305,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17621880",
                    "text": "A phase I/II clinical trial in CTCL and CBCL was recently completed, and in November 2006 Transgene initiated a phase II clinical trial in CBCL.",
                    "offsetInBeginSection": 209,
                    "offsetInEndSection": 353,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12020052",
                    "text": "Following a meeting with the FDA, La Jolla planned a phase III trial of abetimus and expected this to begin in the second half of 2000 [364916].",
                    "offsetInBeginSection": 452,
                    "offsetInEndSection": 596,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12020052",
                    "text": "In September 2000, phase III trials were initiated [382931].",
                    "offsetInBeginSection": 149,
                    "offsetInEndSection": 209,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25454208",
                    "text": "In November 2013, landiolol hydrochloride (Onoact(\u00ae) 50 for Injection, Ono Pharamaceutical, Osaka, Japan) was approved with the indication for \"tachyarrhythmia (AF/AFL) in patients with cardiac dysfunction.\"",
                    "offsetInBeginSection": 309,
                    "offsetInEndSection": 517,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11249584",
                    "text": "Phase I trials to determine the maximum tolerated dose in patients, the nature of the dose-limiting toxicity and the pharmacokinetics of the drug commenced in the US in November 1999 [347964].",
                    "offsetInBeginSection": 1009,
                    "offsetInEndSection": 1201,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28671135",
                    "text": "METHODS All HD clinical trials registered in the WHO International Clinical Trials Search Portal, from inception to May 2017, were analyzed.",
                    "offsetInBeginSection": 488,
                    "offsetInEndSection": 628,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28493171",
                    "text": "Atezolizumab, approved in May 2016, and nivolumab, approved in February 2017, are the first Food and Drug Administration (FDA)-approved immune-checkpoint inhibitors in bladder cancer for platinum-pretreated patients based on phase II data.",
                    "offsetInBeginSection": 1282,
                    "offsetInEndSection": 1521,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a777ab9faa1ab7d2e00000a",
            "body": "What is the drug target(s) for Belsomra?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25336862",
                "http://www.ncbi.nlm.nih.gov/pubmed/29066641",
                "http://www.ncbi.nlm.nih.gov/pubmed/27390287",
                "http://www.ncbi.nlm.nih.gov/pubmed/27471419",
                "http://www.ncbi.nlm.nih.gov/pubmed/17883836",
                "http://www.ncbi.nlm.nih.gov/pubmed/20011153",
                "http://www.ncbi.nlm.nih.gov/pubmed/21314453",
                "http://www.ncbi.nlm.nih.gov/pubmed/20678007",
                "http://www.ncbi.nlm.nih.gov/pubmed/22067455",
                "http://www.ncbi.nlm.nih.gov/pubmed/22962489"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25336862",
                    "text": "Idelalisib (Zydelig) for certain types of leukemia and lymphoma, peginterferon beta-1a (Plegridy) for relapsing forms of multiple sclerosis, and suvorexant (Belsomra) for insomnia.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27390287",
                    "text": "Starting from suvorexant (trade name Belsomra), we successfully identified interesting templates leading to potent dual orexin receptor antagonists (DORAs) via a scaffold-hopping approach.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 188,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27471419",
                    "text": "Dual orexin receptor antagonists represent a new class of medications for the treatment of insomnia, which block the binding of wakefulness-promoting neuropeptides orexin A and orexin B to their respective receptor sites.",
                    "offsetInBeginSection": 557,
                    "offsetInEndSection": 778,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27471419",
                    "text": "Suvorexant (Belsomra) is the first dual orexin receptor antagonist to be approved in the US and Japan and has demonstrated efficacy in decreasing time to sleep onset and increasing total sleep time.",
                    "offsetInBeginSection": 779,
                    "offsetInEndSection": 977,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27471419",
                    "text": "Suvorexant is not likely to replace benzodiazepines or nonbenzodiazepine receptor antagonists as a first-line sleep agent but does represent a novel option for the treatment of patients with chronic insomnia.",
                    "offsetInBeginSection": 1622,
                    "offsetInEndSection": 1830,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17883836",
                    "text": "In the current study, based on the properties of known drug targets, we have developed a sequence-based drug target prediction method for fast identification of novel drug targets.",
                    "offsetInBeginSection": 657,
                    "offsetInEndSection": 837,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17883836",
                    "text": "Identifying potential drug targets is the first step in the process of modern drug discovery for developing novel therapeutic agents.",
                    "offsetInBeginSection": 193,
                    "offsetInEndSection": 326,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20011153",
                    "text": "UNLABELLED A Genomic Target Database (GTD) has been developed having putative genomic drug targets for human bacterial pathogens.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21314453",
                    "text": "In this article, we introduce a novel framework--Similarity-based Inference of drug-TARgets (SITAR)--for incorporating multiple drug-drug and gene-gene similarity measures for drug target prediction.",
                    "offsetInBeginSection": 368,
                    "offsetInEndSection": 567,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20678007",
                    "text": "Our results demonstrated that mir-drug-targets preferentially interact with other mir-drug-targets and tend to be hub-bottlenecks.",
                    "offsetInBeginSection": 918,
                    "offsetInEndSection": 1048,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8861eb8cb19eca6b000001",
            "body": "List the two most important synaptic markers.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27906174",
                "http://www.ncbi.nlm.nih.gov/pubmed/10888735",
                "http://www.ncbi.nlm.nih.gov/pubmed/24127213",
                "http://www.ncbi.nlm.nih.gov/pubmed/15236469",
                "http://www.ncbi.nlm.nih.gov/pubmed/22009345",
                "http://www.ncbi.nlm.nih.gov/pubmed/22206847",
                "http://www.ncbi.nlm.nih.gov/pubmed/22319471",
                "http://www.ncbi.nlm.nih.gov/pubmed/17154715",
                "http://www.ncbi.nlm.nih.gov/pubmed/8269086",
                "http://www.ncbi.nlm.nih.gov/pubmed/25755633"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27906174",
                    "text": "Alzheimer's disease (AD) is characterized by synaptic and neuronal loss, which occurs at least partially through oxidative stress induced by oligomeric amyloid-\u03b2 (A\u03b2)-peptide.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10888735",
                    "text": "The markers applied were from three major groups: 1) antibodies against calcium-binding proteins, such as calbindin, parvalbumin, recoverin, or caldendrin; 2) antibodies that recognize specific transmitter systems, such as glycine, gamma-aminobutyric acid, or acetylcholine; and 3) antibodies that recognize transmitter receptors and show their aggregation at specific synapses.",
                    "offsetInBeginSection": 444,
                    "offsetInEndSection": 822,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15236469",
                    "text": "Activin, a member of the transforming growth factor-beta superfamily of growth and differentiation factors, has recently been added to the list of candidate synaptic regulators.",
                    "offsetInBeginSection": 257,
                    "offsetInEndSection": 434,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15236469",
                    "text": "Neurotrophins play important roles in synaptic plasticity and neuroprotection.",
                    "offsetInBeginSection": 178,
                    "offsetInEndSection": 256,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15236469",
                    "text": "The progressive development of seizures in rats by amygdala kindling, which models temporal lobe epilepsy, allows the study of molecular regulators of enduring synaptic changes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22206847",
                    "text": "The protein and messenger RNA (mRNA) levels of 7 synaptic markers (complexin-1, complexin-2, synaptophysin, synaptobrevin, syntaxin, synaptosomal-associated protein 25 (SNAP-25), and septin-5) were compared in the brains of nondemented and demented individuals ranging from 70 to 103 years of age.",
                    "offsetInBeginSection": 660,
                    "offsetInEndSection": 957,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22319471",
                    "text": "In this review, we list the most relevant isoforms of synaptic and extrasynaptic GABA(A) receptors that are thought to assemble in surface membranes of neurons in the central nervous system.",
                    "offsetInBeginSection": 500,
                    "offsetInEndSection": 690,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8269086",
                    "text": "Such probes are useful markers of synaptic function and synaptic population density in the nervous system.",
                    "offsetInBeginSection": 699,
                    "offsetInEndSection": 805,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8269086",
                    "text": "The most extensively studied synaptic proteins are synaptophysin, the synapsins, growth associated protein 43 (GAP-43), SV-2, and p65.",
                    "offsetInBeginSection": 236,
                    "offsetInEndSection": 370,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25755633",
                    "text": "Synaptic failure and neurofibrillary degeneration are two major neuropathological substrates of cognitive dysfunction in Alzheimer's disease (AD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a75ee7e83b0d9ea66000005",
            "body": "List symptoms of the Zieve's syndrome.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7110955",
                "http://www.ncbi.nlm.nih.gov/pubmed/2616809",
                "http://www.ncbi.nlm.nih.gov/pubmed/464793",
                "http://www.ncbi.nlm.nih.gov/pubmed/8819039",
                "http://www.ncbi.nlm.nih.gov/pubmed/26203455",
                "http://www.ncbi.nlm.nih.gov/pubmed/966632",
                "http://www.ncbi.nlm.nih.gov/pubmed/11761804",
                "http://www.ncbi.nlm.nih.gov/pubmed/548954",
                "http://www.ncbi.nlm.nih.gov/pubmed/2355237",
                "http://www.ncbi.nlm.nih.gov/pubmed/1217221"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7110955",
                    "text": "Zieve's syndrome therefore is not benign but precedes acute alcoholic hepatitis episodes on a normal, fibrotic or cirrhotic liver.",
                    "offsetInBeginSection": 508,
                    "offsetInEndSection": 638,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7110955",
                    "text": "Zieve's syndrome, characterized by jaundice, hyperlipaemia and haemolytic anaemia, usually develops in young, chronically alcoholic subjects with enlarged fatty liver.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2616809",
                    "text": "The clinical manifestations of the syndrome contains no pathognomonic symptoms and suggests rather cholecystopathy.",
                    "offsetInBeginSection": 132,
                    "offsetInEndSection": 247,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2616809",
                    "text": "This is possibly the cause of rare recognition of the syndrome.",
                    "offsetInBeginSection": 248,
                    "offsetInEndSection": 311,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/464793",
                    "text": "The Zieve's syndrome consists of the transient association of cholestatic jaundice, hemolytic anemia, hyperlipemia, in a chronic alcoholic.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 139,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8819039",
                    "text": "Zieve's syndrome consists of transient haemolytic anaemic, jaundice, hyperlipidaemia and alcohol-induced liver disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11761804",
                    "text": "We report a case of recurrent Zieve's syndrome, consisting of jaundice, hemolytic anemia and hyperlipoproteinemia, initiated by alcohol abuse.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/548954",
                    "text": "A patient with Zieve's syndrome is described.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 45,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2355237",
                    "text": "Zieve's syndrome (hyperlipidaemia, anaemia and fatty liver degeneration) may rarely occur with intracranial haemorrhage.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1217221",
                    "text": "The macroscopic and microscopic findings of a case of Zieve's syndrome are described (fatty liver, icterus, hyperlipemia and hemolytic anemia in chronic alcoholism).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 165,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7636d39e632bc066000004",
            "body": "Which R packages have been developed for the discovery of mutational signatures in cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27091472",
                "http://www.ncbi.nlm.nih.gov/pubmed/29028923",
                "http://www.ncbi.nlm.nih.gov/pubmed/29145625",
                "http://www.ncbi.nlm.nih.gov/pubmed/27591080",
                "http://www.ncbi.nlm.nih.gov/pubmed/26163694",
                "http://www.ncbi.nlm.nih.gov/pubmed/26438695",
                "http://www.ncbi.nlm.nih.gov/pubmed/26630308",
                "http://www.ncbi.nlm.nih.gov/pubmed/28669865",
                "http://www.ncbi.nlm.nih.gov/pubmed/21342567",
                "http://www.ncbi.nlm.nih.gov/pubmed/25192743"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27091472",
                    "text": "RESULTS MutSpec includes a set of tools that perform variant annotation and use advanced statistics for the identification of mutation signatures present in cancer genomes and for comparing the obtained signatures with those published in the COSMIC database and other sources.",
                    "offsetInBeginSection": 699,
                    "offsetInEndSection": 975,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028923",
                    "text": "Results We proposed two complementary ways of measuring confidence and stability of decomposition results and applied them to analyze mutational signatures in breast cancer genomes.",
                    "offsetInBeginSection": 882,
                    "offsetInEndSection": 1063,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028923",
                    "text": "We identified both very stable and highly unstable signatures, as well as signatures that previously have not been associated with breast cancer.",
                    "offsetInBeginSection": 1064,
                    "offsetInEndSection": 1209,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29145625",
                    "text": "Deciphering mutational signatures in cancer is a new topic in cancer research.",
                    "offsetInBeginSection": 256,
                    "offsetInEndSection": 334,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29145625",
                    "text": "mSignatureDB (http://tardis.cgu.edu.tw/msignaturedb) integrates R packages and in-house scripts to determine the contributions of the published signatures in 15 780 individual tumors from 73 TCGA/ICGC cancer projects, making comparison of signature patterns within and between projects become possible.",
                    "offsetInBeginSection": 875,
                    "offsetInEndSection": 1177,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29145625",
                    "text": "A cancer genome bears the cumulative effects of mutational processes during tumor development.",
                    "offsetInBeginSection": 161,
                    "offsetInEndSection": 255,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591080",
                    "text": "RESULTS Here we present a new method for the statistical estimation of mutational signatures based on an empirical Bayesian treatment of the NMF model.",
                    "offsetInBeginSection": 749,
                    "offsetInEndSection": 900,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591080",
                    "text": "These signatures have been identified from high throughput sequencing data generated from cancer genomes by using non-negative matrix factorisation (NMF) techniques.",
                    "offsetInBeginSection": 191,
                    "offsetInEndSection": 356,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26163694",
                    "text": "UNLABELLED Mutational signatures are patterns in the occurrence of somatic single-nucleotide variants that can reflect underlying mutational processes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 151,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26438695",
                    "text": "An application to leukemia patient primary cell models demonstrated how the target deconvolution approach offers functional insights into patient-specific addiction patterns, such as those indicative of their receptor-type tyrosine-protein kinase FLT3 internal tandem duplication (FLT3-ITD) status and co-addiction partners, which may lead to clinically actionable, personalized drug treatment developments.",
                    "offsetInBeginSection": 1421,
                    "offsetInEndSection": 1828,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8dc57ffcd1d6a10c000025",
            "body": "Are the human bombesin receptors, GRPR and NMBR, frequently overexpressed G-protein-coupled-receptors by lung-cancers?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23096238",
                "http://www.ncbi.nlm.nih.gov/pubmed/19628633",
                "http://www.ncbi.nlm.nih.gov/pubmed/12959933",
                "http://www.ncbi.nlm.nih.gov/pubmed/8018339",
                "http://www.ncbi.nlm.nih.gov/pubmed/11463790",
                "http://www.ncbi.nlm.nih.gov/pubmed/10828496",
                "http://www.ncbi.nlm.nih.gov/pubmed/23826298",
                "http://www.ncbi.nlm.nih.gov/pubmed/25554218",
                "http://www.ncbi.nlm.nih.gov/pubmed/25209280",
                "http://www.ncbi.nlm.nih.gov/pubmed/21421741"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23096238",
                    "text": "Mammalian bombesin-like peptides neuromedin B (NMB) and gastrin-releasing peptide (GRP) act by activating NMB receptors (NMBR, BBl) and GRP receptors (GRPR,BB2), respectively.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23096238",
                    "text": "These two bombesin receptors are members of the G-protein-coupled receptor (GPCR) superfamily.In the brain, NMBR and GRPR are highly expressed in the brain areas involved in memory processing and emotional responses, such as the hippocampus and the amygdaloid nuclei.",
                    "offsetInBeginSection": 176,
                    "offsetInEndSection": 443,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19628633",
                    "text": "The mammalian bombesin (Bn) peptides, neuromedin B (NMB) and gastrin-releasing peptide (GRP), have widespread actions in many tissues, and their effects are mediated by two closely related G-protein-coupled receptors, the NMBR and GRPR.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 236,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12959933",
                    "text": "Dexamethasone and bombesin increased GRPR mRNA, bombesin downregulated NMBR, and neither agent affected BRS-3.",
                    "offsetInBeginSection": 1077,
                    "offsetInEndSection": 1187,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12959933",
                    "text": "To test the hypothesis that such effects are mediated by known mammalian bombesin receptors [gastrin-releasing peptide (GRP)/bombesin-preferring receptor (GRPR), neuromedin B (NMB) receptor (NMBR), and the orphan bombesin receptor subtype-3 (BRS-3)], we analyzed the ontogeny of GRPR, NMBR, and BRS-3 gene expression in mouse lung.",
                    "offsetInBeginSection": 148,
                    "offsetInEndSection": 479,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8018339",
                    "text": "Three receptors have been identified for bombesin and its analogs, namely gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype 3 (BRS-3).",
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 448,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10828496",
                    "text": "In this study, we used the reverse transcription-polymerase chain reaction (RT-PCR) method to evaluate the mRNA expression of three bombesin receptor subtypes: gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype 3 (BRS-3), in 22 specimens of human epithelial ovarian cancer and in two human ovarian cancer lines.",
                    "offsetInBeginSection": 305,
                    "offsetInEndSection": 668,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23826298",
                    "text": "receptors for gastrin-releasing peptide (GRPr) and neuromedin B (NMBr) differentially regulate itch scratching.",
                    "offsetInBeginSection": 194,
                    "offsetInEndSection": 305,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21421741",
                    "text": "Antagonists selective for GRPr [(d-Tpi6, Leu13\u03a8(CH2-NH)-Leu14)Bombesin(6-14) (RC-3095)] and NMBr [(S)-\u03b1-methyl-\u03b1-[[[(4-nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-1H-indole-3-propanamide (PD168368)] were used to define the role of GRPr and NMBr in the scratching response.",
                    "offsetInBeginSection": 585,
                    "offsetInEndSection": 888,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21421741",
                    "text": "Bombesin has high affinity for the gastrin-releasing peptide (GRP) receptor (GRPr) and the neuromedin B (NMB) receptor (NMBr).",
                    "offsetInBeginSection": 90,
                    "offsetInEndSection": 216,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7602be83b0d9ea6600000f",
            "body": "Describe King\u2013Kopetzky syndrome.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25709171",
                "http://www.ncbi.nlm.nih.gov/pubmed/2188546",
                "http://www.ncbi.nlm.nih.gov/pubmed/17326116",
                "http://www.ncbi.nlm.nih.gov/pubmed/20583180",
                "http://www.ncbi.nlm.nih.gov/pubmed/18592912",
                "http://www.ncbi.nlm.nih.gov/pubmed/20446161",
                "http://www.ncbi.nlm.nih.gov/pubmed/6703533",
                "http://www.ncbi.nlm.nih.gov/pubmed/12002153",
                "http://www.ncbi.nlm.nih.gov/pubmed/18334805",
                "http://www.ncbi.nlm.nih.gov/pubmed/835533"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2188546",
                    "text": "The authors report six of these very rare syndromes discovered among their patients: a KID syndrome, a Leopard syndrome, a Norrie syndrome, a Jervell and Lange Nielsen syndrome, a recently described entity called CEE with deafness and an External Neuro-Cochleo-Pancreatic syndrome which would not appear to have been previously described.",
                    "offsetInBeginSection": 511,
                    "offsetInEndSection": 849,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20583180",
                    "text": "The purpose of this paper is to describe two new unrelated cases of this unique syndrome that further delineate the phenotype, compare to phenotypically similar syndromes, and postulate that Petty syndrome could represent a new laminopathy.",
                    "offsetInBeginSection": 882,
                    "offsetInEndSection": 1122,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18592912",
                    "text": "The Peutz-Jeghers syndrome, the Juvenile plyposys syndrome, the PTEN hamartomatous tumor syndrome, and other less frequent hamartomatous syndroms are described.",
                    "offsetInBeginSection": 274,
                    "offsetInEndSection": 434,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18592912",
                    "text": "Several hereditary syndromes with multiple digestive hamartomatous polyps are described; they are produced by germline mutations.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6703533",
                    "text": "Authors describe the phenotype and review the literature on this syndrome.",
                    "offsetInBeginSection": 159,
                    "offsetInEndSection": 233,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6703533",
                    "text": "A new case of Robinow dwarfism syndrome, in a 26 month old child is described.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 78,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12002153",
                    "text": "Two sibs from an inbred Arab family are described with an autosomal syndrome of choanal atresia, hypothelia/athelia and thyroid gland anomalies overlapping Bamforth syndrome, ANOTHER syndrome and methimazole embryopathy.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 220,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18334805",
                    "text": "We describe a neonate with this syndrome having colonic atresia leading to cecal rupture and pneumoperitoneum.",
                    "offsetInBeginSection": 206,
                    "offsetInEndSection": 316,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18334805",
                    "text": "Fraser cryptophthalmos syndrome is a severe genetic disorder comprising of cryptophthalmos, syndactyly and genitourinary abnormalities.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/835533",
                    "text": "It is suggested that this syndrome is inherited as an autosomal-recessive condition.",
                    "offsetInBeginSection": 265,
                    "offsetInEndSection": 349,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a67c284b750ff4455000011",
            "body": "What is GenomeVIP?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28522612"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612",
                    "text": "GenomeVIP orchestrates the analysis of whole-genome and exome sequence data using a set of robust and popular task-specific tools, including VarScan, GATK, Pindel, BreakDancer, Strelka, and Genome STRiP, through a web interface.",
                    "offsetInBeginSection": 790,
                    "offsetInEndSection": 1018,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612",
                    "text": "GenomeVIP has been used for genomic analysis in large-data projects such as the TCGA PanCanAtlas and in other projects, such as the ICGC Pilots, CPTAC, ICGC-TCGA DREAM Challenges, and the 1000 Genomes SV Project.",
                    "offsetInBeginSection": 1019,
                    "offsetInEndSection": 1231,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612",
                    "text": "Here, we introduce the Genome Variant Investigation Platform (GenomeVIP), an open-source framework for performing genomics variant discovery and annotation using cloud- or local high-performance computing infrastructure.",
                    "offsetInBeginSection": 569,
                    "offsetInEndSection": 789,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612",
                    "text": "Identifying genomic variants is a fundamental first step toward the understanding of the role of inherited and acquired variation in disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612",
                    "text": "The accelerating growth in the corpus of sequencing data that underpins such analysis is making the data-download bottleneck more evident, placing substantial burdens on the research community to keep pace.",
                    "offsetInBeginSection": 142,
                    "offsetInEndSection": 348,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612",
                    "text": "Here, we demonstrate GenomeVIP's ability to provide high-confidence annotated somatic, germline, and de novo variants of potential biological significance using publicly available data sets.",
                    "offsetInBeginSection": 1232,
                    "offsetInEndSection": 1422,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612",
                    "text": "As a result, the search for alternative approaches to the traditional \"download and analyze\" paradigm on local computing resources has led to a rapidly growing demand for cloud-computing solutions for genomics analysis.",
                    "offsetInBeginSection": 349,
                    "offsetInEndSection": 568,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a981e66fcd1d6a10c00002f",
            "body": "According to guidelines, insulin resistance is one risk factor in the diagnosis of metabolic syndrome, name 3 more risk factors.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16762931",
                "http://www.ncbi.nlm.nih.gov/pubmed/16505579",
                "http://www.ncbi.nlm.nih.gov/pubmed/21068471",
                "http://www.ncbi.nlm.nih.gov/pubmed/17456293",
                "http://www.ncbi.nlm.nih.gov/pubmed/17125447",
                "http://www.ncbi.nlm.nih.gov/pubmed/12643148",
                "http://www.ncbi.nlm.nih.gov/pubmed/15547646",
                "http://www.ncbi.nlm.nih.gov/pubmed/19838492",
                "http://www.ncbi.nlm.nih.gov/pubmed/19108808",
                "http://www.ncbi.nlm.nih.gov/pubmed/15940204"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16505579",
                    "text": "Soon, metabolic syndrome will overtake cigarette smoking as the number one risk factor for heart disease among the US population.",
                    "offsetInBeginSection": 1182,
                    "offsetInEndSection": 1311,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16505579",
                    "text": "The syndrome has been given several names, including- the metabolic syndrome, the insulin resistance syndrome, the plurimetabolic syndrome, and the deadly quartet.",
                    "offsetInBeginSection": 75,
                    "offsetInEndSection": 238,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21068471",
                    "text": "This article provides a comprehensive discussion of metabolic risk factors, the history of MetS, and its diagnosis, epidemiology, etiology, pathophysiology, and treatment.",
                    "offsetInBeginSection": 616,
                    "offsetInEndSection": 787,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17456293",
                    "text": "Factors including genetic disposition, obesity, insulin resistance and inflammation have been suggested as being involved.",
                    "offsetInBeginSection": 867,
                    "offsetInEndSection": 989,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17125447",
                    "text": "Abdominal adiposity is considered high-risk fat, and it is associated with insulin resistance, hyperglycemia, dyslipidemia, hypertension, and prothrombotic and/or proinflammatory states.",
                    "offsetInBeginSection": 905,
                    "offsetInEndSection": 1091,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17125447",
                    "text": "First-line therapy for individuals with metabolic syndrome should be directed to the major CVD risk factors, namely, elevated low-density lipoprotein cholesterol levels, hypertension, and diabetes, and it should emphasize lifestyle modification.",
                    "offsetInBeginSection": 1226,
                    "offsetInEndSection": 1471,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17125447",
                    "text": "Until additional research better defines the most appropriate therapies, conventional cardiovascular risk factors, such as lipid levels, blood pressure, and diabetes, should be managed in individuals with metabolic syndrome according to nationally accepted clinical guidelines.",
                    "offsetInBeginSection": 1472,
                    "offsetInEndSection": 1749,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12643148",
                    "text": "Also, there is new and better understanding of the complex dyslipidemias and other risk factors strongly associated with the metabolic syndrome, which greatly increase the risk of clinical atherosclerotic events.",
                    "offsetInBeginSection": 394,
                    "offsetInEndSection": 606,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15547646",
                    "text": "Insulin resistance is the key factor for the clustering of risk factors characterizing the metabolic syndrome.",
                    "offsetInBeginSection": 272,
                    "offsetInEndSection": 382,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19108808",
                    "text": "The metabolic syndrome has 5 criteria: central obesity, hypertriglyceridemia, low high-density lipoprotein (HDL) levels, fasting hyperglycemia, and hypertension.",
                    "offsetInBeginSection": 1021,
                    "offsetInEndSection": 1182,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a76080683b0d9ea66000015",
            "body": "Is cilengitide effective for treatment of glioblastoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23354807",
                "http://www.ncbi.nlm.nih.gov/pubmed/24014381",
                "http://www.ncbi.nlm.nih.gov/pubmed/21739168",
                "http://www.ncbi.nlm.nih.gov/pubmed/24442484",
                "http://www.ncbi.nlm.nih.gov/pubmed/17277694",
                "http://www.ncbi.nlm.nih.gov/pubmed/25163906",
                "http://www.ncbi.nlm.nih.gov/pubmed/24153102",
                "http://www.ncbi.nlm.nih.gov/pubmed/22866207",
                "http://www.ncbi.nlm.nih.gov/pubmed/20439646",
                "http://www.ncbi.nlm.nih.gov/pubmed/22976135"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014381",
                    "text": "BACKGROUND Cilengitide, an \u03b1v integrin antagonist, has demonstrated activity in recurrent adult glioblastoma (GBM).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014381",
                    "text": "CONCLUSIONS We conclude that cilengitide is not effective as a single agent for refractory pediatric HGG.",
                    "offsetInBeginSection": 1417,
                    "offsetInEndSection": 1522,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21739168",
                    "text": "Cilengitide is a cyclic pentapeptide that is a specific inhibitor of the \u03b1v\u03b23 and \u03b1v\u03b25 integrins.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 101,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24442484",
                    "text": "The integrin antagonist cilengitide has been explored as an adjunct with anti-angiogenic properties to standard of care temozolomide chemoradiotherapy (TMZ/RT \u2192 TMZ) in newly diagnosed glioblastoma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 200,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24153102",
                    "text": "These data suggest that the combination of radiation therapy and cilengitide may prove to be effective where radiation is utilized for the treatment of gross disease in breast cancer, such as in the setting of brain metastasis.",
                    "offsetInBeginSection": 2204,
                    "offsetInEndSection": 2431,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22866207",
                    "text": "A foundation of encouraging preclinical studies led to a well-designed clinical development plan that culminated in a pivotal phase III study of cilengitide in combination with radiation therapy and temozolomide chemotherapy for newly diagnosed glioblastoma patients.",
                    "offsetInBeginSection": 545,
                    "offsetInEndSection": 812,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22866207",
                    "text": "Although several integrin inhibitors are under clinical evaluation, cilengitide is the most clinically advanced and is emerging as a prototype for this class of anticancer therapy.",
                    "offsetInBeginSection": 364,
                    "offsetInEndSection": 544,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20439646",
                    "text": "Integrin inhibition using cilengitide has shown synergy with chemotherapy and radiotherapy in vitro and promising activity in recurrent glioblastoma.",
                    "offsetInBeginSection": 109,
                    "offsetInEndSection": 258,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22976135",
                    "text": "Among them, cilengitide is a novel integrin antagonist for the treatment of glioblastoma.",
                    "offsetInBeginSection": 648,
                    "offsetInEndSection": 737,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22976135",
                    "text": "Cilengitide is currently being assessed in phase III trials for patients with glioblastoma multiforme and in phase II trials for other types of cancers, demonstrating promising therapeutic outcomes to date.",
                    "offsetInBeginSection": 1016,
                    "offsetInEndSection": 1222,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6a3464b750ff4455000026",
            "body": "Which algorithm has been developed in order to improve multiple circular sequence alignment using refined sequences?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28088189",
                "http://www.ncbi.nlm.nih.gov/pubmed/19627599",
                "http://www.ncbi.nlm.nih.gov/pubmed/16086841",
                "http://www.ncbi.nlm.nih.gov/pubmed/8590178",
                "http://www.ncbi.nlm.nih.gov/pubmed/16044462",
                "http://www.ncbi.nlm.nih.gov/pubmed/25101328",
                "http://www.ncbi.nlm.nih.gov/pubmed/7796270",
                "http://www.ncbi.nlm.nih.gov/pubmed/27505054",
                "http://www.ncbi.nlm.nih.gov/pubmed/18437229",
                "http://www.ncbi.nlm.nih.gov/pubmed/17105653"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189",
                    "text": "RESULTS We present MARS, a new heuristic method for improving Multiple circular sequence Alignment using Refined Sequences.",
                    "offsetInBeginSection": 917,
                    "offsetInEndSection": 1040,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189",
                    "text": "A solution for these inconsistencies would be to identify a suitable rotation (cyclic shift) for each sequence; these refined sequences may in turn lead to improved multiple sequence alignments using the preferred multiple sequence alignment program.",
                    "offsetInBeginSection": 664,
                    "offsetInEndSection": 914,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189",
                    "text": "CONCLUSIONS Analysing multiple sequences simultaneously is fundamental in biological research and multiple sequence alignment has been found to be a popular method for this task.",
                    "offsetInBeginSection": 1729,
                    "offsetInEndSection": 1907,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19627599",
                    "text": "RESULTS In this paper we propose an efficient algorithm that identifies the most interesting region to cut circular genomes in order to improve phylogenetic analysis when using standard multiple sequence alignment algorithms.",
                    "offsetInBeginSection": 876,
                    "offsetInEndSection": 1101,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19627599",
                    "text": "Researchers interested in aligning circular DNA sequences must first rotate them to the \"right\" place using an essentially manual process, before they can use multiple sequence alignment tools.",
                    "offsetInBeginSection": 680,
                    "offsetInEndSection": 873,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19627599",
                    "text": "CONCLUSION The results show that a circularization and rotation pre-processing step significantly improves the efficiency of public available multiple sequence alignment algorithms when used in the alignment of circular DNA sequences.",
                    "offsetInBeginSection": 1796,
                    "offsetInEndSection": 2030,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19627599",
                    "text": "Although a large number of multiple sequence alignment algorithms have been proposed to date, they all deal with linear DNA and cannot handle directly circular DNA.",
                    "offsetInBeginSection": 515,
                    "offsetInEndSection": 679,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16086841",
                    "text": "CONCLUSION We have implemented a genetic algorithm in parallel mode to optimize multiple genomic sequence alignments initially generated by various alignment tools.",
                    "offsetInBeginSection": 2174,
                    "offsetInEndSection": 2338,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16086841",
                    "text": "We describe a new program, GenAlignRefine, which improves the overall quality of global multiple alignments by using a genetic algorithm to improve local regions of alignment.",
                    "offsetInBeginSection": 846,
                    "offsetInEndSection": 1021,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7796270",
                    "text": "To date, most multiple alignment systems have employed a tree-based algorithm, which combines the results of two-way dynamic programming in a tree-like order of sequence similarity.",
                    "offsetInBeginSection": 72,
                    "offsetInEndSection": 253,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a74e9ad0384be955100000a",
            "body": "What is a SERM?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/10629380",
                "http://www.ncbi.nlm.nih.gov/pubmed/12036407",
                "http://www.ncbi.nlm.nih.gov/pubmed/24930824",
                "http://www.ncbi.nlm.nih.gov/pubmed/20446043",
                "http://www.ncbi.nlm.nih.gov/pubmed/26343247",
                "http://www.ncbi.nlm.nih.gov/pubmed/11795362",
                "http://www.ncbi.nlm.nih.gov/pubmed/17020999",
                "http://www.ncbi.nlm.nih.gov/pubmed/12650712",
                "http://www.ncbi.nlm.nih.gov/pubmed/23925896",
                "http://www.ncbi.nlm.nih.gov/pubmed/28185712"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10629380",
                    "text": "Raloxifene is a SERM with a chemical structure different from triphenylethylenes.",
                    "offsetInBeginSection": 1366,
                    "offsetInEndSection": 1447,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24930824",
                    "text": "Tamoxifen, a pioneering selective estrogen receptor modulator (SERM), has long been a therapeutic choice for all stages of estrogen receptor (ER)-positive breast cancer.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 169,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20446043",
                    "text": "A new target in treating postmenopausal osteoporosis is the tissue estrogen complex or the pairing of a SERM with a conjugated estrogen known as a tissue selective estrogen complex (TSEC).",
                    "offsetInBeginSection": 1528,
                    "offsetInEndSection": 1716,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20446043",
                    "text": "Several agents are available in the U.S., including bisphosphonates, hormone therapy, calcitonin, parathyroid hormone and the selective estrogen receptor modulator (SERM) raloxifene.",
                    "offsetInBeginSection": 675,
                    "offsetInEndSection": 857,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17020999",
                    "text": "PURPOSE We tested whether a selective estrogen receptor modulator (SERM) and a rexinoid are active for prevention and treatment in the mouse mammary tumor virus-neu mouse model of estrogen receptor-negative breast cancer.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 221,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12650712",
                    "text": "Tibolone, selective estrogen receptor modulators (SERMs) like tamoxifen and raloxifene, and estrogen (+/-progestogen) treatments prevent bone loss in postmenopausal women.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23925896",
                    "text": "Estrogen and selective estrogen receptor modulator (SERM) treatments for acromegaly have received limited attention since the development of newer pharmacologic therapies.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28185712",
                    "text": "The third-generation SERM bazedoxifene (BZA) effectively prevents osteoporosis while preventing estrogenic stimulation of breast and uterus.",
                    "offsetInBeginSection": 367,
                    "offsetInEndSection": 507,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28185712",
                    "text": "Tamoxifen, a first generation SERM, is used for treatment of ER positive breast cancer.",
                    "offsetInBeginSection": 192,
                    "offsetInEndSection": 279,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28185712",
                    "text": "Raloxifene, a second generation SERM, was used to prevent postmenopausal osteoporosis.",
                    "offsetInBeginSection": 280,
                    "offsetInEndSection": 366,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7610ca83b0d9ea6600001b",
            "body": "What is the role of nimotuzumab in treatment of pontine glioma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24696052",
                "http://www.ncbi.nlm.nih.gov/pubmed/25926743",
                "http://www.ncbi.nlm.nih.gov/pubmed/24847085",
                "http://www.ncbi.nlm.nih.gov/pubmed/23754473",
                "http://www.ncbi.nlm.nih.gov/pubmed/21171927",
                "http://www.ncbi.nlm.nih.gov/pubmed/23043252",
                "http://www.ncbi.nlm.nih.gov/pubmed/19903064",
                "http://www.ncbi.nlm.nih.gov/pubmed/23926436",
                "http://www.ncbi.nlm.nih.gov/pubmed/21858608",
                "http://www.ncbi.nlm.nih.gov/pubmed/27379495"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696052",
                    "text": "Findings on the role of EGFR signaling in the onset of childhood DIPG prompted the use of nimotuzumab, an anti-EGFR monoclonal antibody.",
                    "offsetInBeginSection": 92,
                    "offsetInEndSection": 228,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696052",
                    "text": "Radiotherapy is the only treatment definitely indicated for diffuse pontine gliomas (DIPG).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 91,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696052",
                    "text": "Assuming a potential synergy with both radiotherapy and vinorelbine, a pilot phase 2 protocol was launched that combined nimotuzumab with concomitant radiation and vinorelbine.",
                    "offsetInBeginSection": 229,
                    "offsetInEndSection": 405,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25926743",
                    "text": "We found that nimotuzumab with or without radiotherapy, chemotherapy in newly diagnosed or recurrent HGG, such as glioblastoma multiforme (GBM), anaplastic astrocytomas (AA), and diffuse intrinsic pontine glioma (DIPG), might improve the response rate or the survival time.",
                    "offsetInBeginSection": 499,
                    "offsetInEndSection": 772,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25926743",
                    "text": "We review the humanized epidermal growth factor receptor (EGFR) and the major EGFR target drugs in HGG treatments, focusing on the EGFR antibody nimotuzumab as a new therapeutic strategy in HGG.",
                    "offsetInBeginSection": 304,
                    "offsetInEndSection": 498,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24847085",
                    "text": "CONCLUSIONS Modest activity of nimotuzumab in DIPG, which has been shown previously, was confirmed: A small subset of DIPG patients appeared to benefit from anti-EGFR antibody treatment.",
                    "offsetInBeginSection": 1499,
                    "offsetInEndSection": 1685,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23754473",
                    "text": "Primary metastatic diffuse intrinsic pontine glioma (DIPG) is relatively rare and associated with a dismal prognosis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21171927",
                    "text": "The activity of nimotuzumab, a humanized anti-EGFR monoclonal antibody, was therefore studied within a Phase II trial in 47 relapsing pediatric patients with DIPG and high-grade gliomas, showing an interesting, persistent response, especially in the first group treated.",
                    "offsetInBeginSection": 571,
                    "offsetInEndSection": 841,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19903064",
                    "text": "Emerging trials suggest a promising role for nimotuzumab as a therapeutic agent in patients with high-grade gliomas.",
                    "offsetInBeginSection": 537,
                    "offsetInEndSection": 653,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27379495",
                    "text": "Targeted therapy protocols included radiation therapy along with treatment by erlotinib, cilengitide, or an association of nimotuzumab and vinblastine.",
                    "offsetInBeginSection": 864,
                    "offsetInEndSection": 1015,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6a35b7b750ff4455000027",
            "body": "What is libgapmis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24564250"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "libgapmis is based on an algorithm computing a modified version of the traditional dynamic-programming matrix for sequence alignment.",
                    "offsetInBeginSection": 1240,
                    "offsetInEndSection": 1373,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "The open-source code of libgapmis is available at http://www.exelixis-lab.org/gapmis.",
                    "offsetInBeginSection": 2289,
                    "offsetInEndSection": 2374,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "CONCLUSIONS We present libgapmis, a library for extending pairwise short-read alignments.",
                    "offsetInBeginSection": 1942,
                    "offsetInEndSection": 2031,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "RESULTS In this article, we present libgapmis, a library for extending pairwise short-read alignments.",
                    "offsetInBeginSection": 1042,
                    "offsetInEndSection": 1144,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "We show that libgapmis is better-suited and more efficient than existing algorithms for this task.",
                    "offsetInBeginSection": 2032,
                    "offsetInEndSection": 2130,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "The fact that the reads are rather short and that the gap occurrence frequency observed in various studies is rather low suggest that aligning (parts of) those reads with a single gap is in fact desirable.",
                    "offsetInBeginSection": 834,
                    "offsetInEndSection": 1039,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "After aligning a substring of the reference sequence against the high-quality prefix of a short read--the seed--an important problem is to find the best possible alignment between a substring of the reference sequence succeeding and the remaining suffix of low quality of the read--extend.",
                    "offsetInBeginSection": 544,
                    "offsetInEndSection": 833,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "BACKGROUND A wide variety of short-read alignment programmes have been published recently to tackle the problem of mapping millions of short reads to a reference genome, focusing on different aspects of the procedure such as time and memory efficiency, sensitivity, and accuracy.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 279,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "The seed-and-extend strategy is applied in most short-read alignment programmes.",
                    "offsetInBeginSection": 463,
                    "offsetInEndSection": 543,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "The library also provides the user the flexibility to split the read into fragments, based on the observed gap occurrence frequency and the length of the read, thereby allowing for a variable, but bounded, number of gaps in the alignment.",
                    "offsetInBeginSection": 1701,
                    "offsetInEndSection": 1939,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a76016683b0d9ea6600000d",
            "body": "Down's syndrome occurs when an individual has an extra copy or part of a copy of chromosome 21, yes or no?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19458618",
                "http://www.ncbi.nlm.nih.gov/pubmed/19212162",
                "http://www.ncbi.nlm.nih.gov/pubmed/1838097",
                "http://www.ncbi.nlm.nih.gov/pubmed/25738006",
                "http://www.ncbi.nlm.nih.gov/pubmed/28959732",
                "http://www.ncbi.nlm.nih.gov/pubmed/11399108",
                "http://www.ncbi.nlm.nih.gov/pubmed/26243569",
                "http://www.ncbi.nlm.nih.gov/pubmed/24980541",
                "http://www.ncbi.nlm.nih.gov/pubmed/9050924",
                "http://www.ncbi.nlm.nih.gov/pubmed/9800738"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458618",
                    "text": "Furthermore, we show that the modest increase in expression afforded by a single extra transgenic copy of Dscr1 is sufficient to confer significant suppression of tumour growth in mice, and that such resistance is a consequence of a deficit in tumour angiogenesis arising from suppression of the calcineurin pathway.",
                    "offsetInBeginSection": 600,
                    "offsetInEndSection": 916,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19212162",
                    "text": "Down syndrome is a genetic disorder, occurring when an individual has all or part of an extra copy of chromosome 21.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1838097",
                    "text": "Analysis of individual distribution of satellite between homologues of chromosome 21 provides new possibilities for determination of the origin of extra chromosome in the patients with trisomy 21.",
                    "offsetInBeginSection": 802,
                    "offsetInEndSection": 998,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1838097",
                    "text": "The difference in the copy number between two homologues chromosomes, 13 and 21 reaches up to 5 times.",
                    "offsetInBeginSection": 602,
                    "offsetInEndSection": 704,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25738006",
                    "text": "Downs syndrome (DS) occurs due to an extra copy of chromosome 21.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 65,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11399108",
                    "text": "The augmented antioxidant protection resulting from an extra copy of chromosome 21 may, with time, selectively protect human oocytes from apoptosis, increasing their proportion with age, explaining the higher incidence of this disease.",
                    "offsetInBeginSection": 872,
                    "offsetInEndSection": 1107,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26243569",
                    "text": "Down syndrome, which arises in individuals carrying an extra copy of chromosome 21, is associated with a greatly increased risk of early-onset Alzheimer disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 161,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24980541",
                    "text": "Aneuploidy refers to the presence of an extra copy of a specific chromosome, or trisomy, as seen in Down's syndrome (trisomy 21), or the absence of a single chromosome, or monosomy, as seen in Turner syndrome (a single X chromosome in females: 45, X).",
                    "offsetInBeginSection": 518,
                    "offsetInEndSection": 769,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9050924",
                    "text": "On analysis of 34 cases of Down's syndrome, including two cases of unbalanced translocation 46, XY, der (14; 21) (q10; q10), + 21, and 100 normal individuals, the relative ratio of the PFKM-CH1/PFKL-CH21 product was 1.33 +/- 0.323 (mean +/- SD) and 0.40 +/- 0.16 (mean +/- SD) for disomy DNA and trisomy DNA, respectively.",
                    "offsetInBeginSection": 547,
                    "offsetInEndSection": 869,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9800738",
                    "text": "In a masked prospective study, we investigated the feasibility of PCR amplification of chromosome 21 markers for the prenatal diagnosis of Down's syndrome.",
                    "offsetInBeginSection": 218,
                    "offsetInEndSection": 373,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7615af83b0d9ea6600001f",
            "body": "Is vorinostat effective for glioblastoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24576944",
                "http://www.ncbi.nlm.nih.gov/pubmed/20135194",
                "http://www.ncbi.nlm.nih.gov/pubmed/19307505",
                "http://www.ncbi.nlm.nih.gov/pubmed/23996800",
                "http://www.ncbi.nlm.nih.gov/pubmed/22086447",
                "http://www.ncbi.nlm.nih.gov/pubmed/29016887",
                "http://www.ncbi.nlm.nih.gov/pubmed/22028388",
                "http://www.ncbi.nlm.nih.gov/pubmed/22090453",
                "http://www.ncbi.nlm.nih.gov/pubmed/24838514",
                "http://www.ncbi.nlm.nih.gov/pubmed/19635146"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24576944",
                    "text": "We present two patients with glioblastoma multiforme who developed severe hemolytic anemia shortly after initiating therapy with vorinostat, a pan-active histone deacetylase inhibitor, while on prophylactic dapsone.",
                    "offsetInBeginSection": 827,
                    "offsetInEndSection": 1042,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24576944",
                    "text": "Patients undergoing treatment for glioblastoma multiforme are routinely placed on prophylactic treatment for Pneumocystis jirovecii pneumonia because of significant therapy-induced lymphopenia.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20135194",
                    "text": "Histone deacetylase (HDAC) inhibitors represent a promising class of anti-cancer agents that are actively being evaluated in the context of clinical trials in solid tumors, including glioblastoma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20135194",
                    "text": "The effects of the HDAC inhibitor vorinostat and SN38, which is the active metabolite of the topoisomerase I inhibitor CPT-11, was evaluated using the clonogenic assay.",
                    "offsetInBeginSection": 694,
                    "offsetInEndSection": 862,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19307505",
                    "text": "PURPOSE Vorinostat, a histone deacetylase inhibitor, represents a rational therapeutic target in glioblastoma multiforme (GBM).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086447",
                    "text": "Histone deacetylase inhibitors (HDACIs) represent a class of agents that can modulate gene expression to reduce tumor growth, and we and others have noted some antiglioma activity from HDACIs, such as vorinostat, although insufficient to warrant use as monotherapy.",
                    "offsetInBeginSection": 81,
                    "offsetInEndSection": 346,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22090453",
                    "text": "Vorinostat, a histone deacetylase (HDAC) inhibitor, has shown evidence of single-agent activity in glioblastoma (GBM), and in preclinical studies, we have demonstrated significant synergistic cytotoxicity between HDAC inhibitors and proteasome inhibitors in GBM cell lines.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 273,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24838514",
                    "text": "Multiple phase II trials with vorinostat in combination with targeted agents, temozolomide and radiotherapy are currently recruiting.",
                    "offsetInBeginSection": 1155,
                    "offsetInEndSection": 1288,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24838514",
                    "text": "Vorinostat is the most advanced HDAC inhibitor that entered clinical trials in glioblastoma, showing activity in recurrent disease.",
                    "offsetInBeginSection": 1023,
                    "offsetInEndSection": 1154,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19635146",
                    "text": "Ongoing and planned studies will further evaluate the potential of vorinostat in combination therapy, including combinations with radiation, in patients with diverse malignancy types, including non-small-cell lung cancer, glioblastoma multiforme, multiple myeloma, and myelodysplastic syndrome.",
                    "offsetInBeginSection": 1515,
                    "offsetInEndSection": 1809,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6a7869b750ff4455000028",
            "body": "Describe SNP2TFBS",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27899579",
                "http://www.ncbi.nlm.nih.gov/pubmed/25709171",
                "http://www.ncbi.nlm.nih.gov/pubmed/15861591",
                "http://www.ncbi.nlm.nih.gov/pubmed/15986475",
                "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                "http://www.ncbi.nlm.nih.gov/pubmed/8734268",
                "http://www.ncbi.nlm.nih.gov/pubmed/7516089",
                "http://www.ncbi.nlm.nih.gov/pubmed/25543586",
                "http://www.ncbi.nlm.nih.gov/pubmed/28800283",
                "http://www.ncbi.nlm.nih.gov/pubmed/23617612"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899579",
                    "text": "SNP2TFBS is also accessible over a web interface, enabling users to view the information provided for an individual SNP, to extract SNPs based on various search criteria, to annotate uploaded sets of SNPs or to display statistics about the frequencies of binding sites affected by selected SNPs.",
                    "offsetInBeginSection": 762,
                    "offsetInEndSection": 1057,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25709171",
                    "text": "We describe a rare, newly described syndrome with features of overgrowth and vascular malformations.",
                    "offsetInBeginSection": 113,
                    "offsetInEndSection": 213,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15861591",
                    "text": "Experience of SA-RPE using the simplified technique described by Pogrel et al is describe.",
                    "offsetInBeginSection": 585,
                    "offsetInEndSection": 675,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15986475",
                    "text": "Although initially used to describe a conversion disorder, early authors also recognized organic camptocormia occurring in old age, or \"camptocormie senile,\" as well as traumatic and arthritic camptocormia.",
                    "offsetInBeginSection": 67,
                    "offsetInEndSection": 273,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                    "text": "We describe first a field deployable mass spectrometer, based on an ion trap analyzer, and variants of that system.",
                    "offsetInBeginSection": 375,
                    "offsetInEndSection": 490,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                    "text": "We describe four sensing and characterization technologies recently developed at Los Alamos National Laboratory; a select set of mass spectral and optical techniques is emphasized.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                    "text": "We then describe a hand-held, battery-operated optical spectrometer, usable in either absorption, or fluorescence excitation mode.",
                    "offsetInBeginSection": 491,
                    "offsetInEndSection": 621,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8734268",
                    "text": "After describing the histopathology and the clinical characteristics of the lesion, we describe a most unusual atypical endolaryngeal location.",
                    "offsetInBeginSection": 263,
                    "offsetInEndSection": 406,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7516089",
                    "text": "We describe here the first case of unilateral, tubal twin pregnancy to be documented by ultrasound, with cardiac activity of two foetuses detected by the endovaginal probe.",
                    "offsetInBeginSection": 609,
                    "offsetInEndSection": 781,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23617612",
                    "text": "PURPOSE To describe a case of unilateral intracranial arachnoid cyst in association with enophthalmos and epiphora on the same side.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7706b79e632bc066000009",
            "body": "What is trismus?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/2090084",
                "http://www.ncbi.nlm.nih.gov/pubmed/26098612",
                "http://www.ncbi.nlm.nih.gov/pubmed/9063134",
                "http://www.ncbi.nlm.nih.gov/pubmed/24151558",
                "http://www.ncbi.nlm.nih.gov/pubmed/24985733",
                "http://www.ncbi.nlm.nih.gov/pubmed/23193958",
                "http://www.ncbi.nlm.nih.gov/pubmed/27627138",
                "http://www.ncbi.nlm.nih.gov/pubmed/22632890",
                "http://www.ncbi.nlm.nih.gov/pubmed/21794962",
                "http://www.ncbi.nlm.nih.gov/pubmed/22131672"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26098612",
                    "text": "The prevalence of trismus increases with increasing doses of RT to mastication structures.",
                    "offsetInBeginSection": 1121,
                    "offsetInEndSection": 1211,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26098612",
                    "text": "A mouth opening of 35 mm or less should be regarded as trismus.",
                    "offsetInBeginSection": 81,
                    "offsetInEndSection": 144,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26098612",
                    "text": "BACKGROUND Trismus indicates severely restricted mouth opening of any aetiology.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 80,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24151558",
                    "text": "Trismus pseudocamptodactyly syndrome is a very rare autosomal dominant inherited disorder characterized by the inability to completely open the mouth (trismus) and the presence of abnormally short tendon units causing the fingers to curve (camptodactyly).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 255,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23193958",
                    "text": "Trismus severely impairs HRQL and negatively affects daily life activities in patients with H&N cancer.",
                    "offsetInBeginSection": 1632,
                    "offsetInEndSection": 1735,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27627138",
                    "text": "BACKGROUND Trismus, a restricted mouth opening in head and neck cancer patients may be caused by tumor infiltration in masticatory muscles, radiation-induced fibrosis or scarring after surgery.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27627138",
                    "text": "Maximal mouth opening is a significant predictor for developing trismus at all time points.",
                    "offsetInBeginSection": 1627,
                    "offsetInEndSection": 1718,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22632890",
                    "text": "Trismus is frequently a sequel of temporomandibular joint (TMJ) involvement in a zygomaticomaxillary complex (ZMC) fracture.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 124,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21794962",
                    "text": "QoL variables showed that pain, eating, chewing, taste, saliva, social functioning, social contact, and dry mouth were significantly more impaired in the trismus group than among those without trismus.",
                    "offsetInBeginSection": 774,
                    "offsetInEndSection": 975,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22131672",
                    "text": "Trismus occurs most frequently in maxillectomy patient following surgical procedure.",
                    "offsetInBeginSection": 205,
                    "offsetInEndSection": 289,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a67ab79b750ff445500000b",
            "body": "CURB65 score is used for stratification of which disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28168816",
                "http://www.ncbi.nlm.nih.gov/pubmed/20920140",
                "http://www.ncbi.nlm.nih.gov/pubmed/18304365",
                "http://www.ncbi.nlm.nih.gov/pubmed/20529344",
                "http://www.ncbi.nlm.nih.gov/pubmed/16928720",
                "http://www.ncbi.nlm.nih.gov/pubmed/21539743",
                "http://www.ncbi.nlm.nih.gov/pubmed/24573987",
                "http://www.ncbi.nlm.nih.gov/pubmed/26186637",
                "http://www.ncbi.nlm.nih.gov/pubmed/21660535",
                "http://www.ncbi.nlm.nih.gov/pubmed/24931899"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20920140",
                    "text": "The CURB65 score was as effective in predicting early mortality in our cohort of acute COPD exacerbations as it was in previous cohorts with community acquired pneumonia.",
                    "offsetInBeginSection": 1509,
                    "offsetInEndSection": 1679,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20920140",
                    "text": "The CURB65 score was developed to predict mortality risk in community acquired pneumonia.",
                    "offsetInBeginSection": 228,
                    "offsetInEndSection": 317,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20529344",
                    "text": "METHODS We assessed clinical parameters and five biomarkers, the precursor levels of adrenomedullin (ADM), endothelin-1 (ET1), atrial-natriuretic peptide (ANP), anti-diuretic hormone (copeptin), and procalcitonin in patients with LRTI and CAP enrolled in the multicenter ProHOSP study.",
                    "offsetInBeginSection": 232,
                    "offsetInEndSection": 517,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743",
                    "text": "CONCLUSIONS The new CURB65-A risk score combining CURB65 risk classes with ProADM cut-off values accurately predicts adverse events and mortality in patients with CAP and non-CAP-LRTI.",
                    "offsetInBeginSection": 1744,
                    "offsetInEndSection": 1928,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743",
                    "text": "We aimed to derive a practical algorithm combining the CURB65 score with ProADM-levels in patients with community-acquired pneumonia (CAP) and non-CAP-LRTI.",
                    "offsetInBeginSection": 162,
                    "offsetInEndSection": 318,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743",
                    "text": "RESULTS CURB65 and ProADM predicted both adverse events and mortality similarly well in CAP and non-CAP-LRTI.",
                    "offsetInBeginSection": 658,
                    "offsetInEndSection": 767,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743",
                    "text": "The combined CURB65-A risk score provided better prediction of death and adverse events than the CURB65 score in the entire cohort and in CAP and non-CAP-LRTI patients.",
                    "offsetInBeginSection": 768,
                    "offsetInEndSection": 936,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743",
                    "text": "A composite score (CURB65-A) was created combining CURB65 classes with ProADM cut-offs to further risk-stratify patients.",
                    "offsetInBeginSection": 534,
                    "offsetInEndSection": 655,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743",
                    "text": "If outpatient treatment was recommended for CURB65-A risk class I and short hospitalization for CURB65-A risk class II, 17.9% and 40.8% of 1217 hospitalized patients could have received ambulatory treatment or a short hospitalization, respectively.",
                    "offsetInBeginSection": 1493,
                    "offsetInEndSection": 1741,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24931899",
                    "text": "CONCLUSION Presepsin is a valuable biomarker in predicting severity and outcome in CAP patients in the ED and Presepsin in combination with CURB65 score significantly enhanced the predictive accuracy.",
                    "offsetInBeginSection": 1704,
                    "offsetInEndSection": 1904,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6cfe27b750ff4455000029",
            "body": "What is SMiLE-seq?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28092692",
                "http://www.ncbi.nlm.nih.gov/pubmed/29122820",
                "http://www.ncbi.nlm.nih.gov/pubmed/27239334",
                "http://www.ncbi.nlm.nih.gov/pubmed/19429690",
                "http://www.ncbi.nlm.nih.gov/pubmed/19690166",
                "http://www.ncbi.nlm.nih.gov/pubmed/28964655",
                "http://www.ncbi.nlm.nih.gov/pubmed/11552760",
                "http://www.ncbi.nlm.nih.gov/pubmed/9918640",
                "http://www.ncbi.nlm.nih.gov/pubmed/22989151",
                "http://www.ncbi.nlm.nih.gov/pubmed/20877729"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692",
                    "text": "Here, we present a novel, semiautomated protein-DNA interaction characterization technology, selective microfluidics-based ligand enrichment followed by sequencing (SMiLE-seq).",
                    "offsetInBeginSection": 127,
                    "offsetInEndSection": 303,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692",
                    "text": "SMiLE-seq is neither limited by DNA bait length nor biased toward strong affinity binders; it probes the DNA-binding properties of TFs over a wide affinity range in a fast and cost-effective fashion.",
                    "offsetInBeginSection": 304,
                    "offsetInEndSection": 503,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692",
                    "text": "We validated SMiLE-seq by analyzing 58 full-length human, mouse, and Drosophila TFs from distinct structural classes.",
                    "offsetInBeginSection": 504,
                    "offsetInEndSection": 621,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19429690",
                    "text": "Moreover, SMILE interacts with specific HDACs (histone deacetylases) and SMILE-mediated repression is released by HDAC inhibitor trichostatin A, in a NR-specific manner.",
                    "offsetInBeginSection": 836,
                    "offsetInEndSection": 1005,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19429690",
                    "text": "SMILE (small heterodimer partner interacting leucine zipper protein) has been identified as a coregulator in ER signaling.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19429690",
                    "text": "Adenoviral overexpression of SMILE represses GR-, CAR- and HNF4 alpha-mediated target gene expression.",
                    "offsetInBeginSection": 1131,
                    "offsetInEndSection": 1233,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19690166",
                    "text": "SMILE (small heterodimer partner interacting leucine zipper protein) has been identified as a corepressor of the glucocorticoid receptor, constitutive androstane receptor, and hepatocyte nuclear factor 4alpha.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19690166",
                    "text": "Interestingly, the repression of SMILE on ERRgamma is released by SIRT1 inhibitors, a catalytically inactive SIRT1 mutant, and SIRT1 small interfering RNA but not by histone protein deacetylase inhibitor.",
                    "offsetInBeginSection": 645,
                    "offsetInEndSection": 849,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19690166",
                    "text": "Overall, these findings implicate SMILE as a novel corepressor of ERRgamma and recruitment of SIRT1 as a novel repressive mechanism for SMILE and ERRgamma inverse agonist.",
                    "offsetInBeginSection": 1641,
                    "offsetInEndSection": 1812,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20877729",
                    "text": "The five smiles with each the highest and lowest scores were analyzed for seven parameters: buccal corridor, smile index, smile symmetry, smile line ratio, upper lip line, smile arc, and upper lip curvature.",
                    "offsetInBeginSection": 296,
                    "offsetInEndSection": 503,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a77072c9e632bc06600000a",
            "body": "What is craniosynostosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24071792",
                "http://www.ncbi.nlm.nih.gov/pubmed/27159853",
                "http://www.ncbi.nlm.nih.gov/pubmed/17980312",
                "http://www.ncbi.nlm.nih.gov/pubmed/27622416",
                "http://www.ncbi.nlm.nih.gov/pubmed/15828709",
                "http://www.ncbi.nlm.nih.gov/pubmed/27226847",
                "http://www.ncbi.nlm.nih.gov/pubmed/28654618",
                "http://www.ncbi.nlm.nih.gov/pubmed/24364243",
                "http://www.ncbi.nlm.nih.gov/pubmed/28060197",
                "http://www.ncbi.nlm.nih.gov/pubmed/26910679"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24071792",
                    "text": "RESULTS The incidence rate of craniosynostosis was highest for first-degree relatives of probands with metopic craniosynostosis (6.4%), followed by those with complex craniosynostosis (4.9%), sagittal craniosynostosis (3.8%), lambdoid craniosynostosis (3.9%), and coronal craniosynostosis (0.7%).",
                    "offsetInBeginSection": 457,
                    "offsetInEndSection": 753,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27622416",
                    "text": "Prenatal ultrasound`s detection rate of craniosynostosis is low.",
                    "offsetInBeginSection": 735,
                    "offsetInEndSection": 799,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15828709",
                    "text": "Nonsyndromic craniosynostosis is usually confined to cranial changes.",
                    "offsetInBeginSection": 334,
                    "offsetInEndSection": 403,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27226847",
                    "text": "FGFR2, FGFR3, FGFR1, TWIST1 and EFNB1 genes are major causative genes of genetic syndromes associated with craniosynostosis.",
                    "offsetInBeginSection": 632,
                    "offsetInEndSection": 756,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28654618",
                    "text": "When anomalies outside the skull are present, craniosynostosis is often part of a syndrome and usually involves multiple sutures (syndromic craniosynostosis).",
                    "offsetInBeginSection": 1017,
                    "offsetInEndSection": 1175,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24364243",
                    "text": "Among non-syndromic monosynostosis sagittal craniosynostosis (scaphocephaly) is the most common.",
                    "offsetInBeginSection": 91,
                    "offsetInEndSection": 187,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24364243",
                    "text": "Endoscopic method refers to minimally invasive technique in surgical correction of craniosynostosis.",
                    "offsetInBeginSection": 266,
                    "offsetInEndSection": 366,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28060197",
                    "text": "The role of fibroblast growth factor receptor (FGFR) mutations in the etiology of certain eponymous forms of craniosynostosis is now well elucidated; the most common syndromes associated with craniosynostosis are Pfeifer (FGFR1, FGFR2), Apert (FGFR2), Crouzon (FGFR2), Saethre-Chotzen (TWIST1), Jackson-Weiss (FGFR2), Greig (GL13), and Muenke (FGFR3) syndromes.",
                    "offsetInBeginSection": 289,
                    "offsetInEndSection": 650,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26910679",
                    "text": "Among various craniosynostosis forms, sagittal nonsyndromic craniosynostosis is the most prevalent.",
                    "offsetInBeginSection": 114,
                    "offsetInEndSection": 213,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26910679",
                    "text": "FGFR1-3 mutational hotspots and the entire TWIST1, RAB23, and BMP2 coding regions were screened because of their known roles in human nonsyndromic or syndromic sagittal craniosynostosis, expression patterns, and/or animal model studies.",
                    "offsetInBeginSection": 615,
                    "offsetInEndSection": 851,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a67b152b750ff445500000e",
            "body": "Describe nursemaid's elbow injury.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19657259",
                "http://www.ncbi.nlm.nih.gov/pubmed/27294496",
                "http://www.ncbi.nlm.nih.gov/pubmed/21317693",
                "http://www.ncbi.nlm.nih.gov/pubmed/11153321",
                "http://www.ncbi.nlm.nih.gov/pubmed/7773660",
                "http://www.ncbi.nlm.nih.gov/pubmed/7560033",
                "http://www.ncbi.nlm.nih.gov/pubmed/24276229",
                "http://www.ncbi.nlm.nih.gov/pubmed/20971397",
                "http://www.ncbi.nlm.nih.gov/pubmed/19468873",
                "http://www.ncbi.nlm.nih.gov/pubmed/12093966"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19657259",
                    "text": "Activities such as swinging a child by the hands or pulling on the pronated upper extremity can cause nursemaid's elbow.",
                    "offsetInBeginSection": 324,
                    "offsetInEndSection": 444,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19657259",
                    "text": "Nursemaid's elbow is a common injury in young children that can often be prevented.",
                    "offsetInBeginSection": 144,
                    "offsetInEndSection": 227,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27294496",
                    "text": "This article also reviews successful reduction maneuvers for nursemaid's elbow.",
                    "offsetInBeginSection": 803,
                    "offsetInEndSection": 882,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27294496",
                    "text": "Nursemaid's elbow and elbow fractures are both common causes of acute elbow pain, but the mechanism of injury is quite different.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21317693",
                    "text": "Nursemaid's elbow (subluxation of the radial head) is a common pediatric upper extremity injury encountered in the emergency and urgent care settings.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 150,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11153321",
                    "text": "Nursemaid's elbow, also known as a pulled elbow or a subluxated radial head, may result from the specific activities described above and is the most common dislocation injury handled by pediatricians.",
                    "offsetInBeginSection": 520,
                    "offsetInEndSection": 720,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7773660",
                    "text": "Subluxation of the radial head, or \"nursemaid's elbow,\" is a common injury among children aged 1 to 4 years.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7560033",
                    "text": "Acute annular ligament interposition into the radiocapitellar joint (\"nursemaid's elbow\") is a common injury in children younger than 5 years.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19468873",
                    "text": "Youth baseball pitchers and throwers are particularly at risk for overuse injuries of the elbow, most of which are related to an injury mechanism termed \"valgus extension overload\".",
                    "offsetInBeginSection": 427,
                    "offsetInEndSection": 608,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12093966",
                    "text": "Annular ligament displacement (ALD)--also termed radial head subluxation, nursemaid's elbow, or pulled elbow--can be successfully diagnosed and treated over the telephone by properly trained medical professionals instructing nonmedical caretakers.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 247,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6d08d5b750ff445500002c",
            "body": "Which stapled peptide has been designed to target Ctf4?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28815832",
                "http://www.ncbi.nlm.nih.gov/pubmed/25848797",
                "http://www.ncbi.nlm.nih.gov/pubmed/26673461",
                "http://www.ncbi.nlm.nih.gov/pubmed/28496125",
                "http://www.ncbi.nlm.nih.gov/pubmed/25921752",
                "http://www.ncbi.nlm.nih.gov/pubmed/26159518",
                "http://www.ncbi.nlm.nih.gov/pubmed/25084543",
                "http://www.ncbi.nlm.nih.gov/pubmed/27397685",
                "http://www.ncbi.nlm.nih.gov/pubmed/27057630",
                "http://www.ncbi.nlm.nih.gov/pubmed/24336354"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832",
                    "text": "Herein, we report the design, optimization, and validation of double-click stapled peptides encoding the Ctf4-interacting peptide (CIP) of the replicative helicase subunit Sld5.",
                    "offsetInBeginSection": 313,
                    "offsetInEndSection": 490,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832",
                    "text": "By screening stapling positions in the Sld5 CIP, we identified an unorthodox i,i+6 stapled peptide with improved, submicromolar binding to Ctf4.",
                    "offsetInBeginSection": 491,
                    "offsetInEndSection": 635,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832",
                    "text": "The mode of interaction with Ctf4 was confirmed by a crystal structure of the stapled Sld5 peptide bound to Ctf4.",
                    "offsetInBeginSection": 636,
                    "offsetInEndSection": 749,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832",
                    "text": "The stapled Sld5 peptide was able to displace the Ctf4 partner DNA polymerase\u2005\u03b1 from the replisome in yeast extracts.",
                    "offsetInBeginSection": 750,
                    "offsetInEndSection": 870,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832",
                    "text": "The Ctf4/AND-1 protein hub, which links DNA replication, repair, and chromosome segregation, represents a novel target for the synthetic lethality approach.",
                    "offsetInBeginSection": 156,
                    "offsetInEndSection": 312,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25921752",
                    "text": "Six all-hydrocarbon-stapled Cdt1 MBD-derived peptides have been designed and synthesized to perturb the Cdt1-Mcm6 interaction, which is involved in DNA replication.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 164,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27397685",
                    "text": "Here, we identify new Ctf4 partners in\u00a0addition to Pol \u03b1 and helicase, all of which contain a \"Ctf4-interacting-peptide\" or CIP-box.",
                    "offsetInBeginSection": 266,
                    "offsetInEndSection": 400,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27057630",
                    "text": "Our results demonstrate both the high level of structural p53 mimicry employed by PM2 to engage HDM2, and the potential resilience of stapled peptide antagonists to mutations in target proteins.",
                    "offsetInBeginSection": 1038,
                    "offsetInEndSection": 1232,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27057630",
                    "text": "Interrogation of a large collection of randomly mutated HDM2 proteins failed to identify point mutations that could selectively abrogate binding by a stapled peptide inhibitor (PM2).",
                    "offsetInBeginSection": 671,
                    "offsetInEndSection": 853,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24336354",
                    "text": "Stapled peptides represent an emerging class of therapeutics that can target protein: protein interactions.",
                    "offsetInBeginSection": 267,
                    "offsetInEndSection": 374,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a773c50faa1ab7d2e000002",
            "body": "Has ATF4 transcription factor been linked to cancer and neoplastic transformation?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22102693",
                "http://www.ncbi.nlm.nih.gov/pubmed/21338441",
                "http://www.ncbi.nlm.nih.gov/pubmed/26961881",
                "http://www.ncbi.nlm.nih.gov/pubmed/12213216",
                "http://www.ncbi.nlm.nih.gov/pubmed/14695187",
                "http://www.ncbi.nlm.nih.gov/pubmed/8601634",
                "http://www.ncbi.nlm.nih.gov/pubmed/14500907",
                "http://www.ncbi.nlm.nih.gov/pubmed/17466566",
                "http://www.ncbi.nlm.nih.gov/pubmed/21915330",
                "http://www.ncbi.nlm.nih.gov/pubmed/9119878"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693",
                    "text": "Here, we report that ATF4 promotes oncogene-induced neoplastic transformation by suppressing the expression of cellular senescence-associated genes.",
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 409,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693",
                    "text": "Many cancers overexpress ATF4, a stress-induced transcription factor that promotes cell survival under hypoxic conditions and other stresses of the tumor microenvironment, but the potential contributions of ATF4 to oncogenesis itself have been little explored.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 260,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21338441",
                    "text": "These include mitogen-activated protein kinase kinase (MAPKK), CCAAT/enhancer-binding protein (C/EBP), activating transcription factor 4 (ATF4) and C/EBP-homologous protein (CHOP).",
                    "offsetInBeginSection": 234,
                    "offsetInEndSection": 414,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26961881",
                    "text": "In Per2 mutant and Cry1/2-null cells, the introduction of oncogenes induced expression of ATF4, a potent repressor of cell senescence-associated proteins p16INK4a and p19ARF.",
                    "offsetInBeginSection": 1001,
                    "offsetInEndSection": 1175,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12213216",
                    "text": "H-ras transformation of MCF-10a cells resulted in upregulation of MAP kinase and PI 3-kinase signals, upregulation of sterol regulatory element binding protein 1 (SREBP-1) transcription factor levels, and upregulation of FAS expression and FA synthesis.",
                    "offsetInBeginSection": 659,
                    "offsetInEndSection": 912,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14500907",
                    "text": "The Polycomb Group Protein EZH2 is a transcriptional repressor involved in controlling cellular memory and has been linked to aggressive prostate cancer.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17466566",
                    "text": "ATF4 expression is upregulated in cancer.",
                    "offsetInBeginSection": 971,
                    "offsetInEndSection": 1012,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17466566",
                    "text": "Activating transcription factor 4 (ATF4) belongs to the ATF/CREB (activating transcription factor/cyclic AMP response element binding protein) family of basic region-leucine zipper (bZip) transcription factors, which have the consensus binding site cAMP responsive element (CRE).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 279,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21915330",
                    "text": "These data suggest that distinct shifts of the HPV 16 methylome are linked to differentiation dependent transcription and replication control and may trigger neoplastic transformation.",
                    "offsetInBeginSection": 1587,
                    "offsetInEndSection": 1771,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9119878",
                    "text": "It should be considered that some HMG proteins, acting as architectural proteins that bring many of the transcription factors into precise three-dimensional shapes, may have a similar critical role in neoplastic transformation to that of some transcription factors themselves.",
                    "offsetInBeginSection": 802,
                    "offsetInEndSection": 1078,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a68eabab750ff4455000015",
            "body": "Is there an association between Klinefelter syndrome and breast cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/3111653",
                "http://www.ncbi.nlm.nih.gov/pubmed/22274665",
                "http://www.ncbi.nlm.nih.gov/pubmed/16106025",
                "http://www.ncbi.nlm.nih.gov/pubmed/21246928",
                "http://www.ncbi.nlm.nih.gov/pubmed/7841064",
                "http://www.ncbi.nlm.nih.gov/pubmed/11976824",
                "http://www.ncbi.nlm.nih.gov/pubmed/9283592",
                "http://www.ncbi.nlm.nih.gov/pubmed/23464700",
                "http://www.ncbi.nlm.nih.gov/pubmed/20698148",
                "http://www.ncbi.nlm.nih.gov/pubmed/1690312"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16106025",
                    "text": "CONCLUSIONS These results support a hormonal etiology for breast cancer in men and for prostate cancer and suggest that men with Klinefelter syndrome may be at substantially elevated risks for non-Hodgkin lymphoma, breast cancer, and, perhaps, lung cancer.",
                    "offsetInBeginSection": 1368,
                    "offsetInEndSection": 1624,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16106025",
                    "text": "Compared with the general population, men with Klinefelter syndrome had higher mortality from lung cancer (SMR = 1.5, 95% CI = 1.0 to 2.0), breast cancer (SMR = 57.8, 95% CI = 18.8 to 135.0), and non-Hodgkin lymphoma (SMR = 3.5, 95% CI = 1.6 to 6.6) and lower mortality from prostate cancer (SMR = 0, 95% CI = 0 to 0.7).",
                    "offsetInBeginSection": 737,
                    "offsetInEndSection": 1057,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21246928",
                    "text": "Klinefelter syndrome has been consistently associated with breast cancer in men (MBC).",
                    "offsetInBeginSection": 109,
                    "offsetInEndSection": 195,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21246928",
                    "text": "Klinefelter syndrome, in which patients carry XXY chromosome, may be present in men with breast cancer for this reason they often develop gynecomastia.",
                    "offsetInBeginSection": 1285,
                    "offsetInEndSection": 1436,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7841064",
                    "text": "Many case reports have suggested an association between Klinefelter syndrome (KS) and cancer, but studies of the cancer incidence in larger groups of men with KS are lacking.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11976824",
                    "text": "Since the early 1960s, numerous reports have appeared of an increased risk of malignant neoplasms among patients with Klinefelter syndrome.",
                    "offsetInBeginSection": 439,
                    "offsetInEndSection": 578,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9283592",
                    "text": "Patients with a 47,XXY karyotype (Klinefelter syndrome) appear to have an increased risk of developing cancer, especially male breast cancer and germ cell tumors, but rarely malignant hematologic disorders.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 206,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23464700",
                    "text": "Male breast cancer risk factors show strong association with BRCA2 mutations, as well as Klinefelter syndrome.",
                    "offsetInBeginSection": 418,
                    "offsetInEndSection": 528,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20698148",
                    "text": "Patients with 47, XXY karyotype (Klinefelter syndrome) appear to have increased risk of developing cancer, especially male breast cancer, germ cell tumours and non Hodgkin lymphomas, but rarely acute myeloid leukaemia.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 218,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1690312",
                    "text": "While the association of Klinefelter's syndrome and breast cancer is well known, only recently an increased incidence of mediastinal germ cell tumors in this syndrome has been established, which again is demonstrated in this case report.",
                    "offsetInBeginSection": 285,
                    "offsetInEndSection": 522,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6d1733b750ff4455000030",
            "body": "Which resource contains accurate enhancer predictions in the developing limb?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28827824",
                "http://www.ncbi.nlm.nih.gov/pubmed/22077990",
                "http://www.ncbi.nlm.nih.gov/pubmed/21347315",
                "http://www.ncbi.nlm.nih.gov/pubmed/29159193",
                "http://www.ncbi.nlm.nih.gov/pubmed/21637758",
                "http://www.ncbi.nlm.nih.gov/pubmed/24995410",
                "http://www.ncbi.nlm.nih.gov/pubmed/15212693",
                "http://www.ncbi.nlm.nih.gov/pubmed/22080555",
                "http://www.ncbi.nlm.nih.gov/pubmed/2226209",
                "http://www.ncbi.nlm.nih.gov/pubmed/26091399"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824",
                    "text": "Here we present the Limb-Enhancer Genie (LEG), a collection of highly accurate, genome-wide predictions of enhancers in the developing limb, available through a user-friendly online interface.",
                    "offsetInBeginSection": 415,
                    "offsetInEndSection": 607,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824",
                    "text": "We predict limb enhancers using a combination of >50 published limb-specific datasets and clusters of evolutionarily conserved transcription factor binding sites, taking advantage of the patterns observed at previously in vivo validated elements.",
                    "offsetInBeginSection": 608,
                    "offsetInEndSection": 854,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824",
                    "text": "Moreover, we describe general features that can guide the type of datasets to include when predicting tissue-specific enhancers genome-wide, while providing an accessible resource to the general biological community and facilitating the functional interpretation of genetic studies of limb malformations.",
                    "offsetInBeginSection": 1285,
                    "offsetInEndSection": 1589,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21347315",
                    "text": "To overcome this problem, we develop a novel computational method that combines accurate quantification of 2D limb bud morphologies and growth modeling to analyze mouse clonal data of early limb development.",
                    "offsetInBeginSection": 559,
                    "offsetInEndSection": 766,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29159193",
                    "text": "While further work is needed to potentially incorporate sensory and cognitive factors, the algorithm can be used within days of stroke to provide accurate predictions of upper limb functional outcomes at 3\u00a0months after stroke.",
                    "offsetInBeginSection": 1451,
                    "offsetInEndSection": 1678,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15212693",
                    "text": "CONCLUSION Phospho.ELM will be a valuable tool both for molecular biologists working on protein phosphorylation sites and for bioinformaticians developing computational predictions on the specificity of phosphorylation reactions.",
                    "offsetInBeginSection": 1247,
                    "offsetInEndSection": 1476,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2226209",
                    "text": "Most models for the specification of the skeletal elements in the developing limb bud are based on a chemical specification well before overt cartilage differentiation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 168,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2226209",
                    "text": "The models thus make quite different predictions as to when the rudiments are specified.",
                    "offsetInBeginSection": 348,
                    "offsetInEndSection": 436,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26091399",
                    "text": "Integrating shape features with a machine-learning algorithm AdaBoost, we developed an enhancer predicting method, DELTA (Distal Enhancer Locating Tool based on AdaBoost).",
                    "offsetInBeginSection": 721,
                    "offsetInEndSection": 892,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26091399",
                    "text": "We show that DELTA significantly outperforms current enhancer prediction methods in prediction accuracy on different datasets and can predict enhancers in one cell type using models trained in other cell types without loss of accuracy.",
                    "offsetInBeginSection": 893,
                    "offsetInEndSection": 1128,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7877c0faa1ab7d2e00000c",
            "body": "What is the first line treatment for sarcoidosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26357609",
                "http://www.ncbi.nlm.nih.gov/pubmed/26419478",
                "http://www.ncbi.nlm.nih.gov/pubmed/26478443",
                "http://www.ncbi.nlm.nih.gov/pubmed/28696638",
                "http://www.ncbi.nlm.nih.gov/pubmed/26120005",
                "http://www.ncbi.nlm.nih.gov/pubmed/23196575",
                "http://www.ncbi.nlm.nih.gov/pubmed/16536004",
                "http://www.ncbi.nlm.nih.gov/pubmed/26330764",
                "http://www.ncbi.nlm.nih.gov/pubmed/24151828",
                "http://www.ncbi.nlm.nih.gov/pubmed/27846819"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357609",
                    "text": "For symptomatic patients, the first line treatment includes corticosteroids or ursodeoxycholic acid.",
                    "offsetInBeginSection": 892,
                    "offsetInEndSection": 992,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26419478",
                    "text": "While corticosteroids remain the first line of treatment, tumour necrosis factor alpha (TNF-\u03b1) inhibitors have been investigated as one potential steroid sparing treatment for sarcoidosis.",
                    "offsetInBeginSection": 122,
                    "offsetInEndSection": 311,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26419478",
                    "text": "Paradoxically, in some patients treated with biologic TNF-\u03b1 inhibitors for other diseases, treatment can induce the development of sarcoidosis.",
                    "offsetInBeginSection": 541,
                    "offsetInEndSection": 685,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28696638",
                    "text": "Systemic corticosteroids are the first line treatment in sarcoidosis.",
                    "offsetInBeginSection": 323,
                    "offsetInEndSection": 392,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26120005",
                    "text": "This case reports a rare presentation of preschool sarcoidosis as well as the novel and successful use of pulse methylprednisolone in paediatric pulmonary sarcoidosis.",
                    "offsetInBeginSection": 505,
                    "offsetInEndSection": 672,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23196575",
                    "text": "For patients who are refractory to or intolerant of corticosteroid therapy, second-line agents include azathioprine, methotrexate, cyclosporine, cyclophosphamide, and mycophenolate mofetil (MMF).",
                    "offsetInBeginSection": 1008,
                    "offsetInEndSection": 1203,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16536004",
                    "text": "Corticosteroids are still the first-line treatment, but alternative therapy with anti-TNF agents, like pentoxifylline, thalidomide and anti-TNF monoclonal antibodies become more interesting, especially in refractory sarcoidosis.",
                    "offsetInBeginSection": 299,
                    "offsetInEndSection": 527,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26330764",
                    "text": "Rituximab is an anti-CD20 chimeric monoclonal antibody, currently used for the treatment of B cell malignancies and systemic autoimmune diseases.",
                    "offsetInBeginSection": 329,
                    "offsetInEndSection": 474,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26330764",
                    "text": "Provided that steroids represent the gold standard as a first line treatment, many immune suppressants drugs are currently used in the disease management.",
                    "offsetInBeginSection": 118,
                    "offsetInEndSection": 272,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24151828",
                    "text": "Methotrexate is considered by many to be the first choice drug in second-line therapeutics of sarcoidosis.",
                    "offsetInBeginSection": 393,
                    "offsetInEndSection": 499,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a68f005b750ff4455000016",
            "body": "Which personality disorder is treated using dialectical behavior therapy?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16173357",
                "http://www.ncbi.nlm.nih.gov/pubmed/17496179",
                "http://www.ncbi.nlm.nih.gov/pubmed/27642799",
                "http://www.ncbi.nlm.nih.gov/pubmed/7977884",
                "http://www.ncbi.nlm.nih.gov/pubmed/20579633",
                "http://www.ncbi.nlm.nih.gov/pubmed/18186120",
                "http://www.ncbi.nlm.nih.gov/pubmed/15930077",
                "http://www.ncbi.nlm.nih.gov/pubmed/9603574",
                "http://www.ncbi.nlm.nih.gov/pubmed/26160623",
                "http://www.ncbi.nlm.nih.gov/pubmed/25373068"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16173357",
                    "text": "Treatment outcome data for Dialectical Behavior Therapy of borderline personality disorder and Trauma Model Therapy of dissociative identity disorder are reviewed.",
                    "offsetInBeginSection": 177,
                    "offsetInEndSection": 340,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17496179",
                    "text": "OBJECTIVE The authors describe the use of dialectical behavior therapy (DBT) in treating borderline personality disorder during psychiatry residency, and assess the status of DBT education within psychiatry residencies in the United States.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 240,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27642799",
                    "text": "Dialectical behavior therapy (DBT) was originally developed by Marsha Linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, DBT is also increasingly being recommended for the treatment of CD and APD.",
                    "offsetInBeginSection": 343,
                    "offsetInEndSection": 646,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7977884",
                    "text": "CONCLUSIONS These results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder.",
                    "offsetInBeginSection": 882,
                    "offsetInEndSection": 1106,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20579633",
                    "text": "A central component of Dialectical Behavior Therapy (DBT) is the teaching of specific behavioral skills with the aim of helping individuals with Borderline Personality Disorder (BPD) replace maladaptive behaviors with skillful behavior.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 236,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18186120",
                    "text": "Dialectical behavior therapy (DBT) was originally designed as a treatment of emotionally dysregulated, impulsive, and dramatic disorders (e.g., borderline personality disorder) and populations (e.g., parasuicidal women).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 220,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15930077",
                    "text": "OBJECTIVE The aim of this study was to determine the efficacy and safety of dialectical behavior therapy plus olanzapine compared with dialectical behavior therapy plus placebo in patients with borderline personality disorder.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 226,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9603574",
                    "text": "Dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 201,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26160623",
                    "text": "Dialectical Behavior Therapy (DBT) and Mentalization-Based Treatment (MBT) are two approaches to the treatment of borderline personality disorder (BPD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 152,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25373068",
                    "text": "CONTEXT Dialectical Behavior Therapy (DBT) is an evidence-based therapy developed for the treatment of suicidal behaviors and disorders characterized by emotional and behavioral dyscontrol that is effective in veteran populations.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 230,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6d186db750ff4455000031",
            "body": "Is there any role of Dlx1 and Dlx2 transcription factors in cortical interneurons?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29028947",
                "http://www.ncbi.nlm.nih.gov/pubmed/17259176",
                "http://www.ncbi.nlm.nih.gov/pubmed/16766712",
                "http://www.ncbi.nlm.nih.gov/pubmed/28821666",
                "http://www.ncbi.nlm.nih.gov/pubmed/17582322",
                "http://www.ncbi.nlm.nih.gov/pubmed/19026749",
                "http://www.ncbi.nlm.nih.gov/pubmed/12724837",
                "http://www.ncbi.nlm.nih.gov/pubmed/24735821",
                "http://www.ncbi.nlm.nih.gov/pubmed/10934256",
                "http://www.ncbi.nlm.nih.gov/pubmed/17678855"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028947",
                    "text": "The postnatal functions of the Dlx1&2 transcription factors in cortical interneurons (CINs) are unknown.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 104,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17259176",
                    "text": "Dlx1/Dlx2 null mice die at birth with an abnormal cortical phenotype, including impaired differentiation and migration of GABAergic interneurons to the neocortex.",
                    "offsetInBeginSection": 79,
                    "offsetInEndSection": 241,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17259176",
                    "text": "This is the first report that DLX1 or DLX2 can function as transcriptional repressors.",
                    "offsetInBeginSection": 967,
                    "offsetInEndSection": 1053,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16766712",
                    "text": "Toward elucidating the mechanisms underlying the generation of interneuron diversity, we have studied in mice the expression patterns in differentiating and mature neocortical interneurons of 8 transcription factors, including 6 homeobox (Dlx1, Dlx2, Dlx5, Arx, Lhx6, Cux2), 1 basic helix-loop-helix, (NPAS1), and 1 bZIP (MafB).",
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 589,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28821666",
                    "text": "DLX1 and/or DLX2 activated the transcription of both Gad genes, and defects in Dlx function disrupted the differentiation of GABAergic interneurons with global reduction in GABA levels in the forebrains of the Dlx1/Dlx2 double knock-out mouse in vivo Identification of Gad genes as direct Dlx transcriptional targets is significant; it extends our understanding of Dlx gene function in the developing forebrain beyond the regulation of tangential interneuron migration to the differentiation of GABAergic interneurons arising from the basal telencephalon, and may help to unravel the pathogenesis of several developmental brain disorders.SIGNIFICANCE STATEMENT GABA is the major inhibitory neurotransmitter in the brain.",
                    "offsetInBeginSection": 1014,
                    "offsetInEndSection": 1734,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28821666",
                    "text": "We have discovered that specific promoter regulatory elements of glutamic acid decarboxylase isoforms (Gad1 and Gad2), which regulate GABA synthesis from the excitatory neurotransmitter glutamate, are direct transcriptional targets of both DLX1 and DLX2 homeoproteins in vivo Further gain- and loss-of-function studies in vitro and in vivo demonstrated that both DLX1 and DLX2 are necessary and sufficient for Gad gene expression.",
                    "offsetInBeginSection": 583,
                    "offsetInEndSection": 1013,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17582322",
                    "text": "In this issue of Neuron, Rubenstein and colleagues demonstrate that the homeobox proteins Dlx1 and Dlx2 promote interneuron migration in part by preventing the premature expression of PAK3, a serine/threonine kinase that is later involved in neurite outgrowth and other aspects of interneuron maturation.",
                    "offsetInBeginSection": 172,
                    "offsetInEndSection": 476,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026749",
                    "text": "DLX1 and DLX2 transcription factors are necessary for forebrain GABAergic neuron differentiation, migration, and survival.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12724837",
                    "text": "Our results support a possible role for Dlx1 and Dlx2 in inner retinal development and in the terminal differentiation and/or maintenance of INL interneurons and ganglion cells in the adult.",
                    "offsetInBeginSection": 1206,
                    "offsetInEndSection": 1396,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10934256",
                    "text": "Similar analysis of mice lacking the Mash1 basic helix-loop-helix (bHLH) or both the Dlx1 and Dlx2 homeodomain transcription factors demonstrates that these genes are required for the differentiation of striatal interneurons.",
                    "offsetInBeginSection": 1083,
                    "offsetInEndSection": 1308,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a79d0b8faa1ab7d2e00000d",
            "body": "What cellular process are okazaki fragments associated with?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19779567",
                "http://www.ncbi.nlm.nih.gov/pubmed/21278448",
                "http://www.ncbi.nlm.nih.gov/pubmed/23729670",
                "http://www.ncbi.nlm.nih.gov/pubmed/20178844",
                "http://www.ncbi.nlm.nih.gov/pubmed/12228807",
                "http://www.ncbi.nlm.nih.gov/pubmed/12806117",
                "http://www.ncbi.nlm.nih.gov/pubmed/227871",
                "http://www.ncbi.nlm.nih.gov/pubmed/24035200",
                "http://www.ncbi.nlm.nih.gov/pubmed/9121462",
                "http://www.ncbi.nlm.nih.gov/pubmed/23451868"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19779567",
                    "text": "We propose that TbPIF5 unwinds RNA primers after lagging strand synthesis, thus facilitating processing of Okazaki fragments.",
                    "offsetInBeginSection": 1315,
                    "offsetInEndSection": 1440,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448",
                    "text": "Therefore, efficient processing of Okazaki fragments is vital for DNA replication and cell proliferation.",
                    "offsetInBeginSection": 263,
                    "offsetInEndSection": 368,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12228807",
                    "text": "These include temperature sensitivity, Okazaki fragment processing, a mutator phenotype, a G2/M cell cycle arrest, minichromosome loss, and methyl methane sulfonate sensitivity.",
                    "offsetInBeginSection": 967,
                    "offsetInEndSection": 1144,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12228807",
                    "text": "RNA primer removal from Okazaki fragments during lagging-strand replication and the excision of damaged DNA bases requires the action of structure-specific nucleases, such as the mammalian flap endonuclease 1 (FEN-1).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 217,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12806117",
                    "text": "Because of this peculiarity the major role of the DNA polymerase alpha-primase complex (pol-prim) is in the initiation of DNA replication at chromosomal origins and in the discontinuous synthesis of Okazaki fragments on the lagging strand of the replication fork.",
                    "offsetInBeginSection": 274,
                    "offsetInEndSection": 537,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/227871",
                    "text": "These intermediates accumulated during excision of RNA primers in the presence of adenine 9-beta-D-arabinoside 5'-triphosphate, and those Okazaki fragments blocked by RNA primers (class III) were found to have originated the farthest from the 5' ends of long nascent DNA strands.",
                    "offsetInBeginSection": 2359,
                    "offsetInEndSection": 2638,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/227871",
                    "text": "However, when washed nuclei were incubated in the abscence of cytosol, both class I and class II Okazaki fragments accumulated despite the excision of RNA primers: class III Okazaki fragments and RNA-DNA covalent linkages both disappeared at similar rates.",
                    "offsetInBeginSection": 1172,
                    "offsetInEndSection": 1428,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24035200",
                    "text": "Lagging strand DNA replication requires the concerted actions of DNA polymerase \u03b4, Fen1 and DNA ligase I for the removal of the RNA/DNA primers before ligation of Okazaki fragments.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 182,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9121462",
                    "text": "FEN-1 is implicated in DNA replication and repair in yeast, and the mammalian homolog of yFEN-1 (DNase IV, FEN-1, or MF1) participates in Okazaki fragment maturation.",
                    "offsetInBeginSection": 218,
                    "offsetInEndSection": 384,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23451868",
                    "text": "Substrate specificity allows FEN1 to process intermediates of Okazaki fragment maturation, long-patch base excision repair, telomere maintenance, and stalled replication fork rescue.",
                    "offsetInBeginSection": 206,
                    "offsetInEndSection": 388,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a68f633b750ff4455000019",
            "body": "Is creatinine assessment included in the MELD score?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15482344",
                "http://www.ncbi.nlm.nih.gov/pubmed/27480755",
                "http://www.ncbi.nlm.nih.gov/pubmed/22380485",
                "http://www.ncbi.nlm.nih.gov/pubmed/24601755",
                "http://www.ncbi.nlm.nih.gov/pubmed/23293714",
                "http://www.ncbi.nlm.nih.gov/pubmed/28628497",
                "http://www.ncbi.nlm.nih.gov/pubmed/20827408",
                "http://www.ncbi.nlm.nih.gov/pubmed/15545175",
                "http://www.ncbi.nlm.nih.gov/pubmed/19892752",
                "http://www.ncbi.nlm.nih.gov/pubmed/17370333"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344",
                    "text": "The MELD score has a short-term prognostic yield that is better than what is provided by both the CTP and CTP creatinine-modified scores, even in cirrhotic patients who are not critically ill.",
                    "offsetInBeginSection": 1912,
                    "offsetInEndSection": 2104,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344",
                    "text": "However, the MELD score proved to be better at defining patients' prognosis in the short-term as compared with both the traditional CTP score (P=0.012) and the creatinine-modified CTP (P=0.047).",
                    "offsetInBeginSection": 1404,
                    "offsetInEndSection": 1598,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24601755",
                    "text": "The MELD-Bicarbonate equation, which included three variables (international normalized ratio, creatinine level, and HCO3 level), showed better prognostic value than the original MELD score in critically ill patients with cirrhosis.",
                    "offsetInBeginSection": 1362,
                    "offsetInEndSection": 1594,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23293714",
                    "text": "CONCLUSION Incorporating eGFR obtained by the 6-variable MDRD equation into the MELD score showed an equal predictive performance in in-hospital mortality compared to a creatinine-based MELD score.",
                    "offsetInBeginSection": 3159,
                    "offsetInEndSection": 3356,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23293714",
                    "text": "MELD-MDRD-6 included 6-variable MDRD eGFR as one of the variables and showed an improvement over MELD score, as suggested by an increase in chi-square (2293.82 vs 2198.32) and a decrease in -2 log (likelihood) (2810.77 vs 2664.79).",
                    "offsetInBeginSection": 2353,
                    "offsetInEndSection": 2584,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23293714",
                    "text": "Finally, when serum creatinine was replaced by CKD-EPI eGFR, it showed a slight improvement compared to the original MELD score (chi-square: 2199.16, -2 log (likelihood): 2773.07).",
                    "offsetInBeginSection": 2585,
                    "offsetInEndSection": 2765,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23293714",
                    "text": "MELD-MDRD-4 excluded serum creatinine, with the coefficients refit among the remaining 3 variables, i.e., total bilirubin, INR and 4-variable MDRD eGFR.",
                    "offsetInBeginSection": 2014,
                    "offsetInEndSection": 2166,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28628497",
                    "text": "Reassessment of the MELD, Glasgow Alcoholic Hepatitis Score, and Age, serum Bilirubin, International normalized ratio, and serum Creatinine score scores after 1 week further improved mortality prediction.",
                    "offsetInBeginSection": 1635,
                    "offsetInEndSection": 1839,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28628497",
                    "text": "Survival rates were the highest among patients showing a decrease in the MELD, Glasgow Alcoholic Hepatitis Score, and Age, serum Bilirubin, International normalized ratio, and serum Creatinine score over the first week of admission.",
                    "offsetInBeginSection": 1280,
                    "offsetInEndSection": 1512,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17370333",
                    "text": "Univariate analysis showed that age, duration of jaundice, jaundice-encephalopathy interval (JEI), grade of encephalopathy, presence of cerebral edema, bilirubin, prothrombin time, creatinine, and MELD score were significantly different between survivors and nonsurvivors.",
                    "offsetInBeginSection": 787,
                    "offsetInEndSection": 1059,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6d196db750ff4455000032",
            "body": "Which resource has been developed in order to study the transcriptional regulation of GABAergic cell fate?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27710791",
                "http://www.ncbi.nlm.nih.gov/pubmed/24370451",
                "http://www.ncbi.nlm.nih.gov/pubmed/24643195",
                "http://www.ncbi.nlm.nih.gov/pubmed/26843111",
                "http://www.ncbi.nlm.nih.gov/pubmed/17910758",
                "http://www.ncbi.nlm.nih.gov/pubmed/21943598",
                "http://www.ncbi.nlm.nih.gov/pubmed/17678855",
                "http://www.ncbi.nlm.nih.gov/pubmed/17611227",
                "http://www.ncbi.nlm.nih.gov/pubmed/25556833",
                "http://www.ncbi.nlm.nih.gov/pubmed/21602925"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27710791",
                    "text": "Thus, these subpallial enhancer transgenic lines are data and tool\u00a0resources to study transcriptional regulation of GABAergic cell fate.",
                    "offsetInBeginSection": 896,
                    "offsetInEndSection": 1033,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24370451",
                    "text": "The basic helix-loop-helix (bHLH) transcriptional activator Ptf1a determines inhibitory GABAergic over excitatory glutamatergic neuronal cell fate in progenitors of the vertebrate dorsal spinal cord, cerebellum and retina.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 222,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24370451",
                    "text": "Thus, Prdm13 is a novel crucial component of the Ptf1a regulatory pathway that, by modulating the transcriptional activity of bHLH factors such as Neurog2, controls the balance between GABAergic and glutamatergic neuronal fate in the dorsal and caudal part of the vertebrate neural tube.",
                    "offsetInBeginSection": 1328,
                    "offsetInEndSection": 1615,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24643195",
                    "text": "Our data show that GABAergic inducing activity of Ascl1 requires the direct transcriptional regulation of Ptf1a, providing therefore a new piece of the network governing neurotransmitter subtype specification during retinogenesis.",
                    "offsetInBeginSection": 1219,
                    "offsetInEndSection": 1449,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24643195",
                    "text": "We showed that it is necessary for retinal GABAergic cell genesis and sufficient in overexpression experiments to bias a subset of retinal precursor cells towards a GABAergic fate.",
                    "offsetInBeginSection": 510,
                    "offsetInEndSection": 690,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26843111",
                    "text": "In order to study its role in the regulation of vestibulo-motor development, we investigated a transgenic mouse expressing Isl1 under the Pax2 promoter control (Tg +/- ).",
                    "offsetInBeginSection": 282,
                    "offsetInEndSection": 452,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17910758",
                    "text": "Therefore, we investigated whether Ptf1a promotes the fate of these two cell types or acts directly as a GABAergic subtype determination factor.",
                    "offsetInBeginSection": 1145,
                    "offsetInEndSection": 1289,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21943598",
                    "text": "Genetic targeting allows reliable identification, monitoring, and manipulation of cortical GABAergic neurons, thereby enabling a systematic and comprehensive analysis from cell fate specification, migration, and connectivity, to their functions in network dynamics and behavior.",
                    "offsetInBeginSection": 711,
                    "offsetInEndSection": 989,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17678855",
                    "text": "We show that Dlx homeobox transcription factors, required for GABAergic interneuron production, repress oligodendrocyte precursor cell (OPC) formation by acting on a common progenitor to determine neuronal versus oligodendroglial cell fate acquisition.",
                    "offsetInBeginSection": 300,
                    "offsetInEndSection": 552,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25556833",
                    "text": "This multifaceted study generates a powerful resource and informs understanding of the transcriptional regulation underlying pyramidal neuron diversity in the neocortex.",
                    "offsetInBeginSection": 953,
                    "offsetInEndSection": 1122,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a79d195faa1ab7d2e00000e",
            "body": "Is celiac disease caused by gliadin-induced transglutaminase-2 (TG2)-dependent events ?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24240659",
                "http://www.ncbi.nlm.nih.gov/pubmed/22878839",
                "http://www.ncbi.nlm.nih.gov/pubmed/22314661",
                "http://www.ncbi.nlm.nih.gov/pubmed/15290344",
                "http://www.ncbi.nlm.nih.gov/pubmed/15511629",
                "http://www.ncbi.nlm.nih.gov/pubmed/27613408",
                "http://www.ncbi.nlm.nih.gov/pubmed/18793760",
                "http://www.ncbi.nlm.nih.gov/pubmed/27263022",
                "http://www.ncbi.nlm.nih.gov/pubmed/26503953",
                "http://www.ncbi.nlm.nih.gov/pubmed/25816160"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659",
                    "text": "The present study examined the capability of different oat cultivars of activating the gliadin-induced transglutaminase-2 (TG2)-dependent events in some in vitro models of CD.",
                    "offsetInBeginSection": 275,
                    "offsetInEndSection": 450,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22878839",
                    "text": "Gluten-derived gliadin peptides are deamidated by transglutaminase 2 (TG2), leading to an immune response in the small-intestinal mucosa.",
                    "offsetInBeginSection": 198,
                    "offsetInEndSection": 335,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22878839",
                    "text": "TG2 inhibitors have therefore been suggested as putative drugs for celiac disease.",
                    "offsetInBeginSection": 336,
                    "offsetInEndSection": 418,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15290344",
                    "text": "The discovery that type 2 transglutaminase (TG2) is the main, if not the sole, target of the endomysium CD-specific autoantibodies assigned to this enzyme a master regulator role of CD.",
                    "offsetInBeginSection": 222,
                    "offsetInEndSection": 407,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15511629",
                    "text": "Deamidation may be catalysed by intestinal tissue transglutaminase (TG2), a protein which is also the main autoantigen in celiac disease.",
                    "offsetInBeginSection": 195,
                    "offsetInEndSection": 332,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27613408",
                    "text": "Type 2 transglutaminase (TG2) has an important pathogenic role in celiac disease (CD), an inflammatory intestinal disease that is caused by the ingestion of gluten-containing cereals.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18793760",
                    "text": "The in vivo deamidation of gliadin peptides plays an important role in the immunopathogenesis of celiac disease (CD).",
                    "offsetInBeginSection": 112,
                    "offsetInEndSection": 229,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27263022",
                    "text": "A key player in the pathogenetic process leading to the enteropathy is played by a protein called transglutaminase 2 (TG2), which is able to enzymatically modify gluten-derived gliadin peptides.",
                    "offsetInBeginSection": 382,
                    "offsetInEndSection": 576,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26503953",
                    "text": "Autoantibodies specific for the enzyme transglutaminase 2 (TG2) are a hallmark of the gluten-sensitive enteropathy celiac disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25816160",
                    "text": "The enzyme transglutaminase 2 (TG2) plays a crucial role in the initiation of celiac disease by catalyzing the deamidation of gluten peptides.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a68f965b750ff445500001a",
            "body": "Clue cells are characteristics to which causative bacteria of vaginitis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/3497132",
                "http://www.ncbi.nlm.nih.gov/pubmed/6610607",
                "http://www.ncbi.nlm.nih.gov/pubmed/10932748",
                "http://www.ncbi.nlm.nih.gov/pubmed/21524046",
                "http://www.ncbi.nlm.nih.gov/pubmed/4000776",
                "http://www.ncbi.nlm.nih.gov/pubmed/6607525",
                "http://www.ncbi.nlm.nih.gov/pubmed/12838684",
                "http://www.ncbi.nlm.nih.gov/pubmed/11845812",
                "http://www.ncbi.nlm.nih.gov/pubmed/420269",
                "http://www.ncbi.nlm.nih.gov/pubmed/6336135"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132",
                    "text": "The specific aetiologies of vaginitis are many.",
                    "offsetInBeginSection": 111,
                    "offsetInEndSection": 158,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132",
                    "text": "Vaginitis of undetermined aetiology is more complex and is characterized by a purulent vaginal discharge, a pH of 4.0-4.6, numerous WBC's, and a high concentration of bacteria.",
                    "offsetInBeginSection": 823,
                    "offsetInEndSection": 999,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10932748",
                    "text": "Lactobacillus populations, which are usually dominant in healthy women, are replaced by a polymicrobial group of organisms that includes G. vaginalis, anaerobic Gram-negative rods such as Prevotella species, Peptostreptococcus species, Mycoplasma hominis, Ureaplasma urealyticum, and often Mobiluncus species.",
                    "offsetInBeginSection": 479,
                    "offsetInEndSection": 788,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21524046",
                    "text": "Bacterial vaginosis, trichomoniasis, and vulvovaginal candidiasis are the most common infectious causes of vaginitis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/4000776",
                    "text": "Nonspecific vaginitis, one of the most common causes of vaginitis in adults, is a polymicrobial infection in which vaginal anaerobes act synergistically with Gardnerella vaginalis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6607525",
                    "text": "Gardnerella-associated vaginosis (Hemophilus vaginalis vaginitis, nonspecific vaginitis) is the most common cause of vaginal discharge and odor.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6607525",
                    "text": "The diagnosis is further confirmed when a microscopic examination of the discharge mixed with normal saline shows a virtual pure culture of tiny bacteria many of which are found clinging to vaginal epithelial cells forming the so-called \"clue cells\".",
                    "offsetInBeginSection": 590,
                    "offsetInEndSection": 840,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12838684",
                    "text": "Gardnerella vaginalis is found in vaginal flora of women with bacterial vaginitis as well as in healthy women, while anaerobic bacteria such as Mobiluncus and Prevotella are the causative agents for bacterial vaginosis.",
                    "offsetInBeginSection": 257,
                    "offsetInEndSection": 476,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11845812",
                    "text": "Aerobic vaginitis was diagnosed if smears were deficient in lactobacilli, positive for cocci or coarse bacilli, positive for parabasal epithelial cells, and/or positive for vaginal leucocytes (plus their granular aspect).",
                    "offsetInBeginSection": 549,
                    "offsetInEndSection": 770,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6336135",
                    "text": "Examination of Gram-stained vaginal smears obtained from infected pig-tailed macaques failed to demonstrate clue cells, a feature which is pathognomonic of non-specific vaginitis in humans.",
                    "offsetInBeginSection": 209,
                    "offsetInEndSection": 398,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6d1db1b750ff4455000033",
            "body": "What is the purpose of the FaceBase consortium?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21458441",
                "http://www.ncbi.nlm.nih.gov/pubmed/27287806",
                "http://www.ncbi.nlm.nih.gov/pubmed/26168040",
                "http://www.ncbi.nlm.nih.gov/pubmed/24303230",
                "http://www.ncbi.nlm.nih.gov/pubmed/24124010",
                "http://www.ncbi.nlm.nih.gov/pubmed/28261023",
                "http://www.ncbi.nlm.nih.gov/pubmed/9682580",
                "http://www.ncbi.nlm.nih.gov/pubmed/19785207",
                "http://www.ncbi.nlm.nih.gov/pubmed/6555222",
                "http://www.ncbi.nlm.nih.gov/pubmed/11532163"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21458441",
                    "text": "The FaceBase Consortium consists of ten interlinked research and technology projects whose goal is to generate craniofacial research data and technology for use by the research community through a central data management and integrated bioinformatics hub.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 255,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27287806",
                    "text": "The FaceBase Consortium, funded by the National Institute of Dental and Craniofacial Research, National Institutes of Health, is designed to accelerate understanding of craniofacial developmental biology by generating comprehensive data resources to empower the research community, exploring high-throughput technology, fostering new scientific collaborations among researchers and human/computer interactions, facilitating hypothesis-driven research and translating science into improved health care to benefit patients.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 521,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27287806",
                    "text": "The resources generated by the FaceBase projects include a number of dynamic imaging modalities, genome-wide association studies, software tools for analyzing human facial abnormalities, detailed phenotyping, anatomical and molecular atlases, global and specific gene expression patterns, and transcriptional profiling over the course of embryonic and postnatal development in animal models and humans.",
                    "offsetInBeginSection": 522,
                    "offsetInEndSection": 924,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26168040",
                    "text": "The NIH FACEBASE consortium was established in part to create a central resource for craniofacial researchers.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26168040",
                    "text": "This FACEBASE resource is designed to promote discovery by the craniofacial research community.",
                    "offsetInBeginSection": 1241,
                    "offsetInEndSection": 1336,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24303230",
                    "text": "We introduce the Ontology of Craniofacial Development and Malformation (OCDM), a project of the NIH-funded FaceBase consortium, whose goal is to gather data from multiple species, at levels ranging from genes to gross anatomy, in order to understand the causes of craniofacial abnormalities.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 291,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24124010",
                    "text": "The OCDM is a project of the NIDCR-sponsored FaceBase Consortium, whose goal is to promote and enable research into the genetic and epigenetic causes of specific craniofacial abnormalities through the provision of publicly accessible, integrated craniofacial data.",
                    "offsetInBeginSection": 333,
                    "offsetInEndSection": 597,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28261023",
                    "text": "Our aim here is to create the Craniofacial Human Development Ontology (CHDO) to support the Ontology of Craniofacial Development and Malformation (OCDM), which provides the infrastructure for integrating multiple and disparate craniofacial data generated by FaceBase researchers.",
                    "offsetInBeginSection": 1284,
                    "offsetInEndSection": 1563,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9682580",
                    "text": "The purpose of this article is to describe the evolution and implementation of the Northern New Jersey Nursing Education consortium--a consortium of seven member institutions established in 1992.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 195,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11532163",
                    "text": "Herein, we describe the structure of the Consortium, pointing out the inherent strengths of linking together multiple independent sites for the purpose of banking HIV-infected nervous system tissues.",
                    "offsetInBeginSection": 521,
                    "offsetInEndSection": 720,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a79d25dfaa1ab7d2e00000f",
            "body": "Does wheat belongs to the genus Avena, yes or no?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24226111",
                "http://www.ncbi.nlm.nih.gov/pubmed/8984007",
                "http://www.ncbi.nlm.nih.gov/pubmed/25120168",
                "http://www.ncbi.nlm.nih.gov/pubmed/12669804",
                "http://www.ncbi.nlm.nih.gov/pubmed/18356948",
                "http://www.ncbi.nlm.nih.gov/pubmed/869897",
                "http://www.ncbi.nlm.nih.gov/pubmed/24202677",
                "http://www.ncbi.nlm.nih.gov/pubmed/15977816",
                "http://www.ncbi.nlm.nih.gov/pubmed/10464792",
                "http://www.ncbi.nlm.nih.gov/pubmed/25188288"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8984007",
                    "text": "A cloned repetitive sequence, pAvKB30, obtained from an Avena vaviloviana (AB genome) genomic library, along with two polymerase chain reaction products derived from the conserved region of the reverse transcriptase (RT) gene of retrotransposons, were characterized molecularly and cytologically.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 296,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8984007",
                    "text": "The cloned DNA fragment was a dispersed repeat present in all Avena species used in this study (A. strigosa, A. clauda, A. vaviloviana, A. magna, and A. sativa).",
                    "offsetInBeginSection": 297,
                    "offsetInEndSection": 458,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25120168",
                    "text": "The present results identify a novel protein family affecting cereal kernel texture and would further elucidate the phylogenetic evolution of Avena genus.",
                    "offsetInBeginSection": 1334,
                    "offsetInEndSection": 1488,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12669804",
                    "text": "The DNA sequence of an extracellular (EXC) domain of an oat (Avena sativa L.) receptor-like kinase (ALrk10) gene was amplified from 23 accessions of 15 Avena species (6 diploid, 6 tetraploid, and 3 hexaploid).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18356948",
                    "text": "These results could explain the roles of A. clauda, A. longiglumis, and A. atlantica in the evolution of the genus Avena.",
                    "offsetInBeginSection": 2178,
                    "offsetInEndSection": 2299,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15977816",
                    "text": "To examine the genomic structure of Avena macrostachya, internal transcribed spacers, ITS1 and ITS2, as well as nuclear 5.8S tRNA genes from three oat species with AsAs karyotype (A. wiestii, A. hirtula, and A. atlantica), and those from A. longiglumis (AlAl), A. canariensis (AcAc), A. ventricosa (CvCv), A. pilosa, and A. clauda (CpCp) were sequenced.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 353,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10464792",
                    "text": "Further, the chromosomes involved in three C-A and three C-D intergenomic translocations in Avena murphyi (AC genomes) and Avena sativa cv.",
                    "offsetInBeginSection": 1101,
                    "offsetInEndSection": 1240,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25188288",
                    "text": "Two uncorrelated nucleotide sequences, chloroplast intergenic spacer psbA-trnH and acetyl CoA carboxylase gene (Acc1), were used to perform phylogenetic analyses in 75 accessions of the genus Avena, representing 13 diploids, seven tetraploid, and four hexaploids by maximum parsimony and Bayesian inference.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 307,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25188288",
                    "text": "The haplotype that seems to represent the D genome clustered with the tetraploid species Avena murphyi and Avena maroccana, which supported the CD genomic designation instead of AC for A. murphyi and A. maroccana.",
                    "offsetInBeginSection": 1022,
                    "offsetInEndSection": 1235,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25188288",
                    "text": "Phylogenic analyses based on the chloroplast intergenic spacer psbA-trnH confirmed that the A genome diploid might be the maternal donor of species of the genus Avena.",
                    "offsetInBeginSection": 308,
                    "offsetInEndSection": 475,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a68fd01b750ff445500001b",
            "body": "What is included in the fourth generation HIV test?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23984592",
                "http://www.ncbi.nlm.nih.gov/pubmed/19320855",
                "http://www.ncbi.nlm.nih.gov/pubmed/29062724",
                "http://www.ncbi.nlm.nih.gov/pubmed/28846743",
                "http://www.ncbi.nlm.nih.gov/pubmed/28710996",
                "http://www.ncbi.nlm.nih.gov/pubmed/24342480",
                "http://www.ncbi.nlm.nih.gov/pubmed/24342477",
                "http://www.ncbi.nlm.nih.gov/pubmed/25464967",
                "http://www.ncbi.nlm.nih.gov/pubmed/21995933",
                "http://www.ncbi.nlm.nih.gov/pubmed/16908076"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592",
                    "text": "To evaluate its performance to diagnose acute HIV infection (AHI), E4G was compared with fourth generation Ag/Ab ELISA test kits, a third generation PA test kit, WB and real-time PCR for the testing of 25 AHI clinical specimens.",
                    "offsetInBeginSection": 721,
                    "offsetInEndSection": 949,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592",
                    "text": "In 2008, the Espline HIV Ag/Ab test kit (E4G, Fujirebio Inc. Japan) was marketed in Japan belonging to the fourth generation of HIV test kits characterized by its ability to detect both viral antigens (Ag) and anti-HIV-1/2 antibodies (Ab).",
                    "offsetInBeginSection": 372,
                    "offsetInEndSection": 611,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19320855",
                    "text": "All HIV-1-positive samples were reactive by the three fourth-generation systems.",
                    "offsetInBeginSection": 1098,
                    "offsetInEndSection": 1178,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29062724",
                    "text": "CONCLUSION The fourth generation DC offered no advantage over current third generation RT in the diagnosis of HIV infection.",
                    "offsetInBeginSection": 1654,
                    "offsetInEndSection": 1778,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29062724",
                    "text": "Determine Combo (DC) is the first fourth generation RT that detects both p24 antigen (p24Ag) and HIV antibodies (Ab), theoretically reducing the window period and increasing detection rates.",
                    "offsetInBeginSection": 215,
                    "offsetInEndSection": 405,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28710996",
                    "text": "STUDY DESIGN 5029 VOICE participants were evaluated with third-generation Alere Determine\u2122 HIV-1/2, OraQuick ADVANCE\u00ae Rapid HIV-1/2, Uni-Gold\u2122 Recombigen\u00ae HIV-1/2 and Bio-Rad GS HIV-1/2+O EIA; and fourth-generation Alere Determine\u2122 HIV-1/2 Ag/Ab Combo, Conformit\u00e9 Europ\u00e9ene (CE)-Marked Alere\u2122 HIV Combo and Bio-Rad HIV Combo Ag/Ab EIA.",
                    "offsetInBeginSection": 464,
                    "offsetInEndSection": 811,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28710996",
                    "text": "OBJECTIVE To determine if fourth-generation antigen/antibody (Ag/Ab) rapid diagnostic tests (RDT) would have detected HIV infection earlier than the third-generation RDT used in MTN-003 (VOICE).",
                    "offsetInBeginSection": 267,
                    "offsetInEndSection": 461,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25464967",
                    "text": "RESULTS Fourth generation immunoassays identified 34 out of 39 HIV early infections using dried serum spot, whereas the Determine\u2122 HIV-1/2 rapid test detected 24 out of 39 HIV positive serum (87.2% vs 61.5% respectively, p = 0.009).",
                    "offsetInBeginSection": 686,
                    "offsetInEndSection": 920,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25464967",
                    "text": "CONCLUSION Fourth generation Ag/Ab immunoassays performed on dried serum spot had good performance for HIV testing during the early phases of HIV infection.",
                    "offsetInBeginSection": 1304,
                    "offsetInEndSection": 1460,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16908076",
                    "text": "The LG HIV Ag-Ab Plus, a new fourth generation diagnostic assay for HIV infection, was evaluated in comparison to the Enzygnost HIV Integral, an established fourth generation HIV assay.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6d2558b750ff4455000036",
            "body": "Does Uc.160 promote cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                "http://www.ncbi.nlm.nih.gov/pubmed/20802525",
                "http://www.ncbi.nlm.nih.gov/pubmed/28857253",
                "http://www.ncbi.nlm.nih.gov/pubmed/26540342",
                "http://www.ncbi.nlm.nih.gov/pubmed/27261573",
                "http://www.ncbi.nlm.nih.gov/pubmed/26999607",
                "http://www.ncbi.nlm.nih.gov/pubmed/28281525",
                "http://www.ncbi.nlm.nih.gov/pubmed/28039457",
                "http://www.ncbi.nlm.nih.gov/pubmed/24151381",
                "http://www.ncbi.nlm.nih.gov/pubmed/27261588"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "text": "CONCLUSIONS These results indicate that Uc.160+ could possibly have a tumor suppressive role in GC.",
                    "offsetInBeginSection": 1498,
                    "offsetInEndSection": 1597,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "text": "Uc.160+, a T-UCR reported to be downregulated in human cancer, has not been examined in GC.",
                    "offsetInBeginSection": 399,
                    "offsetInEndSection": 490,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20802525",
                    "text": "Among the T-UCRs that were reactivated upon drug treatment, Uc.160+, Uc283+A and Uc.346+ were found to undergo specific CpG island hypermethylation-associated silencing in cancer cells compared with normal tissues.",
                    "offsetInBeginSection": 1280,
                    "offsetInEndSection": 1494,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28857253",
                    "text": "Taken together, we demonstrated a TP73-AS1/miR-200a/ZEB1 regulating loop in breast cancer cells, which promote cancer cell invasion and migration through regulating E-cadherin and Twist expression.",
                    "offsetInBeginSection": 801,
                    "offsetInEndSection": 998,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26540342",
                    "text": "Previous studies have shown that hTERT can promote tumor invasion and metastasis of gastric cancer, liver cancer and esophageal cancer.",
                    "offsetInBeginSection": 271,
                    "offsetInEndSection": 406,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26540342",
                    "text": "Taken together, our findings suggest that hTERT can promote cancer metastasis by stimulating EMT through the ZEB1 pathway and therefore inhibiting them may prevent cancer progression.",
                    "offsetInBeginSection": 1065,
                    "offsetInEndSection": 1248,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28281525",
                    "text": "These results suggest that adipocytes promote malignancy of MCT2-expressing breast cancer via \u03b2-hydroxybutyrate potentially by inducing the epigenetic upregulation of tumour-promoting genes.",
                    "offsetInBeginSection": 907,
                    "offsetInEndSection": 1098,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28039457",
                    "text": "Previous studies have found that tumor-associated macrophages (TAMs) promote cancer progression.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28039457",
                    "text": "We previously reported that TAMs promote prostate cancer metastasis via activation of the CCL2-CCR2 axis.",
                    "offsetInBeginSection": 97,
                    "offsetInEndSection": 202,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24151381",
                    "text": "We thus hypothesize that, as a neurite growth-promoting factor, PTN may promote PNI in pancreatic cancer.",
                    "offsetInBeginSection": 519,
                    "offsetInEndSection": 624,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8712af61bb38fb24000002",
            "body": "What is the link between psoriatic arthritis and depression",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27221798",
                "http://www.ncbi.nlm.nih.gov/pubmed/21794775",
                "http://www.ncbi.nlm.nih.gov/pubmed/28507445",
                "http://www.ncbi.nlm.nih.gov/pubmed/27258525",
                "http://www.ncbi.nlm.nih.gov/pubmed/24407907",
                "http://www.ncbi.nlm.nih.gov/pubmed/28320454",
                "http://www.ncbi.nlm.nih.gov/pubmed/19151962",
                "http://www.ncbi.nlm.nih.gov/pubmed/23934051",
                "http://www.ncbi.nlm.nih.gov/pubmed/28733473",
                "http://www.ncbi.nlm.nih.gov/pubmed/24474190"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27221798",
                    "text": "Many epidemiological studies have shown that psoriasis is associated with psoriatic arthritis as well as cardiovascular and metabolic diseases.",
                    "offsetInBeginSection": 83,
                    "offsetInEndSection": 226,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21794775",
                    "text": "CONCLUSION The prevalence of anxiety symptoms and the prevalence of depression symptoms are high among patients suffering psoriatic arthritis in the studied population.",
                    "offsetInBeginSection": 1439,
                    "offsetInEndSection": 1607,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28507445",
                    "text": "CONCLUSION Prevalence of fatigue was moderate to intense in <25% of patients with psoriatic arthritis.",
                    "offsetInBeginSection": 1722,
                    "offsetInEndSection": 1824,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24407907",
                    "text": "The use of pressure algometry in the evaluation of chronic pain in patients affected by rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis that display comorbid depression could represent an additional and integrative method to improve pain/depression overlap management or research.",
                    "offsetInBeginSection": 1367,
                    "offsetInEndSection": 1669,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28320454",
                    "text": "Peripheral arthritis is the most common symptom of psoriatic arthritis and patients also frequently experience involvement of the entheses, spine, skin, and nails.",
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 365,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28320454",
                    "text": "Risks also arise from comorbidities that are associated with psoriatic arthritis such as cardiovascular disease, obesity, diabetes mellitus, and gastrointestinal inflammation.",
                    "offsetInBeginSection": 876,
                    "offsetInEndSection": 1051,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23934051",
                    "text": "Thus, psoriasis-associated diseases or comorbidities are also seen in psoriatic arthritis patients.",
                    "offsetInBeginSection": 85,
                    "offsetInEndSection": 184,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28733473",
                    "text": "OBJECTIVE To investigate the predictive value of baseline depression/anxiety on the likelihood of achieving joint remission in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) as well as the associations between baseline depression/anxiety and the components of the remission criteria at follow-up.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 305,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24474190",
                    "text": "A link is recognized between psoriatic arthritis and inflammatory bowel disease (IBD).",
                    "offsetInBeginSection": 191,
                    "offsetInEndSection": 277,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24474190",
                    "text": "Psoriatic arthritis is a chronic inflammatory joint disease, seen in combination with the chronic inflammatory skin disease psoriasis and belonging to the family of spondylarthritides (SpA).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 190,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6900ebb750ff445500001d",
            "body": "Which disease is diagnosed using the Finkelstein's test?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15680568",
                "http://www.ncbi.nlm.nih.gov/pubmed/23340762",
                "http://www.ncbi.nlm.nih.gov/pubmed/15792200",
                "http://www.ncbi.nlm.nih.gov/pubmed/26538761",
                "http://www.ncbi.nlm.nih.gov/pubmed/1402284",
                "http://www.ncbi.nlm.nih.gov/pubmed/10070674",
                "http://www.ncbi.nlm.nih.gov/pubmed/12723309",
                "http://www.ncbi.nlm.nih.gov/pubmed/24932451",
                "http://www.ncbi.nlm.nih.gov/pubmed/16300037",
                "http://www.ncbi.nlm.nih.gov/pubmed/9763259"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15680568",
                    "text": "PURPOSE Finkelstein's test is the classic diagnostic test for de Quervain's disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 84,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23340762",
                    "text": "The purpose of the study was to compare the accuracy of the Eichhoff's test and wrist hyperflexion and abduction of the thumb test to diagnose correctly de Quervain's disease by comparing clinical findings using those tests with the results on ultrasound.",
                    "offsetInBeginSection": 633,
                    "offsetInEndSection": 888,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23340762",
                    "text": "To compare the Eichhoff's test with a new test, the wrist hyperflexion and abduction of the thumb test, we set up a prospective study over a period of three years for a cohort of 100 patients (88 women, 12 men) presenting spontaneous pain over the radial side of the styloid of the radius (de Quervain tendinopathy).",
                    "offsetInBeginSection": 316,
                    "offsetInEndSection": 632,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23340762",
                    "text": "Our results support that the wrist hyperflexion and abduction of the thumb test is a more precise tool for the diagnosis of de Quervain's disease than the Eichhoff's test and thus could be adopted to guide clinical diagnosis in the early stages of de Quervain's tendinopathy.",
                    "offsetInBeginSection": 1337,
                    "offsetInEndSection": 1612,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15792200",
                    "text": "Three different descriptions of Finkelstein's test were used as described in current literature.",
                    "offsetInBeginSection": 726,
                    "offsetInEndSection": 822,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15792200",
                    "text": "We also found that Finkelstein's test was inaccurately described in literature since Leao's incorrect description in 1958 (quoting Eichhoff's manoeuvre) and the mistake persisted for over 50 years before it could be accredited.",
                    "offsetInBeginSection": 1099,
                    "offsetInEndSection": 1326,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26538761",
                    "text": "The clinical criteria used were Finkelstein's test, tenderness over radial styloid (Ritchie's tenderness scale), grip strength, pain (visual analog scale [VAS]) and radiological criteria was ultrasonographic assessment of change in thickness of APL and EPB tendon sheath.",
                    "offsetInBeginSection": 828,
                    "offsetInEndSection": 1099,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26538761",
                    "text": "MATERIALS AND METHODS Thirty patients clinically diagnosed de Quervains tenosynovitis were included in the study and randomly assigned to two groups.",
                    "offsetInBeginSection": 535,
                    "offsetInEndSection": 684,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10070674",
                    "text": "Although Sun's was derived as a test for discrete data and Finkelstein's and Fay's tests were derived under a grouped continuous model, by writing all tests under one general model we see that as long as the regularity conditions hold, any of these three classes of tests may be applied to either grouped continuous or discrete data.",
                    "offsetInBeginSection": 152,
                    "offsetInEndSection": 485,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24932451",
                    "text": "Data was collected through self-administered questionnaire and severity of the pain was assessed through Universal Pain Assessment Tool and De Quervain's tenosynovitis was diagnosed through Finkelstein test.",
                    "offsetInBeginSection": 363,
                    "offsetInEndSection": 570,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e1280b750ff4455000037",
            "body": "For which type of cancer can uc.189 be used as a potential prognostic biomarker?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28941722",
                "http://www.ncbi.nlm.nih.gov/pubmed/24165311",
                "http://www.ncbi.nlm.nih.gov/pubmed/24057814",
                "http://www.ncbi.nlm.nih.gov/pubmed/26202601",
                "http://www.ncbi.nlm.nih.gov/pubmed/20661575",
                "http://www.ncbi.nlm.nih.gov/pubmed/28607584",
                "http://www.ncbi.nlm.nih.gov/pubmed/28869900",
                "http://www.ncbi.nlm.nih.gov/pubmed/26989022",
                "http://www.ncbi.nlm.nih.gov/pubmed/19424625",
                "http://www.ncbi.nlm.nih.gov/pubmed/25649770"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722",
                    "text": "Uc.189 might be considered as a novel molecule involved in ESCC progression, which provides a potential prognostic biomarker and therapeutic target.",
                    "offsetInBeginSection": 1124,
                    "offsetInEndSection": 1272,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722",
                    "text": "High expression of uc.189 might reflect poor prognosis of ESCC and indicate a potential diagnostic target in ESCC patients.",
                    "offsetInBeginSection": 1000,
                    "offsetInEndSection": 1123,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24165311",
                    "text": "We believe this tool will be useful in accelerating biomarker discovery in cancer and quickly providing results that may indicate disease-specific prognostic value of specific biomarkers.",
                    "offsetInBeginSection": 1207,
                    "offsetInEndSection": 1394,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26202601",
                    "text": "Here, we have used a network-based exploration approach to identify a multi-cancer gene expression biomarker highly connected by ESR1, PRKACA, LRP1, JUN and SMAD2 that can be predictive of clinical outcome in 12 types of cancer from The Cancer Genome Atlas (TCGA) repository.",
                    "offsetInBeginSection": 527,
                    "offsetInEndSection": 802,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26202601",
                    "text": "Comparisons with cancer-type specific and other multi-cancer biomarkers in TCGA and other datasets showed that the performance of the proposed multi-cancer biomarker is superior, making the proposed approach and multi-cancer biomarker potentially useful in research and clinical settings.",
                    "offsetInBeginSection": 1062,
                    "offsetInEndSection": 1350,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20661575",
                    "text": "We and others have identified EMMPRIN as a prognostic biomarker in a variety of tumor diseases.",
                    "offsetInBeginSection": 477,
                    "offsetInEndSection": 572,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26989022",
                    "text": "In conclusion, TMPRSS4 is a novel independent prognostic biomarker regulated by epigenetic changes in SCC and a potential therapeutic target in this tumor type, where targeted therapy is still underdeveloped.",
                    "offsetInBeginSection": 1255,
                    "offsetInEndSection": 1463,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26989022",
                    "text": "Here, we have used several cohorts of NSCLC patients to analyze the prognostic value of both protein expression and DNA promoter methylation status of the prometastatic serine protease TMPRSS4.",
                    "offsetInBeginSection": 482,
                    "offsetInEndSection": 675,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26989022",
                    "text": "Similarly, aberrant hypomethylation in tumors, which correlates with high TMPRSS4 expression, is an independent prognostic predictor in SCC.",
                    "offsetInBeginSection": 873,
                    "offsetInEndSection": 1013,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19424625",
                    "text": "We propose that PRL-3 expression can have a clinical potential as a prognostic biomarker that may facilitate the development of adjuvant chemotherapy for advanced gastric cancer with stage I disease.",
                    "offsetInBeginSection": 1475,
                    "offsetInEndSection": 1674,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a87140a61bb38fb24000003",
            "body": "What is Chronic Wasting Disease (CWD) in deer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17553219",
                "http://www.ncbi.nlm.nih.gov/pubmed/27575545",
                "http://www.ncbi.nlm.nih.gov/pubmed/17092889",
                "http://www.ncbi.nlm.nih.gov/pubmed/12680636",
                "http://www.ncbi.nlm.nih.gov/pubmed/28193766",
                "http://www.ncbi.nlm.nih.gov/pubmed/19697236",
                "http://www.ncbi.nlm.nih.gov/pubmed/27556563",
                "http://www.ncbi.nlm.nih.gov/pubmed/19901375",
                "http://www.ncbi.nlm.nih.gov/pubmed/15362835",
                "http://www.ncbi.nlm.nih.gov/pubmed/16439622"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17553219",
                    "text": "Chronic wasting disease (CWD) of deer and elk is a widespread health concern because its potential for crossspecies transmission is undetermined.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 145,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27575545",
                    "text": "Chronic wasting disease (CWD) is an invariably fatal transmissible spongiform encephalopathy of white-tailed deer, mule deer, elk, and moose.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17092889",
                    "text": "Chronic wasting disease (CWD) is a fatal, emerging disease of cervids associated with transmissible protease-resistant prion proteins.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17092889",
                    "text": "The potential for CWD to cause dramatic declines in deer and elk populations and perceived human health risks associated with consuming CWD-contaminated venison have led wildlife agencies to embark on extensive CWD control programs, typically involving culling to reduce deer populations.",
                    "offsetInBeginSection": 135,
                    "offsetInEndSection": 423,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28193766",
                    "text": "The etiology of chronic wasting disease (CWD), a relatively new and burgeoning prion epidemic in deer, elk, and moose (members of the cervid family), is more enigmatic.",
                    "offsetInBeginSection": 497,
                    "offsetInEndSection": 665,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19697236",
                    "text": "Chronic wasting disease (CWD) is increasingly prevalent in multiple wild mule (Odocoileus hemionus) and white-tailed deer (O. virginianus) herds in North America.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27556563",
                    "text": "The application of a recently developed mathematical model for predicting the spread of chronic wasting disease (CWD) in wild deer was assessed under different scenarios where harvesting is employed in disease management.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 221,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15362835",
                    "text": "The natural occurrence of chronic wasting disease (CWD) in a 1993 cohort of captive white-tailed deer (Odocoileus virginianus) afforded the opportunity to describe epidemic dynamics in this species and to compare dynamics with those seen in contemporary cohorts of captive mule deer (O. hemionus) also infected with CWD.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 320,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16439622",
                    "text": "The emergence of chronic wasting disease (CWD) in deer and elk in an increasingly wide geographic area, as well as the interspecies transmission of bovine spongiform encephalopathy to humans in the form of variant Creutzfeldt Jakob disease, have raised concerns about the zoonotic potential of CWD.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 298,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16439622",
                    "text": "Here bioassays in transgenic mice expressing cervid prion protein revealed the presence of infectious prions in skeletal muscles of CWD-infected deer, demonstrating that humans consuming or handling meat from CWD-infected deer are at risk to prion exposure.",
                    "offsetInBeginSection": 463,
                    "offsetInEndSection": 720,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a69031bb750ff445500001e",
            "body": "Can doxycycline cause photosensitivity?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21879777",
                "http://www.ncbi.nlm.nih.gov/pubmed/10233667",
                "http://www.ncbi.nlm.nih.gov/pubmed/17160610",
                "http://www.ncbi.nlm.nih.gov/pubmed/9214073",
                "http://www.ncbi.nlm.nih.gov/pubmed/26299894",
                "http://www.ncbi.nlm.nih.gov/pubmed/23182067",
                "http://www.ncbi.nlm.nih.gov/pubmed/17315050",
                "http://www.ncbi.nlm.nih.gov/pubmed/10878182",
                "http://www.ncbi.nlm.nih.gov/pubmed/15262663",
                "http://www.ncbi.nlm.nih.gov/pubmed/26189561"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21879777",
                    "text": "Tetracycline, doxycycline, nalidixic acid, voriconazole, amiodarone, hydrochlorothiazide, naproxen, piroxicam, chlorpromazine and thioridazine are among the most commonly implicated medications.",
                    "offsetInBeginSection": 1107,
                    "offsetInEndSection": 1301,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10233667",
                    "text": "Chronic actinic dermatitis (CAD) is an uncommon, eczematous photosensitive eruption affecting predominantly elderly men and to which drug-induced photosensitivity may sometimes appear clinically identical.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 205,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17160610",
                    "text": "Treatment with doxycycline is cheap and relatively safe, but gastrointestinal symptoms and photosensitivity reactions can be expected more often than with ceftriaxone.",
                    "offsetInBeginSection": 1913,
                    "offsetInEndSection": 2080,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17160610",
                    "text": "CONCLUSIONS In patients with previously untreated chronic Lyme borreliosis with symptoms suggesting central nervous system involvement but without overt clinical signs of it, and without pleocytosis in the cerebrospinal fluid, treatment with doxycycline is as effective as with ceftriaxone.",
                    "offsetInBeginSection": 1622,
                    "offsetInEndSection": 1912,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23182067",
                    "text": "CONCLUSION Topical or oral corticosteroids followed by prophylactic doxycycline can be effective in rapidly resolving acute flareups and preventing recurrences of NSAGU.",
                    "offsetInBeginSection": 1580,
                    "offsetInEndSection": 1749,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23182067",
                    "text": "Eight (47%) commenced doxycycline prophylaxis.",
                    "offsetInBeginSection": 966,
                    "offsetInEndSection": 1012,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17315050",
                    "text": "Anti-inflammatory-dose doxycycline should not be used by individuals with known hypersensitivity to tetracyclines or increased photosensitivity, or by pregnant or nursing women (anti-inflammatory-dose doxycycline is a pregnancy category-D medication).",
                    "offsetInBeginSection": 1381,
                    "offsetInEndSection": 1632,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17315050",
                    "text": "Anti-inflammatory-dose doxycycline is not an antibiotic and does not lead to the development of antibiotic-resistant organisms.",
                    "offsetInBeginSection": 787,
                    "offsetInEndSection": 914,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15262663",
                    "text": "BACKGROUND It has been hypothesized that certain Mycoplasma species may cause Gulf War veterans' illnesses (GWVIs), chronic diseases characterized by pain, fatigue, and cognitive symptoms, and that affected patients may benefit from doxycycline treatment.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 255,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26189561",
                    "text": "Doxycycline is a commonly used tetracycline antibiotic showing the broad spectrum of antibacterial action.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 106,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e21b4b750ff445500003a",
            "body": "Are paralog genes co-regulated?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18493055",
                "http://www.ncbi.nlm.nih.gov/pubmed/27634932",
                "http://www.ncbi.nlm.nih.gov/pubmed/20660482",
                "http://www.ncbi.nlm.nih.gov/pubmed/20621981",
                "http://www.ncbi.nlm.nih.gov/pubmed/28010187",
                "http://www.ncbi.nlm.nih.gov/pubmed/29166914",
                "http://www.ncbi.nlm.nih.gov/pubmed/22484699",
                "http://www.ncbi.nlm.nih.gov/pubmed/24682282",
                "http://www.ncbi.nlm.nih.gov/pubmed/17428571",
                "http://www.ncbi.nlm.nih.gov/pubmed/20667114"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18493055",
                    "text": "By analyzing paralogs of testis-biased genes, we identified \"co-regulated\" paralogous pairs in which both genes are testis biased, \"anti-regulated\" pairs in which one paralog is testis biased and the other downregulated in testes, and \"neutral\" pairs in which one paralog is testis biased and the other constitutively expressed.",
                    "offsetInBeginSection": 511,
                    "offsetInEndSection": 839,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27634932",
                    "text": "In eukaryotes, genes are regulated in part by distal enhancer elements through looping interactions with gene promoters.",
                    "offsetInBeginSection": 279,
                    "offsetInEndSection": 399,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27634932",
                    "text": "Paralog genes arise from gene duplication events during evolution, which often lead to similar proteins that cooperate in common pathways and in protein complexes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20660482",
                    "text": "CPEB2, CPEB3 and CPEB4 are paralog proteins very similar among themselves referred as the CPEB2 subfamily.",
                    "offsetInBeginSection": 133,
                    "offsetInEndSection": 239,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28010187",
                    "text": "Other examined G. max homologs of membrane fusion genes include an endosomal bromo domain-containing protein1 (Bro1), syntaxin6 (SYP6), SYP131, SYP71, SYP8, Bet1, coatomer epsilon (\u03f5-COP), a coatomer zeta (\u03b6-COP) paralog and an ER to Golgi component (ERGIC) protein.",
                    "offsetInBeginSection": 1171,
                    "offsetInEndSection": 1439,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28010187",
                    "text": "PEN1 has homology to a Saccharomyces cerevisae gene that regulates a Secretion (Sec) protein, Suppressor of Sec 1 (Sso1p).",
                    "offsetInBeginSection": 363,
                    "offsetInEndSection": 485,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28010187",
                    "text": "Experiments made using the model agricultural Glycine max (soybean) have identified co-regulated gene expression of regulon components.",
                    "offsetInBeginSection": 753,
                    "offsetInEndSection": 888,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28010187",
                    "text": "The regulon is composed partially by the soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptor (SNARE) syntaxin PEN1.",
                    "offsetInBeginSection": 221,
                    "offsetInEndSection": 362,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29166914",
                    "text": "Such clusters could contain one or several operons, which are groups of co-transcribed genes.",
                    "offsetInBeginSection": 145,
                    "offsetInEndSection": 238,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29166914",
                    "text": "As an example, we show the utility of COGNAT in identifying a new type of membrane protein complex that is formed by paralog(s) of one of the membrane subunits of the NADH:quinone oxidoreductase of type 1 (COG1009) and a cytoplasmic protein of unknown function (COG3002).",
                    "offsetInBeginSection": 1219,
                    "offsetInEndSection": 1490,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a87145861bb38fb24000004",
            "body": "What causes Black Lung?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17300721",
                "http://www.ncbi.nlm.nih.gov/pubmed/2933965",
                "http://www.ncbi.nlm.nih.gov/pubmed/16304297",
                "http://www.ncbi.nlm.nih.gov/pubmed/16497850",
                "http://www.ncbi.nlm.nih.gov/pubmed/26437452",
                "http://www.ncbi.nlm.nih.gov/pubmed/29095661",
                "http://www.ncbi.nlm.nih.gov/pubmed/17516558",
                "http://www.ncbi.nlm.nih.gov/pubmed/28450031",
                "http://www.ncbi.nlm.nih.gov/pubmed/2806196",
                "http://www.ncbi.nlm.nih.gov/pubmed/27632152"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17300721",
                    "text": "CONCLUSION Cigarette smoke exposure to a guinea pig model causes oxidative damage, inflammation, apoptosis and lung injury that are prevented by supplementation of black tea.",
                    "offsetInBeginSection": 1426,
                    "offsetInEndSection": 1600,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17300721",
                    "text": "Since black tea has antioxidant property, we examined the preventive effect of black tea on cigarette smoke-induced oxidative damage, apoptosis and lung injury in a guinea pig model.",
                    "offsetInBeginSection": 191,
                    "offsetInEndSection": 373,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16304297",
                    "text": "CONCLUSIONS Our analysis suggests that the lower surgical rate among black patients with early stage lung cancer is mainly due to low rates of acceptance of surgical treatment.",
                    "offsetInBeginSection": 1448,
                    "offsetInEndSection": 1624,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26437452",
                    "text": "In this study, we show that insoluble nanoparticulate carbon black (nCB) accumulates in human myeloid dendritic cells (mDCs) from emphysematous lung and in CD11c(+) lung antigen presenting cells (APC) of mice exposed to smoke.",
                    "offsetInBeginSection": 274,
                    "offsetInEndSection": 500,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29095661",
                    "text": "However, the study results are consistent with the mechanism that, at high enough concentrations, carbon black causes inflammation and oxidative stress in the lung leading to mutations, which is a secondary genotoxic mechanism.",
                    "offsetInBeginSection": 664,
                    "offsetInEndSection": 891,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17516558",
                    "text": "CONCLUSIONS The findings suggest that carbon black, or chemicals associated with the production of carbon black, had an effect on later stages of lung cancer carcinogenesis at two of the plants but that no such effect was found at the other plants.",
                    "offsetInBeginSection": 1330,
                    "offsetInEndSection": 1578,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28450031",
                    "text": "METHODS We collected survival time data for 105,121 Hispanic, non-Hispanic Asian, non-Hispanic black, and non-Hispanic white patients with early-stage (IA, IB, IIA, and IIB) lung cancer diagnosed between 2004 and 2013 from the Surveillance, Epidemiology, and End-Results registries.",
                    "offsetInBeginSection": 411,
                    "offsetInEndSection": 693,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28450031",
                    "text": "BACKGROUND Black patients with lung cancer diagnosed at early stages-for which surgical resection offers a potential cure-experience worse overall survival than do their white counterparts.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 189,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2806196",
                    "text": "The results of these studies support a preeminent role for elastase in neutrophil-induced lung lesions.",
                    "offsetInBeginSection": 1483,
                    "offsetInEndSection": 1586,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27632152",
                    "text": "In 2014, the top five causes of cancer deaths for the total population were lung, colorectal, female breast, pancreatic, and prostate cancer.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f7e6ab750ff4455000052",
            "body": "List four principles of medical ethics.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11794075",
                "http://www.ncbi.nlm.nih.gov/pubmed/7463428",
                "http://www.ncbi.nlm.nih.gov/pubmed/21625670",
                "http://www.ncbi.nlm.nih.gov/pubmed/23975951",
                "http://www.ncbi.nlm.nih.gov/pubmed/26793677",
                "http://www.ncbi.nlm.nih.gov/pubmed/14519842",
                "http://www.ncbi.nlm.nih.gov/pubmed/14519837",
                "http://www.ncbi.nlm.nih.gov/pubmed/15183570",
                "http://www.ncbi.nlm.nih.gov/pubmed/25587553",
                "http://www.ncbi.nlm.nih.gov/pubmed/18552646"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11794075",
                    "text": "Only 6% of both graduates and students were able to list the four principles of medical ethics as described by Raanan.",
                    "offsetInBeginSection": 810,
                    "offsetInEndSection": 928,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7463428",
                    "text": "Through a critique of six positions regarding the aims of medical ethics, four principles are established which are the basis of a philosophy of education for medical ethics.",
                    "offsetInBeginSection": 264,
                    "offsetInEndSection": 438,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7463428",
                    "text": "The paper concludes with practical examples of a clinically-based medical ethics programme following from the four principles.",
                    "offsetInBeginSection": 594,
                    "offsetInEndSection": 720,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26793677",
                    "text": "There are four principles of medical ethics; Beneficence, Respect for autonomy, Non-maleficence, and Justice.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26793677",
                    "text": "It is not easy to apply to principles of medical ethics in the special circumstances of obstetrics and gynecology.",
                    "offsetInBeginSection": 110,
                    "offsetInEndSection": 224,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26793677",
                    "text": "Student doctors must learn to be familiar with principles of medical ethics tailored to the special circumstances while the obstetrics and gynecology practice.",
                    "offsetInBeginSection": 225,
                    "offsetInEndSection": 384,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14519842",
                    "text": "It is hypothesised and argued that \"the four principles of medical ethics\" can explain and justify, alone or in combination, all the substantive and universalisable claims of medical ethics and probably of ethics more generally.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 228,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15183570",
                    "text": "The unique role of the chief ethics officer in a sports medicine office is described and guided by the four principles of ethics, as well as the principles and codes of ethics of the American Medical Association, the International Sports Medicine Federation, and the American Academy of Orthopaedic Surgeons.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 308,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15183570",
                    "text": "The chief ethics officer should understand and be conversant with these principles and these codes of medical ethics, and transmit this information in order to further patient goals, physician goals, and employee goals.",
                    "offsetInBeginSection": 309,
                    "offsetInEndSection": 528,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18552646",
                    "text": "Four main principles underlie medical ethics: autonomy, nonmaleficence, beneficence, and justice.",
                    "offsetInBeginSection": 224,
                    "offsetInEndSection": 321,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e22b9b750ff445500003b",
            "body": "What is CellMaps?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27296979",
                "http://www.ncbi.nlm.nih.gov/pubmed/27775692",
                "http://www.ncbi.nlm.nih.gov/pubmed/28682833",
                "http://www.ncbi.nlm.nih.gov/pubmed/18544796",
                "http://www.ncbi.nlm.nih.gov/pubmed/22548703",
                "http://www.ncbi.nlm.nih.gov/pubmed/20008397"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27296979",
                    "text": "AVAILABILITY AND IMPLEMENTATION The application is available at: http://cellmaps.babelomics.org/ and the code can be found in: https://github.com/opencb/cell-maps The client is implemented in JavaScript and the server in C and Java.",
                    "offsetInBeginSection": 406,
                    "offsetInEndSection": 638,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27296979",
                    "text": "UNLABELLED : CellMaps is an HTML5 open-source web tool that allows displaying, editing, exploring and analyzing biological networks as well as integrating metadata into them.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27775692",
                    "text": "Pancreatic ductal adenocarcinoma (PDAC) develops in a highly complex and heterogeneous tissue environment and, generally, has a very poor prognosis.",
                    "offsetInBeginSection": 146,
                    "offsetInEndSection": 294,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27775692",
                    "text": "We sought to develop a tIA approach to assess the most common PDAC precursor lesions, pancreatic intraepithelial neoplasia (PanIN), in tissues from KrasLSL-G12D/+; Trp53LSL-R172H/+; Pdx-Cre (KPC) mice, a validated model of PDAC development.",
                    "offsetInBeginSection": 459,
                    "offsetInEndSection": 699,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27775692",
                    "text": "tIA profiling of training regions of PanIN and tumor microenvironment (TME) cells was utilized to guide identification of PanIN/TME tissue compartment stratification criteria.",
                    "offsetInBeginSection": 700,
                    "offsetInEndSection": 875,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28682833",
                    "text": "To address this systematically, an ISH for peptidylprolyl isomerase B (PPIB) (cyclophilin B) mRNA was optimized and applied to a tissue microarray of archival non-small cell lung carcinoma cases, and then automated image analysis for PPIB was refined across 4 commercially available software platforms.",
                    "offsetInBeginSection": 239,
                    "offsetInEndSection": 541,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22548703",
                    "text": "Using a set of growth factor signalling networks as examples (epidermal growth factor, transforming growth factor-beta, tumor necrosis factor, and wingless), we find a multiplicity of network topologies in which receptors couple to downstream components through myriad alternate paths.",
                    "offsetInBeginSection": 1720,
                    "offsetInEndSection": 2005,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22548703",
                    "text": "This ensemble network has many features expected of complex signalling networks assembled from high-throughput data: a power law distribution of both node degree and edge annotations, and topological features of a \"bow tie\" architecture in which diverse pathways converge on a highly conserved set of enzymatic cascades focused around PI3K/AKT, MAPK/ERK, JAK/STAT, NF\u03baB, and apoptotic signaling.",
                    "offsetInBeginSection": 1022,
                    "offsetInEndSection": 1418,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22548703",
                    "text": "As a result of discrepant annotations, it is very difficult to identify biologically meaningful pathways from interactome networks a priori.",
                    "offsetInBeginSection": 2721,
                    "offsetInEndSection": 2861,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20008397",
                    "text": "In addition, one cannot easily escape into high-level holistic approaches, since the essence of all biological systems is that they are encoded as molecular descriptions in their genes and since genes are molecules and exert their functions through other molecules, the molecular explanation must constitute the core of understanding biological systems.",
                    "offsetInBeginSection": 343,
                    "offsetInEndSection": 696,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8714e261bb38fb24000005",
            "body": "Is polyadenylation a process that stabilizes a protein by adding a string of Adenosine residues to the end of the molecule?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/3037325",
                "http://www.ncbi.nlm.nih.gov/pubmed/3019671",
                "http://www.ncbi.nlm.nih.gov/pubmed/2408761",
                "http://www.ncbi.nlm.nih.gov/pubmed/9933592",
                "http://www.ncbi.nlm.nih.gov/pubmed/11557765",
                "http://www.ncbi.nlm.nih.gov/pubmed/2160581",
                "http://www.ncbi.nlm.nih.gov/pubmed/9242905",
                "http://www.ncbi.nlm.nih.gov/pubmed/28537233",
                "http://www.ncbi.nlm.nih.gov/pubmed/2170946",
                "http://www.ncbi.nlm.nih.gov/pubmed/12270133"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3019671",
                    "text": "Processing at the L3 polyadenylation site of human adenovirus-2 involves endonucleolytic cleavage generating the 3' terminal sequence -UAOH to which adenosine residues are added.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 178,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9933592",
                    "text": "The data show that the degradosome requires a single-stranded \"toehold\" 3' to a secondary structure to recognize and degrade the RNA molecule efficiently; polyadenylation can provide this single-stranded 3'-end.",
                    "offsetInBeginSection": 940,
                    "offsetInEndSection": 1151,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11557765",
                    "text": "We show that a 3'- to 5'-exoribonuclease activity is responsible for the preferential degradation of polyadenylated mRNAs as compared with non-polyadenylated mRNAs, and that 20-30 adenosine residues constitute the optimal poly(A) tail size for inducing degradation of RNA substrates in vitro.",
                    "offsetInBeginSection": 478,
                    "offsetInEndSection": 770,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2160581",
                    "text": "These included CYC1 (iso-1-cytochrome c), HIS4 (histidine biosynthesis), GAL7 (galactose-1-phosphate uridyltransferase), H2B2 (histone H2B2), PRT2 (a protein of unknown function), and CBP1 (cytochrome b mRNA processing).",
                    "offsetInBeginSection": 265,
                    "offsetInEndSection": 485,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2160581",
                    "text": "Ammonium sulfate fractionation of a Saccharomyces cerevisiae whole-cell extract yielded a preparation which carried out correct and efficient endonucleolytic cleavage and polyadenylation of yeast precursor mRNA substrates corresponding to a variety of yeast genes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 264,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9242905",
                    "text": "The diversity of polyadenylation sites suggests that mRNA polyadenylation in prokaryotes is a relatively indiscriminate process that can occur at all mRNA's 3'-ends and does not require specific consensus sequences as in eukaryotes.",
                    "offsetInBeginSection": 516,
                    "offsetInEndSection": 748,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28537233",
                    "text": "Polyadenylation is the non-template addition of adenosine nucleotides at the 3'-end of RNA, which occurs after transcription and generates a poly(A) tail up to 250-300 nucleotides long.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28537233",
                    "text": "Nucleotide sequences needed for mRNA cleavage and poly(A) tail synthesis, in particular the AAUAAA polyadenylation signal, as well as numerous proteins and their complexes involved in mRNA cleavage and polyadenylation, is described in detail.",
                    "offsetInBeginSection": 447,
                    "offsetInEndSection": 689,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2170946",
                    "text": "For example, point mutations at the conserved adenosine shift the 3' end of the most abundant 5' half-molecule downstream by a single nucleotide.",
                    "offsetInBeginSection": 841,
                    "offsetInEndSection": 986,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12270133",
                    "text": "It is demonstrated that XCCA adds cytosine and adenosine residues to the ends of prepared tRNA and is therefore a functional CCA-adding enzyme.",
                    "offsetInBeginSection": 275,
                    "offsetInEndSection": 418,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f829eb750ff4455000054",
            "body": "Can multiple myeloma patients develop hyperviscosity syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7699907",
                "http://www.ncbi.nlm.nih.gov/pubmed/2385441",
                "http://www.ncbi.nlm.nih.gov/pubmed/22827791",
                "http://www.ncbi.nlm.nih.gov/pubmed/9046114",
                "http://www.ncbi.nlm.nih.gov/pubmed/26623375",
                "http://www.ncbi.nlm.nih.gov/pubmed/24487115",
                "http://www.ncbi.nlm.nih.gov/pubmed/1537697",
                "http://www.ncbi.nlm.nih.gov/pubmed/5415687",
                "http://www.ncbi.nlm.nih.gov/pubmed/1201229",
                "http://www.ncbi.nlm.nih.gov/pubmed/10861819"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7699907",
                    "text": "Plasmapheresis is known as an efficient method for rapid improvement of the hyperviscosity syndrome, and double filtration plasmapheresis is most commonly used for plasma exchange of multiple myeloma patients in our country.",
                    "offsetInBeginSection": 520,
                    "offsetInEndSection": 744,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7699907",
                    "text": "Five to 10 percent of patients with multiple myeloma are suffered from the hyperviscosity syndrome because of increased serum viscosity due to the presence of myeloma protein.",
                    "offsetInBeginSection": 246,
                    "offsetInEndSection": 421,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2385441",
                    "text": "The present report describes a patient with IgA myeloma complicated by hyperviscosity syndrome and multiple bone fractures.",
                    "offsetInBeginSection": 1290,
                    "offsetInEndSection": 1413,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2385441",
                    "text": "And this syndrome has been associated frequently with macroglobulinemia of Waldenstr\u00f6m, occasionally with immunoglobulin (Ig) G myeloma, rarely with IgA myeloma, and with other dysproteinemia.",
                    "offsetInBeginSection": 864,
                    "offsetInEndSection": 1057,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22827791",
                    "text": "Hyperglobulinemia of multiple myeloma (MM) plays a role in hyperviscosity syndrome (HVS).",
                    "offsetInBeginSection": 205,
                    "offsetInEndSection": 294,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9046114",
                    "text": "PE is the most effective method in the treatment of hyperviscosity syndrome often seen with multiple myeloma and Waldenstr\u00f6m's macroglobulinemia, and it is therapy of choice for this complication.",
                    "offsetInBeginSection": 961,
                    "offsetInEndSection": 1158,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26623375",
                    "text": "The present study reported for the first time the use of double filtration plasmapheresis to reduce clinical signs of hyperviscosity syndrome in a dog with multiple myeloma.",
                    "offsetInBeginSection": 527,
                    "offsetInEndSection": 700,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1537697",
                    "text": "Serum hyperviscosity syndrome was diagnosed in 2 cats with multiple myeloma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 76,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1201229",
                    "text": "Two cases of multiple myeloma with IgA gammopathy and the syndrome of serum hyperviscosity are reported.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 104,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1201229",
                    "text": "The hyperviscosity syndrome is being diagnosed with increasing frequency in association with IgA multiple myeloma, and should be investigated in all cases with monoclonal proteins exceeding a concentration of 3-0 g/dl.",
                    "offsetInBeginSection": 754,
                    "offsetInEndSection": 972,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e2578b750ff445500003d",
            "body": "Which package in Bioconductor has been developed with the aim to analyze differential DNA loops from sequencing data?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22847932",
                "http://www.ncbi.nlm.nih.gov/pubmed/27347386",
                "http://www.ncbi.nlm.nih.gov/pubmed/26834993",
                "http://www.ncbi.nlm.nih.gov/pubmed/24979058",
                "http://www.ncbi.nlm.nih.gov/pubmed/29028898",
                "http://www.ncbi.nlm.nih.gov/pubmed/26184873",
                "http://www.ncbi.nlm.nih.gov/pubmed/24227674",
                "http://www.ncbi.nlm.nih.gov/pubmed/24564732",
                "http://www.ncbi.nlm.nih.gov/pubmed/26578583",
                "http://www.ncbi.nlm.nih.gov/pubmed/29052185"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932",
                    "text": "MOTIVATION RNA sequencing is becoming a standard for expression profiling experiments and many tools have been developed in the past few years to analyze RNA-Seq data.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932",
                    "text": "RESULTS We developed 'easyRNASeq', an R package that simplifies the processing of RNA sequencing data, hiding the complex interplay of the required packages behind a single functionality.",
                    "offsetInBeginSection": 558,
                    "offsetInEndSection": 745,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932",
                    "text": "AVAILABILITY The package is implemented in R (as of version 2.15) and is available from Bioconductor (as of version 2.10) at the URL: http://bioconductor.org/packages/release/bioc/html/easyRNASeq.html, where installation and usage instructions can be found.",
                    "offsetInBeginSection": 748,
                    "offsetInEndSection": 1005,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27347386",
                    "text": "In the context of the ever-growing need for tools analyzing\u00a0Ribo-seq reads, we have developed 'RiboProfiling', a new Bioconductor open-source\u00a0package.",
                    "offsetInBeginSection": 403,
                    "offsetInEndSection": 555,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27347386",
                    "text": "Its\u00a0implementation in Bioconductor enables the modeling and statistical analysis of its output\u00a0through the vast choice of packages available in R. This article illustrates how to identify\u00a0codon-motifs accumulating ribosome footprints, based on data from Escherichia coli.",
                    "offsetInBeginSection": 1105,
                    "offsetInEndSection": 1379,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24979058",
                    "text": "We have previously developed an R/Bioconductor package 'exomePeak' for detecting RNA methylation sites under a specific experimental condition or the identifying the differential RNA methylation sites in a case control study from MeRIP-Seq data.",
                    "offsetInBeginSection": 488,
                    "offsetInEndSection": 733,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24979058",
                    "text": "We therein provide here a detailed and easy-to-use protocol of using exomePeak R/Bioconductor package along with other software programs for analysis of MeRIP-Seq data, which covers raw reads alignment, RNA methylation site detection, motif discovery, differential RNA methylation analysis, and functional analysis.",
                    "offsetInBeginSection": 983,
                    "offsetInEndSection": 1298,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028898",
                    "text": "To systematically assess changes in DNA looping architecture between samples, we introduce diffloop, an R/Bioconductor package that provides a suite of functions for the quality control, statistical testing, annotation, and visualization of DNA loops.",
                    "offsetInBeginSection": 288,
                    "offsetInEndSection": 539,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24227674",
                    "text": "RESULTS Here, we present a major update of the R/Bioconductor package MEDIPS, which allows for an arbitrary number of replicates per group and integrates sophisticated statistical methods for the detection of differential coverage between experimental conditions.",
                    "offsetInBeginSection": 625,
                    "offsetInEndSection": 888,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29052185",
                    "text": "The methylPipe Bioconductor package is adopted for the identification of the differentially methylated regions, and all the steps from the raw data to the required input are described in detail.",
                    "offsetInBeginSection": 642,
                    "offsetInEndSection": 836,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8715a961bb38fb24000006",
            "body": "Silent Allosteric Modulation of mGluR5 is a form of treatment for what disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28683325",
                "http://www.ncbi.nlm.nih.gov/pubmed/25323624",
                "http://www.ncbi.nlm.nih.gov/pubmed/24793143",
                "http://www.ncbi.nlm.nih.gov/pubmed/25148681",
                "http://www.ncbi.nlm.nih.gov/pubmed/26063678",
                "http://www.ncbi.nlm.nih.gov/pubmed/27496211",
                "http://www.ncbi.nlm.nih.gov/pubmed/19100966",
                "http://www.ncbi.nlm.nih.gov/pubmed/27881780",
                "http://www.ncbi.nlm.nih.gov/pubmed/15608073",
                "http://www.ncbi.nlm.nih.gov/pubmed/23189054"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683325",
                    "text": "Our data show that mGluR5's role in A\u03b2o-dependent AD phenotypes is separate from its role in glutamate signaling and silent allosteric modulation of mGluR5 has promise as a disease-modifying AD intervention with a broad therapeutic window.",
                    "offsetInBeginSection": 821,
                    "offsetInEndSection": 1061,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683325",
                    "text": "We used a potent mGluR5 silent allosteric modulator (SAM, BMS-984923) to separate its well-known physiological role in glutamate signaling from a pathological role in mediating amyloid-\u03b2 oligomer (A\u03b2o) action.",
                    "offsetInBeginSection": 184,
                    "offsetInEndSection": 395,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25323624",
                    "text": "The central activity of mGluR5 negative allosteric modulators (2-methyl-6-(phenylethynyl)pyridine (MPEP) and [(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) and positive allosteric modulators (S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone (ADX47273) and (7S)-3-tert-butyl-7-[3-(4-fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine (LSN2814617) was examined on sleep-wake architecture.",
                    "offsetInBeginSection": 803,
                    "offsetInEndSection": 1273,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24793143",
                    "text": "Metabotropic glutamate receptors (mGluRs) are high-profile G-protein coupled receptors drug targets because of their involvement in several neurological disease states, and mGluR5 in particular is a subtype whose controlled allosteric modulation, both positive and negative, can potentially be useful for the treatment of schizophrenia and relief of chronic pain, respectively.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 377,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25148681",
                    "text": "Silent allosteric modulators of mGluR5 do not alter Glu or basal mGluR5 activity, but they disrupt the A\u03b2o-induced interaction of mGluR5 with PrP(C).",
                    "offsetInBeginSection": 1230,
                    "offsetInEndSection": 1380,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27496211",
                    "text": "Herein we describe the structure activity relationships uncovered in the pursuit of an mGluR5 positive allosteric modulator (PAM) for the treatment of schizophrenia.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 165,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19100966",
                    "text": "Following the establishment of a cocaine CPP, rats were treated with the mGluR5 positive allosteric modulator 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB; 0.3, 3 and 30 mg/kg) before extinction test sessions.",
                    "offsetInBeginSection": 559,
                    "offsetInEndSection": 780,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19100966",
                    "text": "CONCLUSIONS Positive allosteric modulation of mGluR5 function facilitates the extinction of a cocaine-associated contextual memory, which may represent a novel approach toward enhancing extinction learning in the context of drug addiction.",
                    "offsetInBeginSection": 1245,
                    "offsetInEndSection": 1484,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15608073",
                    "text": "We found that 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB) is a potent and selective positive allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGluR5).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 186,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23189054",
                    "text": "Positive allosteric modulation of the type-5 metabotropic glutamate receptor (mGluR5) in particular has emerged as a treatment strategy for the enhancement of extinction of drug-motivated behaviors.",
                    "offsetInBeginSection": 175,
                    "offsetInEndSection": 373,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f853ab750ff4455000055",
            "body": "Which disease can be diagnosed with the \"probe to bone\" test?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27369321",
                "http://www.ncbi.nlm.nih.gov/pubmed/7853630",
                "http://www.ncbi.nlm.nih.gov/pubmed/7770390",
                "http://www.ncbi.nlm.nih.gov/pubmed/24356116",
                "http://www.ncbi.nlm.nih.gov/pubmed/19141236",
                "http://www.ncbi.nlm.nih.gov/pubmed/8138315",
                "http://www.ncbi.nlm.nih.gov/pubmed/19485522",
                "http://www.ncbi.nlm.nih.gov/pubmed/15318631",
                "http://www.ncbi.nlm.nih.gov/pubmed/21219428",
                "http://www.ncbi.nlm.nih.gov/pubmed/8443004"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27369321",
                    "text": "The probe-to-bone (PTB) test is a commonly used clinical test for osteomyelitis (OM), but its utility has been questioned in clinical settings where the prevalence of OM is low.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7853630",
                    "text": "DESIGN We prospectively assessed infected pedal ulcers for detectable bone by probing with a sterile, blunt, stainless steel probe.",
                    "offsetInBeginSection": 72,
                    "offsetInEndSection": 203,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7770390",
                    "text": "CONCLUSIONS The minisatellite probes MS31 and MS43 were found to be sensitive, effective tests for bone marrow transplants which can be used in routine follow-up.",
                    "offsetInBeginSection": 835,
                    "offsetInEndSection": 997,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7770390",
                    "text": "This study was undertaken to evaluate the usefulness of the minisatellite probes MS31 and MS43 used as a routine follow-up test after bone marrow transplantation.",
                    "offsetInBeginSection": 224,
                    "offsetInEndSection": 386,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24356116",
                    "text": "However, scintigraphy is a nuclear scanning test to trace bone healing during stress fracture and osteomyelitis and thus can be used to probe the osseointegration process in vivo in the context of the dental implant.",
                    "offsetInBeginSection": 82,
                    "offsetInEndSection": 298,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21219428",
                    "text": "CONCLUSIONS Clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain X-ray, or especially both, are positive.",
                    "offsetInBeginSection": 1470,
                    "offsetInEndSection": 1750,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21219428",
                    "text": "AIMS To investigate the accuracy of the sequential combination of the probe-to-bone test and plain X-rays for diagnosing osteomyelitis in the foot of patients with diabetes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 173,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21219428",
                    "text": "All patients with positive results on either the probe-to-bone test or plain X-ray underwent an appropriate surgical procedure, which included obtaining a bone specimen that was processed for histology and culture.",
                    "offsetInBeginSection": 537,
                    "offsetInEndSection": 751,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8443004",
                    "text": "As with our previous findings in Paget's disease of bone, only the antisense probe was found to hybridize to the osteoblasts and osteoclasts within the affected metaphyses.",
                    "offsetInBeginSection": 738,
                    "offsetInEndSection": 910,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8443004",
                    "text": "Using the technique of in situ hybridisation, we have recently extended our observations that canine distemper virus (CDV) is present in the bone cells of patients with Paget's disease, and have shown that CDV is also detectable in the bone cells of dogs that are naturally infected with the virus.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 298,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e33e4b750ff4455000041",
            "body": "Describe annotatr",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28369316",
                "http://www.ncbi.nlm.nih.gov/pubmed/28800283",
                "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                "http://www.ncbi.nlm.nih.gov/pubmed/15861591",
                "http://www.ncbi.nlm.nih.gov/pubmed/25709171",
                "http://www.ncbi.nlm.nih.gov/pubmed/18428249",
                "http://www.ncbi.nlm.nih.gov/pubmed/8140769",
                "http://www.ncbi.nlm.nih.gov/pubmed/8933228",
                "http://www.ncbi.nlm.nih.gov/pubmed/25543586",
                "http://www.ncbi.nlm.nih.gov/pubmed/7516089"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                    "text": "We describe first a field deployable mass spectrometer, based on an ion trap analyzer, and variants of that system.",
                    "offsetInBeginSection": 375,
                    "offsetInEndSection": 490,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                    "text": "We describe four sensing and characterization technologies recently developed at Los Alamos National Laboratory; a select set of mass spectral and optical techniques is emphasized.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                    "text": "We then describe a hand-held, battery-operated optical spectrometer, usable in either absorption, or fluorescence excitation mode.",
                    "offsetInBeginSection": 491,
                    "offsetInEndSection": 621,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                    "text": "A laser-based mass spectrometer is also described, which used a minimal tunable laser system, and a time-of-flight mass spectrometer.",
                    "offsetInBeginSection": 622,
                    "offsetInEndSection": 755,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15861591",
                    "text": "Experience of SA-RPE using the simplified technique described by Pogrel et al is describe.",
                    "offsetInBeginSection": 585,
                    "offsetInEndSection": 675,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25709171",
                    "text": "We describe a rare, newly described syndrome with features of overgrowth and vascular malformations.",
                    "offsetInBeginSection": 113,
                    "offsetInEndSection": 213,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18428249",
                    "text": "Several support protocols describe methods for adenovirus growth and purification, biotinylation, inactivation with psoralen, and quantitation of the adenovirus particles.",
                    "offsetInBeginSection": 279,
                    "offsetInEndSection": 450,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8140769",
                    "text": "The authors describe another subtype of antigen HLA-B27, described as HLA-B27P3.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 80,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8933228",
                    "text": "The aim of this study is to describe the essential characteristics of a family affected by the newly-described proximal myotonic myopathy (PROMM) The clinical, laboratory and genetic findings are described and compared with those reported in the literature, and the clinical spectrum of the manifestations that are similar to but distinct from myotonic dystrophy (MD) is also explored.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 385,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7516089",
                    "text": "We describe here the first case of unilateral, tubal twin pregnancy to be documented by ultrasound, with cardiac activity of two foetuses detected by the endovaginal probe.",
                    "offsetInBeginSection": 609,
                    "offsetInEndSection": 781,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8718c861bb38fb24000008",
            "body": "What are check point inhibitors?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27528363",
                "http://www.ncbi.nlm.nih.gov/pubmed/26775673",
                "http://www.ncbi.nlm.nih.gov/pubmed/28878676",
                "http://www.ncbi.nlm.nih.gov/pubmed/28865357",
                "http://www.ncbi.nlm.nih.gov/pubmed/27403706",
                "http://www.ncbi.nlm.nih.gov/pubmed/25956379",
                "http://www.ncbi.nlm.nih.gov/pubmed/27722817",
                "http://www.ncbi.nlm.nih.gov/pubmed/27167347",
                "http://www.ncbi.nlm.nih.gov/pubmed/18069260",
                "http://www.ncbi.nlm.nih.gov/pubmed/27654928"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528363",
                    "text": "OBJECTIVE To clarify the role of immune check point inhibitors in GBM management.",
                    "offsetInBeginSection": 490,
                    "offsetInEndSection": 571,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28878676",
                    "text": "Check point antibody inhibitors, such as anti-PD-1/PD-L1, are a novel class of inhibitors that function as a tumor suppressing factor via modulation of immune cell-tumor cell interaction.",
                    "offsetInBeginSection": 236,
                    "offsetInEndSection": 423,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28878676",
                    "text": "In recent times, more than four check point antibody inhibitors have been commercialized for targeting PD-1, PDL-1, and CTLA-4.",
                    "offsetInBeginSection": 588,
                    "offsetInEndSection": 715,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27403706",
                    "text": "check point inhibitors.",
                    "offsetInBeginSection": 296,
                    "offsetInEndSection": 319,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27403706",
                    "text": "Patients with BRAFv600 mutations can be treated with a combination of a BRAF-inhibitor and an MEK-inhibitor.",
                    "offsetInBeginSection": 84,
                    "offsetInEndSection": 192,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27403706",
                    "text": "AREAS COVERED We conducted a comprehensive review of the literature on the efficacy and predictive markers, safety, and pharmacoeconomics of ipilimumab in melanoma Expert commentary: Ipilimumab was the first check point inhibitor reaching the clinic, gaining FDA and EMA approval for metastatic melanoma in 2011.",
                    "offsetInBeginSection": 322,
                    "offsetInEndSection": 634,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25956379",
                    "text": "Check point kinase 1 (Chk1) is an important protein in G2 phase checkpoint arrest required by cancer cells to maintain cell cycle and to prevent cell death.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 156,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27722817",
                    "text": "We implemented this new methodology to develop valid pharmacophore models for check point kinase 1 (Chk1) and beta-secretase 1 (BACE1) inhibitors as case studies.",
                    "offsetInBeginSection": 784,
                    "offsetInEndSection": 946,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18069260",
                    "text": "Accumulating evidences suggest that many molecules are working as inhibitors of proliferation in myeloma cells e.g., PTEN, mTOR(PI3-kinase signal molecules), p53, RB1, INK4 family and KIP/CIP family (cell cycle check point molecules), PF4 (inhibitor of angiogenesis).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 267,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27654928",
                    "text": "These agents include monoclonal antibodies, deacetylase inhibitors, kinase inhibitors, agents affecting various signaling pathways, immune check point inhibitors, and other targeted therapies.",
                    "offsetInBeginSection": 359,
                    "offsetInEndSection": 551,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f87c5b750ff4455000056",
            "body": "Are patients with Sjogren syndrome at increased risk for lymphoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27336863",
                "http://www.ncbi.nlm.nih.gov/pubmed/17562045",
                "http://www.ncbi.nlm.nih.gov/pubmed/25368273",
                "http://www.ncbi.nlm.nih.gov/pubmed/1608349",
                "http://www.ncbi.nlm.nih.gov/pubmed/16462517",
                "http://www.ncbi.nlm.nih.gov/pubmed/2110929",
                "http://www.ncbi.nlm.nih.gov/pubmed/20084442",
                "http://www.ncbi.nlm.nih.gov/pubmed/24159176",
                "http://www.ncbi.nlm.nih.gov/pubmed/28779180",
                "http://www.ncbi.nlm.nih.gov/pubmed/10325663"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27336863",
                    "text": "The heightened risk of non-Hodgkin lymphoma (NHL) development in primary Sjogren syndrome (SS) is well established.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 115,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25368273",
                    "text": "The average risk of lymphoma in RA may be composed of a markedly increased risk in patients with most severe disease.",
                    "offsetInBeginSection": 937,
                    "offsetInEndSection": 1054,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16462517",
                    "text": "RECENT FINDINGS Despite a lack of a strong association between rheumatoid arthritis and cancer overall, studies show an increased risk for the development of lymphoma in rheumatoid arthritis.",
                    "offsetInBeginSection": 447,
                    "offsetInEndSection": 638,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16462517",
                    "text": "Data substantiate an increased risk of certain cancers in systemic lupus erythematosus; the risk appears to be most heightened for lymphoma.",
                    "offsetInBeginSection": 911,
                    "offsetInEndSection": 1051,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2110929",
                    "text": "Clinical features such as age, duration of disease, extent of lymphadenopathy, splenomegaly, or parotid swelling failed to identify those subsets of patients with lymphadenopathy at increased risk for lymphoma.",
                    "offsetInBeginSection": 1026,
                    "offsetInEndSection": 1236,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20084442",
                    "text": "These findings suggest that patients with pSS who have ACA may be a subgroup of patients at increased risk of extraglandular systemic manifestations and lymphoma.",
                    "offsetInBeginSection": 668,
                    "offsetInEndSection": 830,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24159176",
                    "text": "Several autoimmune diseases, including primary Sj\u00f6gren's syndrome (pSS), are associated with an increased risk for lymphoma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 125,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24159176",
                    "text": "The rs2230926 exonic variant was associated with an increased risk for pSS complicated by lymphoma (odds ratio, 3.36 [95% confidence interval, 1.34-8.42], and odds ratio, 3.26 [95% confidence interval, 1.31-8.12], vs controls and pSS patients without lymphoma, respectively; P = .011).",
                    "offsetInBeginSection": 720,
                    "offsetInEndSection": 1005,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28779180",
                    "text": "Primary Sjogren's syndrome (pSS) confers increased risk for non-Hodgkin lymphoma (NHL) development.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 99,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10325663",
                    "text": "We have previously found that anti-Ro antibodies identified patients with more systemic disease, with increased incidence of parotid swelling, lymphadenopathy and lymphoma.",
                    "offsetInBeginSection": 191,
                    "offsetInEndSection": 363,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e3d21b750ff4455000043",
            "body": "What is BBCAnalyzer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28241736"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "RESULTS BBCAnalyzer (Bases By CIGAR Analyzer) provides a novel visual approach to facilitate this step of time-consuming, manual inspection of common mutation sites.",
                    "offsetInBeginSection": 501,
                    "offsetInEndSection": 666,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "CONCLUSIONS BBCAnalyzer provides a unique, novel approach to facilitate variant calling where classical tools frequently fail to call.",
                    "offsetInBeginSection": 1412,
                    "offsetInEndSection": 1546,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "BBCAnalyzer is able to visualize base counts at predefined positions or regions in any sequence alignment data that are available as BAM files.",
                    "offsetInBeginSection": 667,
                    "offsetInEndSection": 810,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "Video demonstrating the exemplary usage of the web application \"BBCAnalyzer\".",
                    "offsetInBeginSection": 2026,
                    "offsetInEndSection": 2103,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "Any expected mutations (e.g.",
                    "offsetInBeginSection": 373,
                    "offsetInEndSection": 401,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "Thereby, the tool provides a straightforward solution for evaluating any list of expected mutations like hotspot mutations, or even whole regions of interest.",
                    "offsetInBeginSection": 811,
                    "offsetInEndSection": 969,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "Information on the counted number of bases, the reference bases, known mutations or polymorphisms, called mutations and base qualities is summarized in a single plot.",
                    "offsetInBeginSection": 1060,
                    "offsetInEndSection": 1226,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "hotspot mutations), that have not been called by the software, need to be investigated manually.",
                    "offsetInBeginSection": 402,
                    "offsetInEndSection": 498,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "BACKGROUND Deriving valid variant calling results from raw next-generation sequencing data is a particularly challenging task, especially with respect to clinical diagnostics and personalized medicine.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 201,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "A documentation of the R package (Additional file 1) as well as the web application (Additional file 2) with detailed descriptions, examples of all input- and output elements, exemplary code as well as exemplary data are included.",
                    "offsetInBeginSection": 1671,
                    "offsetInEndSection": 1901,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a871a6861bb38fb24000009",
            "body": "What disease is the ALK tyrosine kinase associated with?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20223922",
                "http://www.ncbi.nlm.nih.gov/pubmed/25407901",
                "http://www.ncbi.nlm.nih.gov/pubmed/27573755",
                "http://www.ncbi.nlm.nih.gov/pubmed/23714228",
                "http://www.ncbi.nlm.nih.gov/pubmed/25351247",
                "http://www.ncbi.nlm.nih.gov/pubmed/22184391",
                "http://www.ncbi.nlm.nih.gov/pubmed/21829174",
                "http://www.ncbi.nlm.nih.gov/pubmed/23154552",
                "http://www.ncbi.nlm.nih.gov/pubmed/12185581",
                "http://www.ncbi.nlm.nih.gov/pubmed/26294238"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20223922",
                    "text": "NPM-ALK (nucleophosmin-anaplastic lymphoma kinase) and TPM3-ALK (nonmuscular tropomyosin 3-anaplastic lymphoma kinase) are oncogenic tyrosine kinases implicated in the pathogenesis of human ALK-positive lymphoma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 212,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25407901",
                    "text": "In contrast, ALK tyrosine kinase inhibitor (ALK TKI) crizotinib has shown superior effects in combating NSCLCs with EML4-ALK.",
                    "offsetInBeginSection": 450,
                    "offsetInEndSection": 575,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25407901",
                    "text": "It has been suggested that EML4-ALK fusion is associated with the resistance in NSCLCs to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), such as gefitinib and erlotinib.",
                    "offsetInBeginSection": 254,
                    "offsetInEndSection": 449,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25407901",
                    "text": "BACKGROUND The translocations of the anaplastic lymphoma kinase (ALK) gene with the echinoderm microtubule-associated protein-like 4 (EML4) gene on chromosome 2p have been identified in non-small-cell lung cancers (NSCLCs) as oncogenic driver mutations.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 253,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23714228",
                    "text": "CASE PRESENTATION We report that a case of EML4-ALK-positive NSCLC with EGFR mutation had a response of stable disease to both an EGFR tyrosine kinase inhibitor (EGFR-TKI) and ALK inhibitor.",
                    "offsetInBeginSection": 355,
                    "offsetInEndSection": 545,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23714228",
                    "text": "BACKGROUND The EML4-ALK (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) fusion oncogene represents a novel molecular target in a small subset of non-small-cell lung cancers (NSCLCs).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 230,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25351247",
                    "text": "Although tyrosine kinase inhibitors abrogating ALK activity are currently in clinical use for the treatment of ALK-positive (ALK(+)) disease, monotherapy with ALK tyrosine kinase inhibitors may not be an adequate solution for ALK(+) neuroblastoma patients.",
                    "offsetInBeginSection": 84,
                    "offsetInEndSection": 340,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26294238",
                    "text": "Crizotinib is an oral tyrosine kinase inhibitor approved in 2011 as a first-line therapy for patients with metastatic ALK mutation-driven NSCLC.",
                    "offsetInBeginSection": 440,
                    "offsetInEndSection": 584,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26294238",
                    "text": "CONCLUSION The tyrosine kinase inhibitors crizotinib and ceritinib provide an effective treatment approach for patients with ALK-mutated NSCLC.",
                    "offsetInBeginSection": 1442,
                    "offsetInEndSection": 1585,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26294238",
                    "text": "SUMMARY The ALK protein functions as a transmembrane receptor tyrosine kinase; rearrangements of the ALK gene are associated with the development of NSCLC with adenocarcinoma histology.",
                    "offsetInBeginSection": 254,
                    "offsetInEndSection": 439,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f8dc6b750ff4455000058",
            "body": "Is trastuzumab associated cardiotoxicity reversible?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19669637",
                "http://www.ncbi.nlm.nih.gov/pubmed/15177418",
                "http://www.ncbi.nlm.nih.gov/pubmed/26836985",
                "http://www.ncbi.nlm.nih.gov/pubmed/18484781",
                "http://www.ncbi.nlm.nih.gov/pubmed/23282614",
                "http://www.ncbi.nlm.nih.gov/pubmed/21310845",
                "http://www.ncbi.nlm.nih.gov/pubmed/24905295",
                "http://www.ncbi.nlm.nih.gov/pubmed/19147689",
                "http://www.ncbi.nlm.nih.gov/pubmed/20175700",
                "http://www.ncbi.nlm.nih.gov/pubmed/11706392"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19669637",
                    "text": "INTRODUCTION Although having high clinical efficacy in the treatment of human epidermal growth factor receptor-2 (HER2+) metastatic breast cancer, trastuzumab has been associated with cardiotoxicity, and the etiology and pathogenesis of this condition is currently under investigation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 285,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19669637",
                    "text": "RESULTS The increased risk of cardiotoxicity is lower when trastuzumab is given as monotherapy (3%-7%) compared with anthracyclines + trastuzumab therapy (27%).",
                    "offsetInBeginSection": 442,
                    "offsetInEndSection": 602,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836985",
                    "text": "The cardiotoxicity of antibodies has been associated to trastuzumab, a humanized anti-ErbB2 monoclonal antibody currently in clinical use for the therapy of breast carcinomas, which induces cardiac dysfunction when used in monotherapy, or in combination with anthracyclines.",
                    "offsetInBeginSection": 563,
                    "offsetInEndSection": 837,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836985",
                    "text": "Two categories of cardiotoxic side effects of antineoplastic drugs have been previously proposed: Type I cardiotoxicity, defined as permanent cardiotoxicity, is usually caused by anthracyclines; Type II cardiotoxicity, considered as reversible cardiotoxicity, has been mainly related to monoclonal antibodies.",
                    "offsetInBeginSection": 253,
                    "offsetInEndSection": 562,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21310845",
                    "text": "The long-term significance of these events, isolating known cardiotoxic effects of anthracyclines from those of trastuzumab, and the appropriateness of referring to trastuzumab-related cardiotoxicity as reversible rather than responsive to trastuzumab withdrawal and heart failure medical therapy, are issues that continue to be debated.",
                    "offsetInBeginSection": 150,
                    "offsetInEndSection": 487,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21310845",
                    "text": "The use of trastuzumab in the adjuvant and metastatic treatment of breast cancer is associated with both symptomatic and asymptomatic cardiotoxicity.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19147689",
                    "text": "Concomitant anthracycline therapy significantly increases the risk for cardiotoxicity during trastuzumab treatment, and such regimens are therefore not recommended.",
                    "offsetInBeginSection": 415,
                    "offsetInEndSection": 579,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20175700",
                    "text": "Mechanisms of trastuzumab-associated cardiotoxicity are proposed and compared to what is known about anthracycline-induced cardiotoxicity.",
                    "offsetInBeginSection": 820,
                    "offsetInEndSection": 958,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11706392",
                    "text": "Trastuzumab/anthracycline cardiomyopathy may be the first clinically significant cardiotoxicity to emerge from signal transduction therapeutics.",
                    "offsetInBeginSection": 661,
                    "offsetInEndSection": 805,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11706392",
                    "text": "Thus, trastuzumab-associated cardiotoxicity must be explained by some alternative mechanism.",
                    "offsetInBeginSection": 1299,
                    "offsetInEndSection": 1391,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e3fe3b750ff4455000044",
            "body": "Does the human lncRNA LINC-PINT promote tumorigenesis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29078818",
                "http://www.ncbi.nlm.nih.gov/pubmed/27708234",
                "http://www.ncbi.nlm.nih.gov/pubmed/24922071",
                "http://www.ncbi.nlm.nih.gov/pubmed/24381249",
                "http://www.ncbi.nlm.nih.gov/pubmed/26898939",
                "http://www.ncbi.nlm.nih.gov/pubmed/29050257",
                "http://www.ncbi.nlm.nih.gov/pubmed/29041978",
                "http://www.ncbi.nlm.nih.gov/pubmed/24463816",
                "http://www.ncbi.nlm.nih.gov/pubmed/27855392",
                "http://www.ncbi.nlm.nih.gov/pubmed/26807174"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818",
                    "text": "RESULTS Here we characterize the function of the p53-regulated human lncRNA LINC-PINT in cancer.",
                    "offsetInBeginSection": 405,
                    "offsetInEndSection": 501,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818",
                    "text": "We find that LINC-PINT is downregulated in multiple types of cancer and acts as a tumor suppressor lncRNA by reducing the invasive phenotype of cancer cells.",
                    "offsetInBeginSection": 502,
                    "offsetInEndSection": 659,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818",
                    "text": "CONCLUSIONS Our findings support a conserved functional co-dependence between LINC-PINT and PRC2 and lead us to propose a new mechanism where the lncRNA regulates the availability of free PRC2 at the proximity of co-regulated genomic loci.",
                    "offsetInBeginSection": 970,
                    "offsetInEndSection": 1209,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818",
                    "text": "This sequence mediates a specific interaction with PRC2, necessary for the LINC-PINT-dependent repression of a pro-invasion signature of genes regulated by the transcription factor EGR1.",
                    "offsetInBeginSection": 781,
                    "offsetInEndSection": 967,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27708234",
                    "text": "Long intergenic non-protein coding RNA, p53 induced transcript (Linc-pint) is a long noncoding RNA (lncRNA) that regulates tumor cell viability and proliferation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24381249",
                    "text": "We also report growth defects for two additional mutant strains (linc-Brn1b and linc-Pint).",
                    "offsetInBeginSection": 582,
                    "offsetInEndSection": 673,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29050257",
                    "text": "Long intergenic non-protein coding RNA, regulator of reprogramming (linc-ROR) is an intergenic long non-coding RNA (lncRNA) previously shown to contribute to tumorigenesis in several malignancies.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29041978",
                    "text": "RESULTS We identified that linc-RoR functions as an onco-lncRNA to promote estrogen-independent growth of ER+ breast cancer.",
                    "offsetInBeginSection": 1072,
                    "offsetInEndSection": 1196,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24463816",
                    "text": "These studies show that linc-RoR is a hypoxia-responsive lncRNA that is functionally linked to hypoxia signaling in HCC through a miR-145-HIF-1\u03b1 signaling module.",
                    "offsetInBeginSection": 1193,
                    "offsetInEndSection": 1356,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27855392",
                    "text": "Linc-ROR has been shown to be dysregulated in many types of cancers, including breast cancer (BC), pancreatic cancer (PC), hepatocellular cancer (HCC), endometrial cancer (EC), and nasopharyngeal carcinoma (NPC).",
                    "offsetInBeginSection": 763,
                    "offsetInEndSection": 975,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a871b8d61bb38fb2400000a",
            "body": "What body process does the Dentate Gyrus Mossy Cell control?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18189312",
                "http://www.ncbi.nlm.nih.gov/pubmed/24811867",
                "http://www.ncbi.nlm.nih.gov/pubmed/10531454",
                "http://www.ncbi.nlm.nih.gov/pubmed/9187278",
                "http://www.ncbi.nlm.nih.gov/pubmed/14999076",
                "http://www.ncbi.nlm.nih.gov/pubmed/18077687",
                "http://www.ncbi.nlm.nih.gov/pubmed/7721998",
                "http://www.ncbi.nlm.nih.gov/pubmed/1466768",
                "http://www.ncbi.nlm.nih.gov/pubmed/1308178",
                "http://www.ncbi.nlm.nih.gov/pubmed/28284897"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18189312",
                    "text": "In the examined four monkey species, mossy cells were found to be calretinin-positive at the uncal pole and at variable length within the main body of the dentate gyrus but not in the tail part.",
                    "offsetInBeginSection": 580,
                    "offsetInEndSection": 774,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24811867",
                    "text": "This complex arrangement of cells and processes allowed us to study the combined effect of mossy fiber sprouting, altered apical dendritic tree and dendritic spine loss in newborn granule cells on the excitability of the dentate gyrus model.",
                    "offsetInBeginSection": 1305,
                    "offsetInEndSection": 1546,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10531454",
                    "text": "These findings support hypotheses of temporal lobe epileptogenesis that involve mossy cell and somatostatinergic neuron loss and suggest that lateral inhibition in the dentate gyrus does not require mossy cells but, instead, may be generated directly by GABAergic interneurons.",
                    "offsetInBeginSection": 1462,
                    "offsetInEndSection": 1739,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10531454",
                    "text": "Kainate-treated rats lose an average of 52% of their GAD-negative hilar neurons (putative mossy cells) and 13% of their GAD-positive cells (GABAergic interneurons) in the dentate gyrus.",
                    "offsetInBeginSection": 323,
                    "offsetInEndSection": 508,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9187278",
                    "text": "Mossy cells in the hilus of the rat dentate gyrus are the main cells of origin of the dentate commissural and associational projections.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14999076",
                    "text": "However, whether it is the disappearance of hilar mossy cells from the dentate gyrus circuitry after various insults or the subsequent synaptic-cellular alterations (e.g., reactive axonal sprouting) that lead to dentate hyperexcitability has not been rigorously tested, because of the lack of available techniques to rapidly remove specific classes of nonprincipal cells from neuronal networks.",
                    "offsetInBeginSection": 372,
                    "offsetInEndSection": 766,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7721998",
                    "text": "These results establish the validity of Timm staining as a marker for mossy fiber sprouting and support the view that status epilepticus provokes the formation of a novel recurrent excitatory circuit in the dentate gyrus.",
                    "offsetInBeginSection": 1829,
                    "offsetInEndSection": 2050,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1308178",
                    "text": "The present results indicate that connections between granule cells and hilar mossy cells of the human dentate gyrus develop through an extended postnatal period of time that may last until the fifth year.",
                    "offsetInBeginSection": 1584,
                    "offsetInEndSection": 1789,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28284897",
                    "text": "In this study we tested whether prolonged DR results in deleterious alterations in hippocampal neurogenesis, density of granule cell neurons and mossy fibers, all of which support plasticity in the dentate gyrus.",
                    "offsetInBeginSection": 139,
                    "offsetInEndSection": 351,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28284897",
                    "text": "Our findings demonstrate that granule cell neurons in the dentate gyrus are vulnerable to chronic DR and that the reorganization of granule cells in the dentate gyrus subregions is not producing concomitant alterations in dentate gyrus neuronal circuitry with this type of DR.",
                    "offsetInBeginSection": 1416,
                    "offsetInEndSection": 1692,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f922fb750ff4455000059",
            "body": "Can canagliflozin cause euglycemic diabetic ketoacidosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27375734",
                "http://www.ncbi.nlm.nih.gov/pubmed/28090050",
                "http://www.ncbi.nlm.nih.gov/pubmed/27928503",
                "http://www.ncbi.nlm.nih.gov/pubmed/28634592",
                "http://www.ncbi.nlm.nih.gov/pubmed/27471597",
                "http://www.ncbi.nlm.nih.gov/pubmed/27088018",
                "http://www.ncbi.nlm.nih.gov/pubmed/26912914",
                "http://www.ncbi.nlm.nih.gov/pubmed/27717592",
                "http://www.ncbi.nlm.nih.gov/pubmed/29099159",
                "http://www.ncbi.nlm.nih.gov/pubmed/27635409"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375734",
                    "text": "We are reporting a timely case of atypical euglycemic diabetic ketoacidosis in a type 1 diabetic patient treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitor canagliflozin.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 182,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375734",
                    "text": "Euglycemic ketoacidosis did not recur in our patient after discontinuing canagliflozin.",
                    "offsetInBeginSection": 508,
                    "offsetInEndSection": 595,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28090050",
                    "text": "We herein report the case of a 27-year-old Asian woman with type 2 diabetes who was treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor (canagliflozin) who developed euglycemic diabetic ketoacidosis and persistent diuresis in the absence of hyperglycemia.",
                    "offsetInBeginSection": 175,
                    "offsetInEndSection": 442,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27928503",
                    "text": "We present a case of euglycemic diabetic ketoacidosis secondary to canagliflozin in a type 2 diabetic patient.",
                    "offsetInBeginSection": 558,
                    "offsetInEndSection": 668,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27928503",
                    "text": "Ketoacidosis is a significant and often a life-threatening complication of diabetes mellitus seen mostly in type 1 diabetes mellitus as well as occasionally in type 2 diabetes mellitus.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27928503",
                    "text": "Diabetic ketoacidosis usually manifests with high blood glucose more than 250\u2009mg/dL, but euglycemic diabetic ketoacidosis is defined as ketoacidosis associated with blood glucose level less than 250\u2009mg/dL.",
                    "offsetInBeginSection": 186,
                    "offsetInEndSection": 395,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28634592",
                    "text": "SGLT2 inhibitors such as canagliflozin may predispose patients not only to diabetic ketoacidosis but also to prolonged glucosuria.",
                    "offsetInBeginSection": 1103,
                    "offsetInEndSection": 1233,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27088018",
                    "text": "However, some serious side effects, including severe anion gap metabolic acidosis and euglycemic diabetic ketoacidosis (DKA), have been reported.",
                    "offsetInBeginSection": 333,
                    "offsetInEndSection": 478,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29099159",
                    "text": "OBJECTIVE Canagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, one of a class of novel antiglycemic agents that are gaining in popularity in the treatment of diabetes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29099159",
                    "text": "CONCLUSION Treatment with canagliflozin was associated with development of euglycemic ketoacidosis.",
                    "offsetInBeginSection": 561,
                    "offsetInEndSection": 660,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e4136b750ff4455000045",
            "body": "Describe the Match BAM to VCF (MBV) method.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28186259",
                "http://www.ncbi.nlm.nih.gov/pubmed/28369524",
                "http://www.ncbi.nlm.nih.gov/pubmed/24451629",
                "http://www.ncbi.nlm.nih.gov/pubmed/23765705",
                "http://www.ncbi.nlm.nih.gov/pubmed/17891616",
                "http://www.ncbi.nlm.nih.gov/pubmed/19749478",
                "http://www.ncbi.nlm.nih.gov/pubmed/14696220",
                "http://www.ncbi.nlm.nih.gov/pubmed/27899667",
                "http://www.ncbi.nlm.nih.gov/pubmed/27153667",
                "http://www.ncbi.nlm.nih.gov/pubmed/26153076"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28186259",
                    "text": "Results We described here MBV (Match BAM to VCF); a method to quickly solve sample mislabeling and detect cross-sample contamination and PCR amplification bias.",
                    "offsetInBeginSection": 189,
                    "offsetInEndSection": 349,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369524",
                    "text": "Here, we describe NGSCheckMate, a user-friendly software package for verifying sample identities from FASTQ, BAM or VCF files.",
                    "offsetInBeginSection": 438,
                    "offsetInEndSection": 564,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369524",
                    "text": "Our evaluation shows that NGSCheckMate is effective for a variety of data types, including exome sequencing, whole-genome sequencing, RNA-seq, ChIP-seq, targeted sequencing and single-cell whole-genome sequencing, with a minimal requirement for sequencing depth (>0.5X).",
                    "offsetInBeginSection": 772,
                    "offsetInEndSection": 1042,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24451629",
                    "text": "Many current tool chains are based on the widely used file formats BAM and VCF or VCF-derivatives.",
                    "offsetInBeginSection": 203,
                    "offsetInEndSection": 301,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23765705",
                    "text": "BACKGROUND Transthoracic (TTE) and intracardiac echocardiography (ICE) have both been established as modalities for imaging guidance in mitral balloon valvuloplasty (MBV).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17891616",
                    "text": "A perfusion quantification method was applied to obtain MBV maps.",
                    "offsetInBeginSection": 718,
                    "offsetInEndSection": 783,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19749478",
                    "text": "CONCLUSIONS Valsartan, an angiotensin II receptor blocker, corrected the decreased MBV in association with regression of LVH in patients with HT.",
                    "offsetInBeginSection": 1286,
                    "offsetInEndSection": 1431,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899667",
                    "text": "JBrowse now displays BAM, VCF and other annotation tracks, the additional genome assemblies and an embedded VISTA genome comparison viewer.",
                    "offsetInBeginSection": 418,
                    "offsetInEndSection": 557,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27153667",
                    "text": "AVAILABILITY AND IMPLEMENTATION BAM-matcher is licensed under the Creative Commons by Attribution license, and is available from: https://bitbucket.org/sacgf/bam-matcher   SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.",
                    "offsetInBeginSection": 865,
                    "offsetInEndSection": 1121,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26153076",
                    "text": "The tool is a single command script that calls a series of modules based on user-defined options and takes sorted/indexed bam files or vcf files as input.",
                    "offsetInBeginSection": 607,
                    "offsetInEndSection": 761,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a897601fcd1d6a10c000008",
            "body": "A SLEDAI score is associated with Systemic Lupus Erythematosus. What is a SLEDAI score?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19762400",
                "http://www.ncbi.nlm.nih.gov/pubmed/10685800",
                "http://www.ncbi.nlm.nih.gov/pubmed/8235662",
                "http://www.ncbi.nlm.nih.gov/pubmed/11480850",
                "http://www.ncbi.nlm.nih.gov/pubmed/27365721",
                "http://www.ncbi.nlm.nih.gov/pubmed/17477466",
                "http://www.ncbi.nlm.nih.gov/pubmed/23647447",
                "http://www.ncbi.nlm.nih.gov/pubmed/28243944",
                "http://www.ncbi.nlm.nih.gov/pubmed/18668552",
                "http://www.ncbi.nlm.nih.gov/pubmed/29168029"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19762400",
                    "text": "The objective of this study is to determine if digital vasculitis (DV), a clinical manifestation with a high systemic lupus erythematosus disease activity index (SLEDAI) score, is associated with lupus severity.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 211,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19762400",
                    "text": "DV and other clinical manifestations defined according to the SLEDAI were evaluated in 168 consecutive patients with systemic lupus erythematosus (SLE).",
                    "offsetInBeginSection": 212,
                    "offsetInEndSection": 364,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800",
                    "text": "OBJECTIVE To determine whether Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores correlate with the clinician's impression of level of disease activity.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 170,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800",
                    "text": "The SLEDAI score was calculated from the database.",
                    "offsetInBeginSection": 652,
                    "offsetInEndSection": 702,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11480850",
                    "text": "Sociodemographic, disease activity using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), therapy and laboratory variables were evaluated.",
                    "offsetInBeginSection": 384,
                    "offsetInEndSection": 539,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27365721",
                    "text": "Systemic lupus erythematosus disease activity index (SLEDAI), C3, C4 and anti-double stranded DNA levels were estimated and repeated monthly till remission.",
                    "offsetInBeginSection": 297,
                    "offsetInEndSection": 453,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27365721",
                    "text": "Values of serological parameters were then correlated with SLEDAI score.",
                    "offsetInBeginSection": 507,
                    "offsetInEndSection": 579,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17477466",
                    "text": "OBJECTIVE To determine the flare rate and the change in Safety of Estrogens in Lupus Erythematosus: National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA SLEDAI) score with disease flare in pediatric systemic lupus erythematosus (pSLE).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 262,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17477466",
                    "text": "The average change in the SELENA SLEDAI score with disease flare is 2 points.",
                    "offsetInBeginSection": 1608,
                    "offsetInEndSection": 1685,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18668552",
                    "text": "Univariate analysis was used to determine the association among the Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, serum anti-double-stranded DNA (anti-dsDNA), and plasma BLyS levels.",
                    "offsetInBeginSection": 361,
                    "offsetInEndSection": 653,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f941eb750ff445500005b",
            "body": "What is the association between kidney donation risk of gestational complications?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27591246",
                "http://www.ncbi.nlm.nih.gov/pubmed/26090646",
                "http://www.ncbi.nlm.nih.gov/pubmed/26558022",
                "http://www.ncbi.nlm.nih.gov/pubmed/25941060",
                "http://www.ncbi.nlm.nih.gov/pubmed/12351541",
                "http://www.ncbi.nlm.nih.gov/pubmed/22252087",
                "http://www.ncbi.nlm.nih.gov/pubmed/27271097",
                "http://www.ncbi.nlm.nih.gov/pubmed/19353771",
                "http://www.ncbi.nlm.nih.gov/pubmed/18798006",
                "http://www.ncbi.nlm.nih.gov/pubmed/25774590"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591246",
                    "text": "A modest rise in uric acid levels beginning early after donation, and a small (1.4%) increase in the 8-year incidence of gout, have also been reported in comparisons to healthy nondonors.",
                    "offsetInBeginSection": 965,
                    "offsetInEndSection": 1152,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26090646",
                    "text": "Kidney donation seems to elevate the risks of gestational hypertension and pre-eclampsia.",
                    "offsetInBeginSection": 462,
                    "offsetInEndSection": 551,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26090646",
                    "text": "Living kidney donation is associated with an increased risk of end-stage renal disease, although this outcome is uncommon (<0\u00b75% increase in incidence at 15 years).",
                    "offsetInBeginSection": 296,
                    "offsetInEndSection": 461,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12351541",
                    "text": "CONCLUSIONS There is a high risk of obstetric complications in singleton oocyte donation pregnancies, but the perinatal outcomes are favourable.",
                    "offsetInBeginSection": 1189,
                    "offsetInEndSection": 1333,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12351541",
                    "text": "LBW deliveries were significantly associated with PIH, STB, nulliparity and maternal smoking.",
                    "offsetInBeginSection": 950,
                    "offsetInEndSection": 1043,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22252087",
                    "text": "BACKGROUND Although older maternal age is a risk factor for pregnancy complications, an increasing number of women delay conception until the age of 40, and some must resort to IVF with oocyte donation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 202,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27271097",
                    "text": "WIDER IMPLICATIONS Oocyte donation pregnancies are associated with a higher rate of placental disorders of pregnancy, such as gestational hypertension and pre-eclampsia.",
                    "offsetInBeginSection": 1320,
                    "offsetInEndSection": 1489,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27271097",
                    "text": "Oocyte donation also seems to be associated with lower fetal birthweight.",
                    "offsetInBeginSection": 1021,
                    "offsetInEndSection": 1094,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18798006",
                    "text": "We conclude that most donors do not have enough knowledge about possible in-hospital and long-term complications of kidney donation and may not participate in regular follow-up after operation.",
                    "offsetInBeginSection": 1356,
                    "offsetInEndSection": 1549,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25774590",
                    "text": "It disproves a previous assumption of \"non-interference\" between kidney donation and pregnancy outcomes.",
                    "offsetInBeginSection": 408,
                    "offsetInEndSection": 512,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e4592b750ff4455000047",
            "body": "What is the 959 Nematode Genomes initiative?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24058822",
                "http://www.ncbi.nlm.nih.gov/pubmed/22044053",
                "http://www.ncbi.nlm.nih.gov/pubmed/22058131",
                "http://www.ncbi.nlm.nih.gov/pubmed/26927083",
                "http://www.ncbi.nlm.nih.gov/pubmed/28706308",
                "http://www.ncbi.nlm.nih.gov/pubmed/20013198",
                "http://www.ncbi.nlm.nih.gov/pubmed/20507524",
                "http://www.ncbi.nlm.nih.gov/pubmed/21707658",
                "http://www.ncbi.nlm.nih.gov/pubmed/1770495",
                "http://www.ncbi.nlm.nih.gov/pubmed/1367926"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24058822",
                    "text": "To inspire, promote and coordinate genomic sequencing across the diversity of the phylum, we have launched a community wiki and the 959 Nematode Genomes initiative (www.nematodegenomes.org/).",
                    "offsetInBeginSection": 1003,
                    "offsetInEndSection": 1194,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24058822",
                    "text": "Just as the deciphering of the developmental lineage of the 959 cells of the adult hermaphrodite C. elegans was the gateway to broad advances in biomedical science, we hope that a nematode phylogeny with (at least) 959 sequenced species will underpin further advances in understanding the origins of parasitism, the dynamics of genomic change and the adaptations that have made Nematoda one of the most successful animal phyla.",
                    "offsetInBeginSection": 1195,
                    "offsetInEndSection": 1622,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24058822",
                    "text": "The sequencing of the complete genome of the nematode Caenorhabditis elegans was a landmark achievement and ushered in a new era of whole-organism, systems analyses of the biology of this powerful model organism.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 212,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044053",
                    "text": "These efforts are being coordinated through the 959 Nematode Genomes initiative.",
                    "offsetInBeginSection": 1379,
                    "offsetInEndSection": 1459,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22058131",
                    "text": "In this article, we describe '959 Nematode Genomes'--a community-curated semantic wiki to coordinate the sequencing efforts of individual labs to collectively sequence 959 genomes spanning the phylum Nematoda.",
                    "offsetInBeginSection": 130,
                    "offsetInEndSection": 339,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22058131",
                    "text": "Genome sequencing has been democratized by second-generation technologies, and even small labs can sequence metazoan genomes now.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28706308",
                    "text": "The Journal of Nematology now offers publication of Nematode Genome Announcements (NGA) and Nematode Transcriptome Announcements (NTA).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20507524",
                    "text": "The temporal and spatial responses of four differentially expressed genes were analysed using GUS reporter plants following infection with M. incognita and the cyst nematode Heterodera schachtii.",
                    "offsetInBeginSection": 292,
                    "offsetInEndSection": 487,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21707658",
                    "text": "The Wellcome Trust Sanger Institute (WTSI) is producing de novo reference quality genomes for parasitic helminth species from platyhelminth tapeworms (cestodes), flukes (trematodes) and roundworms (nematodes) primarily using second-generation (Illumina and 454) sequencing technologies.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 286,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1770495",
                    "text": "The anthelmintic efficacy of albendazole intra-ruminal slow-release capsules (SRC) and albendazole drench against field strains of 5 genera of nematode parasites of sheep, where compared.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 187,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a897927fcd1d6a10c00000a",
            "body": "What does A1C measure?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18030866",
                "http://www.ncbi.nlm.nih.gov/pubmed/20923490",
                "http://www.ncbi.nlm.nih.gov/pubmed/16336550",
                "http://www.ncbi.nlm.nih.gov/pubmed/23990520",
                "http://www.ncbi.nlm.nih.gov/pubmed/18509211",
                "http://www.ncbi.nlm.nih.gov/pubmed/24511995",
                "http://www.ncbi.nlm.nih.gov/pubmed/21737172",
                "http://www.ncbi.nlm.nih.gov/pubmed/20861123",
                "http://www.ncbi.nlm.nih.gov/pubmed/26630892",
                "http://www.ncbi.nlm.nih.gov/pubmed/18056888"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18030866",
                    "text": "A CONCEPTUAL MODEL FOR ASSESSING THE QUALITY OF GLYCEMIC CONTROL A continuous measure of A1C, as the cornerstone in quality assessment for diabetes, can incorporate each of the Institute of Medicine's (IOM)'s quality domains: effectiveness and equity, patient safety, patient-centered care, timeliness, and efficiency.",
                    "offsetInBeginSection": 933,
                    "offsetInEndSection": 1251,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18030866",
                    "text": "CONCLUSIONS A continuous measure of A1C can better capture than a dichotomous measure the complexity of glycemic control at a population level.",
                    "offsetInBeginSection": 1254,
                    "offsetInEndSection": 1397,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20923490",
                    "text": "BACKGROUND A1c, a surrogate measure of glycemic control, is known to have a strong linear correlation with mean plasma glucose (MPG) when analyzed in populations of patients.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16336550",
                    "text": "OBJECTIVE To study within-patient longitudinal changes in A1c levels at Veterans Health Administration (VHA) facilities as an alternative to cross-sectional measures of quality of diabetes care.",
                    "offsetInBeginSection": 181,
                    "offsetInEndSection": 375,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16336550",
                    "text": "PATIENTS Diabetic veteran users with A1c measurement performed using National Glycosylated Hemoglobin Standardization Project certified A1c lab assay methods.",
                    "offsetInBeginSection": 655,
                    "offsetInEndSection": 813,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16336550",
                    "text": "MAIN OUTCOME MEASURE Monthly change in A1c for average patient cared for at each facility.",
                    "offsetInBeginSection": 961,
                    "offsetInEndSection": 1051,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16336550",
                    "text": "We propose that evaluation of change in A1c levels over time can be used as a new measure to reflect quality of care provided to populations of individuals with chronic disease.",
                    "offsetInBeginSection": 1852,
                    "offsetInEndSection": 2029,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18509211",
                    "text": "We assessed differences in A1C performance measure threshold attainment by case mix factors for A1C >9% and examined how lowering the threshold to A1C >8% or >7% changed these differences.",
                    "offsetInBeginSection": 249,
                    "offsetInEndSection": 437,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21737172",
                    "text": "AIMS The purpose of this study was to develop a measure of psychosocial barriers to adherence in adolescents with type 1 diabetes (T1D) and examine relationships to patient characteristics, adherence, and hemoglobin A1C (A1C).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 226,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056888",
                    "text": "OBJECTIVE Despite the standing of A1C as the most validated and widely used measure for average glycemic control over time, the relationship between A1C and glucose concentrations is not completely understood.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f98e6b750ff445500005d",
            "body": "Which ligament is most commonly injured in dashboard injury?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7377448",
                "http://www.ncbi.nlm.nih.gov/pubmed/3425783",
                "http://www.ncbi.nlm.nih.gov/pubmed/10623985",
                "http://www.ncbi.nlm.nih.gov/pubmed/598118",
                "http://www.ncbi.nlm.nih.gov/pubmed/18980604",
                "http://www.ncbi.nlm.nih.gov/pubmed/15062581",
                "http://www.ncbi.nlm.nih.gov/pubmed/12621261",
                "http://www.ncbi.nlm.nih.gov/pubmed/27623865",
                "http://www.ncbi.nlm.nih.gov/pubmed/22890899",
                "http://www.ncbi.nlm.nih.gov/pubmed/27871663"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7377448",
                    "text": "The anterior cruciate ligament (50%) is most often injured followed by the medial collateral ligament (31%), lateral collateral ligament (13%), and posterior cruciate ligament (6%).",
                    "offsetInBeginSection": 765,
                    "offsetInEndSection": 946,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3425783",
                    "text": "Hyperflexion was the most common mechanism of injury, followed by pretibial trauma in the hyperflexed knee or in the \"dashboard\" injury.",
                    "offsetInBeginSection": 438,
                    "offsetInEndSection": 574,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10623985",
                    "text": "The most common mechanism of injury in motor vehicle accidents is a dashboard injury or direct force to the proximal anterior tibia.",
                    "offsetInBeginSection": 126,
                    "offsetInEndSection": 258,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/598118",
                    "text": "Legs trapped under the dashboard with simultaneous rotational, varus, valgus, or frontal forces by the inertial motion of the body produced serious injuries similar to those recieved in sports.",
                    "offsetInBeginSection": 502,
                    "offsetInEndSection": 695,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18980604",
                    "text": "The thigh, especially the hamstrings, was the overall most commonly injured region in both sexes, while the hip/groin was more commonly injured in male players and the knee in female players.",
                    "offsetInBeginSection": 568,
                    "offsetInEndSection": 759,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12621261",
                    "text": "Distal lateral collateral ligament injuries were commonly associated with distal biceps avulsions and seldom with popliteus tendon avulsions.",
                    "offsetInBeginSection": 1350,
                    "offsetInEndSection": 1491,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27623865",
                    "text": "CONCLUSIONS The anterior inferior tibiofibular ligament is the most commonly injured ligament in the syndesmosis in sports injury and results in subtle variations in the syndesmotic anatomy, which plain radiographs cannot assess.",
                    "offsetInBeginSection": 1181,
                    "offsetInEndSection": 1410,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22890899",
                    "text": "The medial collateral ligament (MCL) is the most commonly injured ligament of the knee.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 87,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27871663",
                    "text": "The anterior cruciate ligament (ACL) is the most commonly injured ligament in conjunction with the MCL.",
                    "offsetInBeginSection": 88,
                    "offsetInEndSection": 191,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27871663",
                    "text": "The medial collateral ligament (MCL) is the most commonly injured ligament of the knee.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 87,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e49a4b750ff445500004b",
            "body": "Is LDB1-mediated enhancer looping dependent on cohesin?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28520978",
                "http://www.ncbi.nlm.nih.gov/pubmed/25605944",
                "http://www.ncbi.nlm.nih.gov/pubmed/23610375",
                "http://www.ncbi.nlm.nih.gov/pubmed/28636938",
                "http://www.ncbi.nlm.nih.gov/pubmed/20720539",
                "http://www.ncbi.nlm.nih.gov/pubmed/25081205",
                "http://www.ncbi.nlm.nih.gov/pubmed/22682246",
                "http://www.ncbi.nlm.nih.gov/pubmed/19956766",
                "http://www.ncbi.nlm.nih.gov/pubmed/27135601",
                "http://www.ncbi.nlm.nih.gov/pubmed/28424523"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978",
                    "text": "Moreover, ENCODE data and our chromatin immunoprecipitation results indicate that cohesin is almost completely absent from validated and predicted LDB1-regulated erythroid enhancer-gene pairs.",
                    "offsetInBeginSection": 1172,
                    "offsetInEndSection": 1364,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25605944",
                    "text": "LDB1-mediated enhancer:promoter looping appears to be required for both activation and repression of these target genes.",
                    "offsetInBeginSection": 658,
                    "offsetInEndSection": 778,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25605944",
                    "text": "Here we report the required actions of LIM domain-binding protein 1 (LDB1)/cofactor of LIM homeodomain protein 2/nuclear LIM interactor, interacting with the enhancer-binding protein achaete-scute complex homolog 1, to mediate looping to target gene promoters and target gene regulation in corticotrope cells.",
                    "offsetInBeginSection": 348,
                    "offsetInEndSection": 657,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23610375",
                    "text": "Ldb1 proteins are capable of coassociation, and long-range Ldb1-mediated oligomerization of enhancer- and promoter-bound Ldb1 complexes has been shown to be required for \u03b2-globin gene expression.",
                    "offsetInBeginSection": 433,
                    "offsetInEndSection": 629,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28636938",
                    "text": "Both LDB1 and CTCF are required for enhancer-Car2 looping, and the domain of LDB1 contacted by CTCF is necessary to rescue Car2 transcription in LDB1-deficient cells.",
                    "offsetInBeginSection": 494,
                    "offsetInEndSection": 660,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28636938",
                    "text": "Genome-wide studies and CRISPR/Cas9 genome editing indicate that LDB1-CTCF enhancer looping underlies activation of a substantial fraction of erythroid genes.",
                    "offsetInBeginSection": 661,
                    "offsetInEndSection": 819,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28636938",
                    "text": "The LDB1 complex mediates enhancer-gene interactions at the \u03b2-globin locus through LDB1 self-interaction.",
                    "offsetInBeginSection": 230,
                    "offsetInEndSection": 336,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20720539",
                    "text": "DNA looping is observed between the enhancers and promoters occupied by mediator and cohesin.",
                    "offsetInBeginSection": 745,
                    "offsetInEndSection": 838,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25081205",
                    "text": "CTCF mediates the interactions between CTCF/cohesin binding sites, some of which have enhancer-blocking insulator activity.",
                    "offsetInBeginSection": 726,
                    "offsetInEndSection": 849,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28424523",
                    "text": "Mammalian genomes are spatially organized by CCCTC-binding factor (CTCF) and cohesin into chromatin loops and topologically associated domains, which have important roles in gene regulation and recombination.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 208,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a897a06fcd1d6a10c00000b",
            "body": "What is the normal body temperature in dogs?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/495147",
                "http://www.ncbi.nlm.nih.gov/pubmed/2759725",
                "http://www.ncbi.nlm.nih.gov/pubmed/28216687",
                "http://www.ncbi.nlm.nih.gov/pubmed/25854787",
                "http://www.ncbi.nlm.nih.gov/pubmed/21102554",
                "http://www.ncbi.nlm.nih.gov/pubmed/1910939",
                "http://www.ncbi.nlm.nih.gov/pubmed/11913416",
                "http://www.ncbi.nlm.nih.gov/pubmed/19575699",
                "http://www.ncbi.nlm.nih.gov/pubmed/28549943",
                "http://www.ncbi.nlm.nih.gov/pubmed/8733095"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/495147",
                    "text": "The effect of intraventricular injection of thyroxine 1 microgram/animal on body temperature was studied in dogs under resting conditions: at normal ambient temperature, at high ambient temperature (35 degrees C) and during administration of pyrogen.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 250,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/495147",
                    "text": "Thyroxine exerted its central action on body temperature only in dogs performing physical exercise.",
                    "offsetInBeginSection": 387,
                    "offsetInEndSection": 486,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/495147",
                    "text": "Besides, changes in body temperature were elucidated in dogs performing physical exercise following I.V.",
                    "offsetInBeginSection": 251,
                    "offsetInEndSection": 355,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21102554",
                    "text": "CONCLUSION These findings document an association between obesity and reduced body temperature in dogs and support the hypothesis that obesity in this and other species of homeotherms may result from an increase in metabolic efficiency achieved by a regulated lowering of body temperature.",
                    "offsetInBeginSection": 1097,
                    "offsetInEndSection": 1386,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21102554",
                    "text": "METHODS We compared the rectal temperature of lean dogs and obese dogs by (a) conducting cross-sectional measurements in 287 dogs of many breeds varying greatly in body size, (b) conducting longitudinal measurements in individual dogs over 7-10 years and (c) tracking rectal temperature of lean and obese dogs at 3-h intervals for 48 consecutive hours in the laboratory.",
                    "offsetInBeginSection": 447,
                    "offsetInEndSection": 817,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21102554",
                    "text": "RESULTS We found that larger dogs have lower rectal temperatures than smaller dogs and that, for the same body mass, obese dogs have lower rectal temperatures than lean dogs.",
                    "offsetInBeginSection": 820,
                    "offsetInEndSection": 994,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11913416",
                    "text": "Compared with normal gravity controls, exposed dogs showed a slower growth rate and a reduced amount of body fat.",
                    "offsetInBeginSection": 557,
                    "offsetInEndSection": 670,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11913416",
                    "text": "Initially, centrifuged dogs showed transient decreases in heart rate and body temperature along with changes in their diurnal rhythm patterns.",
                    "offsetInBeginSection": 414,
                    "offsetInEndSection": 556,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11913416",
                    "text": "In spite of the various changes noted, results from this and other studies affirm the view that dogs can tolerate and adapt to sustained loads as high as 2.5 g without serious impairment of their body structure and function.",
                    "offsetInBeginSection": 1038,
                    "offsetInEndSection": 1262,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28549943",
                    "text": "CONCLUSIONS AND CLINICAL RELEVANCE Using an HME did not alter body temperature in dogs weighing <10\u00a0kg undergoing an MRI, but including dexmedetomidine in the premedication regimen seemed to preserve the body temperature during anaesthesia.",
                    "offsetInBeginSection": 1744,
                    "offsetInEndSection": 1985,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70d12899e2c3af26000001",
            "body": "List symptoms of Heerfordt syndrome.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17637529",
                "http://www.ncbi.nlm.nih.gov/pubmed/20184241",
                "http://www.ncbi.nlm.nih.gov/pubmed/18454397",
                "http://www.ncbi.nlm.nih.gov/pubmed/26885424",
                "http://www.ncbi.nlm.nih.gov/pubmed/22565854",
                "http://www.ncbi.nlm.nih.gov/pubmed/25087562",
                "http://www.ncbi.nlm.nih.gov/pubmed/25685372",
                "http://www.ncbi.nlm.nih.gov/pubmed/2307892",
                "http://www.ncbi.nlm.nih.gov/pubmed/21706840",
                "http://www.ncbi.nlm.nih.gov/pubmed/27549672"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17637529",
                    "text": "This case demonstrates the importance of being aware of the leading clinical signs and symptoms in case of Heerfordt syndrome.",
                    "offsetInBeginSection": 774,
                    "offsetInEndSection": 900,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20184241",
                    "text": "Various clinical symptoms indicated Heerfordt syndrome.",
                    "offsetInBeginSection": 638,
                    "offsetInEndSection": 693,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20184241",
                    "text": "We found no cases of familial sarcoidosis with Heerfordt syndrome in the literature.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 84,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18454397",
                    "text": "BACKGROUND Heerfordt syndrome is rare and is characterized by fever, uveitis, parotid gland enlargement, and facial nerve palsy.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18454397",
                    "text": "Chest computed tomography and transbronchial lymph node biopsy set the diagnosis of sarcoidosis.",
                    "offsetInBeginSection": 668,
                    "offsetInEndSection": 764,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18454397",
                    "text": "We hereby present a case of Heerfordt syndrome with unilateral facial nerve palsy as a presentation of sarcoidosis.",
                    "offsetInBeginSection": 129,
                    "offsetInEndSection": 244,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22565854",
                    "text": "Angiography revealed a dense pattern of hyperfluorescent lesions and these observations resulted in the diagnosis of Heerfordt syndrome.",
                    "offsetInBeginSection": 401,
                    "offsetInEndSection": 537,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25087562",
                    "text": "Other examinations revealed bilateral hilar lymphadenopathy, high serum titer of angiotensin coenzyme, and no response in a tuberculin-tested, non-caseating epithelioid granuloma from lip biopsy, leading to the diagnosis of complete Heerfordt syndrome.",
                    "offsetInBeginSection": 479,
                    "offsetInEndSection": 731,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25685372",
                    "text": "Heerfordt's syndrome as a cause of facial palsy is very rare.",
                    "offsetInBeginSection": 124,
                    "offsetInEndSection": 185,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2307892",
                    "text": "Heerfordt syndrome is an unusual manifestation of systemic sarcoidosis and is characterized by parotitis, uveitis, and facial nerve paralysis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e4b72b750ff445500004c",
            "body": "Is there any link between ERCC1-XPF and cohesin?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28368372",
                "http://www.ncbi.nlm.nih.gov/pubmed/20518486",
                "http://www.ncbi.nlm.nih.gov/pubmed/14512883",
                "http://www.ncbi.nlm.nih.gov/pubmed/12202770",
                "http://www.ncbi.nlm.nih.gov/pubmed/9722633",
                "http://www.ncbi.nlm.nih.gov/pubmed/10882712",
                "http://www.ncbi.nlm.nih.gov/pubmed/18541667",
                "http://www.ncbi.nlm.nih.gov/pubmed/14706347",
                "http://www.ncbi.nlm.nih.gov/pubmed/26074087",
                "http://www.ncbi.nlm.nih.gov/pubmed/24158589"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372",
                    "text": "We propose that ERCC1-XPF cooperates with CTCF and cohesin to facilitate the developmental silencing of imprinted genes and that persistent DNA damage triggers chromatin changes that affect gene expression programs associated with NER disorders.",
                    "offsetInBeginSection": 806,
                    "offsetInEndSection": 1051,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372",
                    "text": "Using an in vivo biotinylation tagging approach in mice, we show that the nucleotide excision repair (NER) structure-specific endonuclease ERCC1-XPF complex interacts with the insulator binding protein CTCF, the cohesin subunits SMC1A and SMC3 and with MBD2; the factors co-localize with ATRX at the promoters and control regions (ICRs) of imprinted genes during postnatal hepatic development.",
                    "offsetInBeginSection": 128,
                    "offsetInEndSection": 521,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372",
                    "text": "Loss of Ercc1 or exposure to MMC triggers the localization of CTCF to heterochromatin, the dissociation of the CTCF-cohesin complex and ATRX from promoters and ICRs, altered histone marks and\u00a0the aberrant developmental expression of imprinted genes without altering DNA methylation.",
                    "offsetInBeginSection": 522,
                    "offsetInEndSection": 805,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20518486",
                    "text": "This binding between FANCG and the ERCC1-XPF endonuclease, combined with our previous studies which show that FANCG is involved in the incision step mediated by ERCC1-XPF, establishes a link between an FA protein and the critical unhooking step of the ICL repair process.",
                    "offsetInBeginSection": 1428,
                    "offsetInEndSection": 1699,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12202770",
                    "text": "In contrast to cells bearing mutations in other components of the nucleotide excision repair apparatus (XPB, XPD, XPG and CSB), cells defective for the ERCC1-XPF structure-specific nuclease are highly sensitive to cisplatin.",
                    "offsetInBeginSection": 155,
                    "offsetInEndSection": 379,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9722633",
                    "text": "A mutation from an XP-F patient that alters the ERCC1-binding domain in XPF indeed affects complex formation with ERCC1.",
                    "offsetInBeginSection": 1420,
                    "offsetInEndSection": 1540,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9722633",
                    "text": "ERCC1-XPF is a heterodimeric protein complexinvolved in nucleotide excision repair and recombinational processes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18541667",
                    "text": "ERCC1-XPF endonuclease is required for nucleotide excision repair (NER) of helix-distorting DNA lesions.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 104,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26074087",
                    "text": "The ERCC1 and ERCC4 genes encode the two subunits of the ERCC1-XPF nuclease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 76,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26074087",
                    "text": "ERCC1-XPF interacts with other proteins including XPA, RPA, SLX4 and TRF2 to perform its functions.",
                    "offsetInBeginSection": 756,
                    "offsetInEndSection": 855,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8afbf2fcd1d6a10c00001c",
            "body": "In quadruped mammals, what bones make up the stifle?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17266668",
                "http://www.ncbi.nlm.nih.gov/pubmed/19378290",
                "http://www.ncbi.nlm.nih.gov/pubmed/23977887",
                "http://www.ncbi.nlm.nih.gov/pubmed/23554931",
                "http://www.ncbi.nlm.nih.gov/pubmed/21113010",
                "http://www.ncbi.nlm.nih.gov/pubmed/19378269",
                "http://www.ncbi.nlm.nih.gov/pubmed/24323904",
                "http://www.ncbi.nlm.nih.gov/pubmed/3218668",
                "http://www.ncbi.nlm.nih.gov/pubmed/27718092",
                "http://www.ncbi.nlm.nih.gov/pubmed/7649818"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17266668",
                    "text": "In the stifle joints of quadrupeds, the MFL is a substantial structure and appears to be related to the caudal tibial slope.",
                    "offsetInBeginSection": 1234,
                    "offsetInEndSection": 1358,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378290",
                    "text": "Based on this survey, I suggest that olecranon orientation can be used for inferring the elbow joint angles of quadruped mammals with prominent olecranons, regardless of taxon, body size, and locomotor guild.",
                    "offsetInBeginSection": 919,
                    "offsetInEndSection": 1127,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23977887",
                    "text": "CONCLUSIONS AND CLINICAL RELEVANCE Compared with results for quadruped dogs, the vertebral column, carpus, and ipsilateral hip and stifle joints had significant biomechanical changes after amputation of a thoracic limb.",
                    "offsetInBeginSection": 1323,
                    "offsetInEndSection": 1542,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21113010",
                    "text": "Monophasic lateral bending and long-axis rotation, biphasic sagittal bending and maximal amplitude of sagittal bending at the lumbo-sacral joint were also found in other quadruped mammals and may represent general aspects of mammalian symmetric gaits.",
                    "offsetInBeginSection": 1270,
                    "offsetInEndSection": 1521,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21113010",
                    "text": "Given the importance of thoraco-lumbar spine movements in the locomotion of mammals, it is surprising that in vivo three-dimensional (3-D) data on the intervertebral movement of the mammalian thoraco-lumbar vertebral column during symmetrical gaits is limited to horses and dogs.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 279,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378269",
                    "text": "Determining scapular position is a major issue in reconstructing the skeletal systems of extinct quadruped archosaurs and mammals, because the proximal portion of the scapulae has no direct skeletal joint with the vertebrae or ribs.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 232,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378269",
                    "text": "This implies that the location of robust ribs is associated with the arrangement of the serratus muscle, and provides a probable candidate for determination of the scapular position for extinct quadruped archosaurs and mammals.",
                    "offsetInBeginSection": 1209,
                    "offsetInEndSection": 1436,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24323904",
                    "text": "High-resolution microtomographic scans were collected of the lunate, scaphoid, and capitate in 41 individuals and eight genera (Homo, Gorilla, Pan, Papio, Pongo, Symphalangus, Hylobates, and Ateles).",
                    "offsetInBeginSection": 632,
                    "offsetInEndSection": 831,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3218668",
                    "text": "MACN-SC 101 may represent the incipient divergence of a generalized platyrrhine arboreal quadruped toward a more suspensory form.",
                    "offsetInBeginSection": 951,
                    "offsetInEndSection": 1080,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3218668",
                    "text": "Primate scapula and ulna fragments of uncertain taxonomic affinity (MACN-SC 101) have been recovered from the Pinturas deposits at Arroyo Feo, Santa Cruz, Argentina in association with Santacrucian (Early Miocene) land mammals.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 227,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70d42899e2c3af26000002",
            "body": "Mutation of which gene causes arterial tortuosity syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18818946",
                "http://www.ncbi.nlm.nih.gov/pubmed/18774132",
                "http://www.ncbi.nlm.nih.gov/pubmed/16550171",
                "http://www.ncbi.nlm.nih.gov/pubmed/19622975",
                "http://www.ncbi.nlm.nih.gov/pubmed/22734312",
                "http://www.ncbi.nlm.nih.gov/pubmed/22488877",
                "http://www.ncbi.nlm.nih.gov/pubmed/17935213",
                "http://www.ncbi.nlm.nih.gov/pubmed/19028722",
                "http://www.ncbi.nlm.nih.gov/pubmed/19781076",
                "http://www.ncbi.nlm.nih.gov/pubmed/15679832"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18818946",
                    "text": "This syndrome is caused by mutations in the SLC2A10 gene.",
                    "offsetInBeginSection": 212,
                    "offsetInEndSection": 269,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18818946",
                    "text": "This mutation in the SLC2A10 gene replaces a cysteine encoding codon with a stop signal.",
                    "offsetInBeginSection": 655,
                    "offsetInEndSection": 743,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18774132",
                    "text": "This syndrome is caused by mutation in SLC2A10 gene which encodes for the facilitative glucose transporter, GLUT10.",
                    "offsetInBeginSection": 310,
                    "offsetInEndSection": 425,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18774132",
                    "text": "In the single patient of Family 1, sequencing of the candidate gene, SLC2A10, identified a novel missense c.313C>T mutation encoding a p.Arg105Cys substitution in the second extracellular domain of GLUT10.",
                    "offsetInBeginSection": 718,
                    "offsetInEndSection": 923,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16550171",
                    "text": "GLUT10 deficiency is associated with upregulation of the TGFbeta pathway in the arterial wall, a finding also observed in Loeys-Dietz syndrome, in which aortic aneurysms associate with arterial tortuosity.",
                    "offsetInBeginSection": 568,
                    "offsetInEndSection": 773,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19622975",
                    "text": "BACKGROUND Arterial tortuosity syndrome is a rare, autosomal recessive, severe, connective tissue disorder caused by a mutation in the SLC2A10 gene.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17935213",
                    "text": "Arterial tortuosity syndrome (ATS) is a rare autosomal recessive connective tissue disease, characterized by widespread arterial involvement with elongation, tortuosity, and aneurysms of the large and middle-sized arteries.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 223,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19028722",
                    "text": "Mutations in the SLC2A10 gene cause arterial tortuosity syndrome (ATS) in humans.",
                    "offsetInBeginSection": 137,
                    "offsetInEndSection": 218,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19781076",
                    "text": "ATS is caused by mutations in SLC2A10 gene, encoding for the facilitative glucose transporter 10 (GLUT10).",
                    "offsetInBeginSection": 290,
                    "offsetInEndSection": 396,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15679832",
                    "text": "An arterial tortuosity locus has recently been mapped to chromosome 20q13.",
                    "offsetInBeginSection": 193,
                    "offsetInEndSection": 267,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f940bb750ff445500005a",
            "body": "What is the aim of the 4D nucleome project?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28905911",
                "http://www.ncbi.nlm.nih.gov/pubmed/29168505",
                "http://www.ncbi.nlm.nih.gov/pubmed/26338265",
                "http://www.ncbi.nlm.nih.gov/pubmed/28745542",
                "http://www.ncbi.nlm.nih.gov/pubmed/28961756",
                "http://www.ncbi.nlm.nih.gov/pubmed/26080430",
                "http://www.ncbi.nlm.nih.gov/pubmed/28385536",
                "http://www.ncbi.nlm.nih.gov/pubmed/26028501",
                "http://www.ncbi.nlm.nih.gov/pubmed/25738524",
                "http://www.ncbi.nlm.nih.gov/pubmed/27052789"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28905911",
                    "text": "The 4D Nucleome Network aims to develop and apply approaches to map the structure and dynamics of the human and mouse genomes in space and time with the goal of gaining deeper mechanistic insights into how the nucleus is organized and functions.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 245,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28905911",
                    "text": "The project will develop and benchmark experimental and computational approaches for measuring genome conformation and nuclear organization, and investigate how these contribute to gene regulation and other genome functions.",
                    "offsetInBeginSection": 246,
                    "offsetInEndSection": 470,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338265",
                    "text": "The 4D nucleome has the potential to render challenges in neuropsychiatric pharmacogenomics more tractable.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 107,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338265",
                    "text": "This perspective assesses recent advances likely to reveal novel pharmacodynamic regulatory pathways in human brain, charting a future new avenue of pharmacogenomics research, using the spatial and temporal architecture of the human epigenome as its foundation.",
                    "offsetInBeginSection": 611,
                    "offsetInEndSection": 872,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28745542",
                    "text": "The recent conference 4D Nucleome: The Cell Nucleus in Space and Time, which was held in Krak\u00f3w in May 2017, was an opportunity to appreciate the growing number of conceptual approaches and newly emerging analytical techniques that are revolutionizing our understanding of the structure of chromatin and the nucleus.",
                    "offsetInBeginSection": 272,
                    "offsetInEndSection": 589,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961756",
                    "text": "Results The 4D Nucleome Analysis Toolbox (NAT) is a user-friendly and powerful MATLAB toolbox for time series analysis of genome-wide chromosome conformation capture (Hi-C) data and gene expression (RNA-seq).",
                    "offsetInBeginSection": 165,
                    "offsetInEndSection": 373,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080430",
                    "text": "The 4D organization of the interphase nucleus, or the 4D Nucleome (4DN), reflects a dynamical interaction between 3D genome structure and function and its relationship to phenotype.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 181,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28385536",
                    "text": "These examples in regulatory pharmacoepigenomics illustrate how ongoing research using the 4D nucleome provides a foundation to further insight into previously unrecognized psychotropic drug pharmacodynamic pathways in the human CNS.",
                    "offsetInBeginSection": 1335,
                    "offsetInEndSection": 1568,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25738524",
                    "text": "We propose the establishment of an International Nucleome Consortium to coordinate this effort worldwide.",
                    "offsetInBeginSection": 508,
                    "offsetInEndSection": 613,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25738524",
                    "text": "Understanding genome function will therefore require the elucidation of the structure-function relationship of the cell nucleus as a complex, dynamic biological system, referred to as the nucleome.",
                    "offsetInBeginSection": 208,
                    "offsetInEndSection": 405,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8b1264fcd1d6a10c00001d",
            "body": "Fusarium oxysporum f. sp lycopersici. is a plant pathogen in plants producing what common food?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18945093",
                "http://www.ncbi.nlm.nih.gov/pubmed/24909710",
                "http://www.ncbi.nlm.nih.gov/pubmed/24561899",
                "http://www.ncbi.nlm.nih.gov/pubmed/18624637",
                "http://www.ncbi.nlm.nih.gov/pubmed/10517025",
                "http://www.ncbi.nlm.nih.gov/pubmed/17302801",
                "http://www.ncbi.nlm.nih.gov/pubmed/18944618",
                "http://www.ncbi.nlm.nih.gov/pubmed/23549903",
                "http://www.ncbi.nlm.nih.gov/pubmed/28321368",
                "http://www.ncbi.nlm.nih.gov/pubmed/9237400"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18945093",
                    "text": "lycopersici.",
                    "offsetInBeginSection": 706,
                    "offsetInEndSection": 718,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18945093",
                    "text": "lycopersici.",
                    "offsetInBeginSection": 706,
                    "offsetInEndSection": 718,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24561899",
                    "text": "lycopersici.",
                    "offsetInBeginSection": 456,
                    "offsetInEndSection": 468,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24561899",
                    "text": "lycopersici.",
                    "offsetInBeginSection": 456,
                    "offsetInEndSection": 468,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025",
                    "text": "lycopersici.",
                    "offsetInBeginSection": 518,
                    "offsetInEndSection": 530,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025",
                    "text": "lycopersici.",
                    "offsetInBeginSection": 518,
                    "offsetInEndSection": 530,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025",
                    "text": "Fusarium oxysporum f. sp.",
                    "offsetInBeginSection": 198,
                    "offsetInEndSection": 223,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23549903",
                    "text": "lycopersici.",
                    "offsetInBeginSection": 1355,
                    "offsetInEndSection": 1367,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28321368",
                    "text": "lycopersici.",
                    "offsetInBeginSection": 444,
                    "offsetInEndSection": 456,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9237400",
                    "text": "Fusarium oxysporum f. sp.",
                    "offsetInBeginSection": 154,
                    "offsetInEndSection": 179,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70d43b99e2c3af26000003",
            "body": "Does prolactinoma increase osteoporosis risk?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11293923",
                "http://www.ncbi.nlm.nih.gov/pubmed/22553947",
                "http://www.ncbi.nlm.nih.gov/pubmed/20205855",
                "http://www.ncbi.nlm.nih.gov/pubmed/26319389",
                "http://www.ncbi.nlm.nih.gov/pubmed/17578827",
                "http://www.ncbi.nlm.nih.gov/pubmed/15816365",
                "http://www.ncbi.nlm.nih.gov/pubmed/27446618",
                "http://www.ncbi.nlm.nih.gov/pubmed/26720589",
                "http://www.ncbi.nlm.nih.gov/pubmed/25472533",
                "http://www.ncbi.nlm.nih.gov/pubmed/9550540"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11293923",
                    "text": "The relative risk for developing osteoporosis in women with prolactinoma was found to be 4.5, indicating that hyperprolactinemia in women is a major risk factor for osteoporosis.",
                    "offsetInBeginSection": 1145,
                    "offsetInEndSection": 1323,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553947",
                    "text": "CONCLUSION In the premenopausal women, patients with prolactinoma or craniopharyngioma are often accompanied with osteopenia or osteoporosis, and disease duration and hypogonadism are the risk factors of bone loss in prolactinoma.",
                    "offsetInBeginSection": 1085,
                    "offsetInEndSection": 1315,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553947",
                    "text": "OBJECTIVE Patients with prolactinoma seem to be at high risk for osteopenia.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 76,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205855",
                    "text": "Prolactinoma in old people may present insidiously with chronic anaemia and osteoporosis with or without sexual dysfunction.",
                    "offsetInBeginSection": 249,
                    "offsetInEndSection": 373,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26319389",
                    "text": "Hyperprolactinaemia related to prolactinoma significantly (more than functional hyperprolactiaemia) increases the risk of osteopenia, osteoporosis and bone fractures.",
                    "offsetInBeginSection": 1014,
                    "offsetInEndSection": 1180,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26319389",
                    "text": "High serum prolactin levels lead to increase of the risk of osteopenia or/and osteoporosis.",
                    "offsetInBeginSection": 782,
                    "offsetInEndSection": 873,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26319389",
                    "text": "Important group of patients threatened by osteoporosis and bone fracture is constituted by women which use antipsychotic drugs (which induce hyperprolactinaemia).",
                    "offsetInBeginSection": 1181,
                    "offsetInEndSection": 1343,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17578827",
                    "text": "INTRODUCTION Osteopenia and osteoporosis because of hyperprolactinaemia caused by prolactinoma may be followed by an increased risk of fracture.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15816365",
                    "text": "In conclusion, men with prolactinoma have high prevalence of osteopenia and osteoporosis.",
                    "offsetInBeginSection": 1442,
                    "offsetInEndSection": 1531,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9550540",
                    "text": "Humans with prolactinoma are at risk for osteoporosis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 54,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6fa31ab750ff445500005e",
            "body": "Which method has been developed for assignment of enhancers to target genes?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29070071",
                "http://www.ncbi.nlm.nih.gov/pubmed/22084256",
                "http://www.ncbi.nlm.nih.gov/pubmed/26390058",
                "http://www.ncbi.nlm.nih.gov/pubmed/26446758",
                "http://www.ncbi.nlm.nih.gov/pubmed/26780995",
                "http://www.ncbi.nlm.nih.gov/pubmed/24278002",
                "http://www.ncbi.nlm.nih.gov/pubmed/3053166",
                "http://www.ncbi.nlm.nih.gov/pubmed/26450747",
                "http://www.ncbi.nlm.nih.gov/pubmed/21713026",
                "http://www.ncbi.nlm.nih.gov/pubmed/8093838"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29070071",
                    "text": "We devised a machine learning approach, McEnhancer, which links target genes to putative enhancers via a semi-supervised learning algorithm that predicts gene expression patterns based on enriched sequence features.",
                    "offsetInBeginSection": 178,
                    "offsetInEndSection": 393,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29070071",
                    "text": "Transcriptional enhancers regulate spatio-temporal gene expression.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 67,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22084256",
                    "text": "This is especially true in mammalian systems, where regulation often occurs through long-range enhancers in gene-rich neighborhoods, rather than proximal promoters, preventing straightforward assignment of a binding site to a target gene.",
                    "offsetInBeginSection": 354,
                    "offsetInEndSection": 592,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26390058",
                    "text": "We carried out an integrative analysis of enhancer landscape and gene expression dynamics during hematopoietic differentiation using DNase-seq, histone mark ChIP-seq and RNA sequencing to model how the early establishment of enhancers and regulatory locus complexity govern gene expression changes at cell state transitions.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 324,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26390058",
                    "text": "Our method suggests a new mechanistic role for PU.1 at transition peaks during B cell specification and can be used to correct assignments of enhancers to genes.",
                    "offsetInBeginSection": 898,
                    "offsetInEndSection": 1059,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26446758",
                    "text": "After reviewing models of enhancer function, we discuss recent methods for identifying target genes of enhancers.",
                    "offsetInBeginSection": 736,
                    "offsetInEndSection": 849,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26780995",
                    "text": "Various experimental and computational approaches including chromatin signature profiling have been developed to predict enhancers on a genome-wide scale, although each method has its advantages and disadvantages.",
                    "offsetInBeginSection": 95,
                    "offsetInEndSection": 308,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26780995",
                    "text": "Enhancers are distal cis-regulatory DNA elements that increase the expression of target genes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3053166",
                    "text": "We demonstrate the method by assignment of the human thymocyte CD1 antigen genes to human chromosome 1q22-23.",
                    "offsetInBeginSection": 609,
                    "offsetInEndSection": 718,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3053166",
                    "text": "A method for in situ hybridization originally developed for mapping genes in the nematode, Caenorhabditis elegans has been adapted for high resolution cytological mapping of genes in the human.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8dc6b4fcd1d6a10c000026",
            "body": "List 2 approved drug treatments for Inflammatory Bowel Disease (IBD).",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27753694",
                "http://www.ncbi.nlm.nih.gov/pubmed/23051720",
                "http://www.ncbi.nlm.nih.gov/pubmed/21936033",
                "http://www.ncbi.nlm.nih.gov/pubmed/27570643",
                "http://www.ncbi.nlm.nih.gov/pubmed/21484967",
                "http://www.ncbi.nlm.nih.gov/pubmed/28868386",
                "http://www.ncbi.nlm.nih.gov/pubmed/28509768",
                "http://www.ncbi.nlm.nih.gov/pubmed/28509817",
                "http://www.ncbi.nlm.nih.gov/pubmed/26631943",
                "http://www.ncbi.nlm.nih.gov/pubmed/28961959"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694",
                    "text": "BACKGROUND Currently, 200 genetic risk loci have been identified for inflammatory bowel disease (IBD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694",
                    "text": "CONCLUSIONS We confirm that proteins encoded by IBD candidate genes are targeted by approved IBD therapies.",
                    "offsetInBeginSection": 1283,
                    "offsetInEndSection": 1390,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23051720",
                    "text": "First-line treatments were defined as the following drug categories: 5-aminosalicylates, budesonide, systemic steroids, azathioprine, 6-mercaptopurine, methotrexate, infliximab, adalimumab and certolizumab pegol.",
                    "offsetInBeginSection": 452,
                    "offsetInEndSection": 664,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21936033",
                    "text": "Infliximab, adalimumab, and certolizumab are monoclonal antibodies against tumor necrosis factor-\u03b1 (TNF\u03b1), a proinflammatory cytokine with an increased expression in the inflamed tissues of inflammatory bowel disease (IBD) patients.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 234,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21936033",
                    "text": "Currently, infliximab is the only anti-TNF drug that has been approved for use in refractory pediatric Crohn's disease (CD).",
                    "offsetInBeginSection": 235,
                    "offsetInEndSection": 359,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27570643",
                    "text": "Inflammatory Bowel Disease (IBD) is a chronic and relapsing disorder, which affects millions people worldwide.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28509768",
                    "text": "RESULTS The 5 things physicians and patients should question: (1) Don't use steroids (e.g., prednisone) for maintenance therapy in IBD; (2) Don't use opioids long-term to manage abdominal pain in inflammatory bowel disease (IBD); (3) Don't unnecessarily prolong the course of intravenous corticosteroids in patients with acute severe ulcerative colitis (UC) in the absence of clinical response; (4) Don't initiate or escalate long-term medical therapies for the treatment of IBD based only on symptoms; and (5) Don't use abdominal computed tomography (CT) scan to assess IBD in the acute setting unless there is suspicion of a complication (obstruction, perforation, abscess) or a non-IBD etiology for abdominal symptoms.",
                    "offsetInBeginSection": 754,
                    "offsetInEndSection": 1475,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28509817",
                    "text": "RESULTS The 5 things physicians and patients should question: (1) Don't use steroids (e.g., prednisone) for maintenance therapy in IBD; (2) Don't use opioids long-term to manage abdominal pain in inflammatory bowel disease (IBD); (3) Don't unnecessarily prolong the course of intravenous corticosteroids in patients with acute severe ulcerative colitis (UC) in the absence of clinical response; (4) Don't initiate or escalate long-term medical therapies for the treatment of IBD based only on symptoms; and (5) Don't use abdominal computed tomography (CT) scan to assess IBD in the acute setting unless there is suspicion of a complication (obstruction, perforation, abscess) or a non-IBD etiology for abdominal symptoms.",
                    "offsetInBeginSection": 754,
                    "offsetInEndSection": 1475,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26631943",
                    "text": "More recently, vedolizumab, an anti-\u03b14\u03b27 integrin monoclonal antibody, has been approved for the treatment of Crohn's disease and ulcerative colitis.",
                    "offsetInBeginSection": 893,
                    "offsetInEndSection": 1044,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961959",
                    "text": "The therapeutic landscape for inflammatory bowel disease (IBD) is rapidly evolving.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 83,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70e4b399e2c3af26000008",
            "body": "Glecaprevir and Pibrentasvir are used for tratment of which disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28688001",
                "http://www.ncbi.nlm.nih.gov/pubmed/28800195",
                "http://www.ncbi.nlm.nih.gov/pubmed/28807904",
                "http://www.ncbi.nlm.nih.gov/pubmed/28412293",
                "http://www.ncbi.nlm.nih.gov/pubmed/29020583",
                "http://www.ncbi.nlm.nih.gov/pubmed/28818546",
                "http://www.ncbi.nlm.nih.gov/pubmed/28925068",
                "http://www.ncbi.nlm.nih.gov/pubmed/28128852",
                "http://www.ncbi.nlm.nih.gov/pubmed/28929412",
                "http://www.ncbi.nlm.nih.gov/pubmed/29152781"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800195",
                    "text": "Glecaprevir and pibrentasvir are direct-acting antiviral agents being developed as combination therapy for the treatment of chronic hepatitis C virus infection.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800195",
                    "text": "The results of these studies demonstrate that race/ethnicity has no clinically meaningful impact on direct-acting antiviral agent exposures, safety, or tolerability of the glecaprevir and pibrentasvir combination.",
                    "offsetInBeginSection": 1388,
                    "offsetInEndSection": 1601,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28807904",
                    "text": "The combination of glecaprevir (formerly ABT-493), a nonstructural protein 3/4A (NS3/4A) protease inhibitor, and pibrentasvir (formerly ABT-530), an NS5A protein inhibitor, is being developed as treatment for HCV genotype 1 to 6 infection.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 239,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28807904",
                    "text": "The pharmacokinetics, pharmacodynamics, safety, and tolerability of methadone or buprenorphine-naloxone when coadministered with the glecaprevir-pibrentasvir combination in HCV-negative subjects on stable opioid maintenance therapy were investigated in a phase 1, single-center, two-arm, multiple-dose, open-label sequential study.",
                    "offsetInBeginSection": 240,
                    "offsetInEndSection": 571,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28412293",
                    "text": "LAY SUMMARY The combination of direct-acting antivirals glecaprevir and pibrentasvir comprise a once-daily, all-oral, pangenotypic treatment for HCV genotype 1-6 infection.",
                    "offsetInBeginSection": 1749,
                    "offsetInEndSection": 1921,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29020583",
                    "text": "METHODS We conducted a multicenter, open-label, phase 3 trial to evaluate the efficacy and safety of treatment with the combination of the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir for 12 weeks in adults who had HCV genotype 1, 2, 3, 4, 5, or 6 infection and also had compensated liver disease (with or without cirrhosis) with severe renal impairment, dependence on dialysis, or both.",
                    "offsetInBeginSection": 460,
                    "offsetInEndSection": 876,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28925068",
                    "text": "A recently approved, pan-genotypic, direct-acting antiviral regimen, glecaprevir and pibrentasvir, may simplify prescribing.",
                    "offsetInBeginSection": 550,
                    "offsetInEndSection": 674,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28128852",
                    "text": "This phase 2, open-label study (MAGELLAN-1) evaluated the efficacy and safety of glecaprevir (GLE) + pibrentasvir (PIB) \u00b1 ribavirin (RBV) in HCV genotype 1-infected patients with prior virologic failure to HCV DAA-containing therapy.",
                    "offsetInBeginSection": 503,
                    "offsetInEndSection": 737,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28128852",
                    "text": "CONCLUSION The combination of GLE and PIB was highly efficacious and well tolerated in patients with HCV genotype 1 infection and prior failure of DAA-containing therapy; RBV coadministration did not improve efficacy.",
                    "offsetInBeginSection": 1588,
                    "offsetInEndSection": 1805,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28929412",
                    "text": "A fixed-dose combination tablet of the hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) glecaprevir and the HCV NS5A inhibitor pibrentasvir [glecaprevir/pibrentasvir; MAVIRET\u2122 (EU); MAVYRET\u2122 (USA)] has been developed by AbbVie.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 237,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6fa417b750ff445500005f",
            "body": "Describe the RNA Centric Annotation System (RCAS)",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28334930",
                "http://www.ncbi.nlm.nih.gov/pubmed/25368315",
                "http://www.ncbi.nlm.nih.gov/pubmed/20689021",
                "http://www.ncbi.nlm.nih.gov/pubmed/11416866",
                "http://www.ncbi.nlm.nih.gov/pubmed/27546377",
                "http://www.ncbi.nlm.nih.gov/pubmed/27337980",
                "http://www.ncbi.nlm.nih.gov/pubmed/17145711",
                "http://www.ncbi.nlm.nih.gov/pubmed/29038749",
                "http://www.ncbi.nlm.nih.gov/pubmed/24578356",
                "http://www.ncbi.nlm.nih.gov/pubmed/2088670"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930",
                    "text": "Here, we present the RNA Centric Annotation System (RCAS), an R package, which is designed to ease the process of creating gene-centric annotations and analysis for the genomic regions of interest obtained from various RNA-based omics technologies.",
                    "offsetInBeginSection": 288,
                    "offsetInEndSection": 536,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930",
                    "text": "The meta-gene profiles, gene-centric annotation, motif analysis and gene-set analysis provided by RCAS provide contextual knowledge which is necessary for understanding the functional aspects of different biological events that involve RNAs.",
                    "offsetInBeginSection": 966,
                    "offsetInEndSection": 1207,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20689021",
                    "text": "Such set-centric features address a host of applications, including microarray data analysis, cross-database annotation mapping and gene-disorder associations for drug targeting.",
                    "offsetInBeginSection": 1011,
                    "offsetInEndSection": 1189,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20689021",
                    "text": "Its gene-centric content is automatically mined and integrated from over 80 digital sources, resulting in a web-based deep-linked card for each of >73,000 human gene entries, encompassing the following categories: protein coding, pseudogene, RNA gene, genetic locus, cluster and uncategorized.",
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 446,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11416866",
                    "text": "It uses an avian leukosis retroviral expression system coupled with a transgenic mouse line expressing the viral receptor tv-a from a tissue-specific promoter (RCAS-TVA system) (Federspiel et al., 1994, and reviewed in Fisher et al., 1999).",
                    "offsetInBeginSection": 99,
                    "offsetInEndSection": 339,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27337980",
                    "text": "The Ensembl gene annotation system has been used to annotate over 70 different vertebrate species across a wide range of genome projects.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 137,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27337980",
                    "text": "The system is based on the alignment of biological sequences, including cDNAs, proteins and RNA-seq reads, to the target genome in order to construct candidate transcript models.",
                    "offsetInBeginSection": 248,
                    "offsetInEndSection": 426,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17145711",
                    "text": "The database is now built around a sophisticated genome browser (Ensembl), our own microarray information management and annotation system (MIMAS) used to extensively describe experimental data obtained with high-density oligonucleotide microarrays (GeneChips) and a comprehensive system for online editing of database entries (MediaWiki).",
                    "offsetInBeginSection": 410,
                    "offsetInEndSection": 749,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29038749",
                    "text": "While the pipeline provides a list of environmental terms on the basis of sample datasets and, therefore, the annotations obtained are at the dataset level, it lacks a taxa centric approach to environmental annotation.",
                    "offsetInBeginSection": 702,
                    "offsetInEndSection": 920,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24578356",
                    "text": "We have attempted to address this challenge by creating a community-centric solution for zebrafish gene annotation.",
                    "offsetInBeginSection": 592,
                    "offsetInEndSection": 707,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a76018c83b0d9ea6600000e",
            "body": "List the ten types of conjoined twins.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/1412053",
                "http://www.ncbi.nlm.nih.gov/pubmed/20305942",
                "http://www.ncbi.nlm.nih.gov/pubmed/19060714",
                "http://www.ncbi.nlm.nih.gov/pubmed/15278382",
                "http://www.ncbi.nlm.nih.gov/pubmed/11744915",
                "http://www.ncbi.nlm.nih.gov/pubmed/21860927",
                "http://www.ncbi.nlm.nih.gov/pubmed/16677900",
                "http://www.ncbi.nlm.nih.gov/pubmed/1031540",
                "http://www.ncbi.nlm.nih.gov/pubmed/8772076",
                "http://www.ncbi.nlm.nih.gov/pubmed/29064095"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1412053",
                    "text": "Intact ectoderm will not fuse to intact ectoderm, and all seven types of conjoined twins are explained by seven possible sites of union in the early embryo.",
                    "offsetInBeginSection": 547,
                    "offsetInEndSection": 703,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19060714",
                    "text": "Conjoined twins are a rare complication of monochorionic twinning.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 66,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15278382",
                    "text": "Fusion of monozygotic twins is no longer believed to be the basis of conjoined twinning.",
                    "offsetInBeginSection": 1541,
                    "offsetInEndSection": 1629,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11744915",
                    "text": "We describe the highly unusual circumstance of the Blazek sisters, an extreme developmental example of the terminal monogenital pygopagus type of conjoined twins in which one of the joined sisters conceived and underwent labor and childbirth.",
                    "offsetInBeginSection": 487,
                    "offsetInEndSection": 729,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21860927",
                    "text": "METHODS A retrospective descriptive analysis of prenatally diagnosed conjoined twins.",
                    "offsetInBeginSection": 118,
                    "offsetInEndSection": 203,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21860927",
                    "text": "RESULTS Forty cases of conjoined twins were included in the study.",
                    "offsetInBeginSection": 601,
                    "offsetInEndSection": 667,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16677900",
                    "text": "RESULTS Ten sets of complete conjoined twins and two sets of parasitic conjoined twins were successfully separated.",
                    "offsetInBeginSection": 392,
                    "offsetInEndSection": 507,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16677900",
                    "text": "BACKGROUND/PURPOSE Conjoined twins are rare and complex anomalies of the newborn.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 81,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1031540",
                    "text": "Twenty-two cases of conjoined twins have been collected in Thailand.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 68,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29064095",
                    "text": "Eight different types of conjoined twins have been described in the literature.",
                    "offsetInBeginSection": 154,
                    "offsetInEndSection": 233,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70e6e899e2c3af26000009",
            "body": "What is the mechanism of action of Fremanezumab?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28972120",
                "http://www.ncbi.nlm.nih.gov/pubmed/28642283",
                "http://www.ncbi.nlm.nih.gov/pubmed/29171818",
                "http://www.ncbi.nlm.nih.gov/pubmed/28862758",
                "http://www.ncbi.nlm.nih.gov/pubmed/28644160",
                "http://www.ncbi.nlm.nih.gov/pubmed/27960628",
                "http://www.ncbi.nlm.nih.gov/pubmed/29110503",
                "http://www.ncbi.nlm.nih.gov/pubmed/28240610",
                "http://www.ncbi.nlm.nih.gov/pubmed/20350658",
                "http://www.ncbi.nlm.nih.gov/pubmed/7517515"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120",
                    "text": "To investigate the basis for this selective inhibitory effect, and further explore the mechanism of action of CGRP-mAbs, we tested the effect of fremanezumab on the cortical spreading depression-evoked activation of mechanosensitive primary afferent meningeal nociceptors that innervate the cranial dura, using single-unit recording in the trigeminal ganglion of anesthetized male rats.",
                    "offsetInBeginSection": 742,
                    "offsetInEndSection": 1128,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120",
                    "text": "The selectivity in its peripheral inhibitory action may partly account for fremanezumab's selective inhibition of high-threshold, as a result of a predominant A-\u03b4 input to high-threshold neurons, but not wide dynamic-range dorsal horn neurons, and why it may not be effective in all migraine patients.SIGNIFICANCE STATEMENT Recently, we reported that humanized CGRP monoclonal antibodies (CGRP-mAbs) prevent activation and sensitization of high-threshold (HT) but not wide-dynamic range trigeminovascular neurons by cortical spreading depression (CSD).",
                    "offsetInBeginSection": 1474,
                    "offsetInEndSection": 2027,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120",
                    "text": "We recently tested the effect of fremanezumab (TEV-48125), a CGRP-mAb, on the activity of second-order trigeminovascular dorsal horn neurons that receive peripheral input from the cranial dura, and found a selective inhibition of high-threshold but not wide-dynamic range class of neurons.",
                    "offsetInBeginSection": 452,
                    "offsetInEndSection": 741,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120",
                    "text": "As the main CGRP-mAb site of action appears to be situated outside the brain, we conclude that the initiation of the headache phase of migraine depends on activation of meningeal nociceptors, and that for selected patients, activation of the A\u03b4-HT pain pathway may be sufficient for the generation of headache perception.",
                    "offsetInBeginSection": 2295,
                    "offsetInEndSection": 2617,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28642283",
                    "text": "However, their mechanism of action is unknown.",
                    "offsetInBeginSection": 1875,
                    "offsetInEndSection": 1921,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28642283",
                    "text": "To answer this question, we used single-unit recording to determine the effects of fremanezumab (30 mg/kg, IV) and its isotype control Ab on spontaneous and evoked activity in naive and cortical spreading depression (CSD)-sensitized trigeminovascular neurons in the spinal trigeminal nucleus of anesthetized male and female rats.",
                    "offsetInBeginSection": 571,
                    "offsetInEndSection": 900,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28642283",
                    "text": "The study demonstrates that, in both sexes, fremanezumab inhibited naive high-threshold (HT) neurons, but not wide-dynamic range trigeminovascular neurons, and that the inhibitory effects on the neurons were limited to their activation from the intracranial dura but not facial skin or cornea.",
                    "offsetInBeginSection": 901,
                    "offsetInEndSection": 1194,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29171818",
                    "text": "Background Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP), is being investigated as a preventive treatment for migraine.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 168,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20350658",
                    "text": "Such studies need to be accompanied by rigorous correlative analysis if we are to understand the importance of various mechanisms of action of rituximab and use that information to improve on what is already an indispensable component of therapy.",
                    "offsetInBeginSection": 922,
                    "offsetInEndSection": 1168,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7517515",
                    "text": "The mechanism of action of gabapentin is not fully understood, but its distinct profile of anticonvulsant activity in animal seizure models and its lack of activity at many drug binding sites associated with other antiepileptic drugs indicate that its mechanism of action is novel.",
                    "offsetInBeginSection": 467,
                    "offsetInEndSection": 748,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6fa61ab750ff4455000060",
            "body": "Which tool exists for microsatellite (SSR) loci detection and primer design?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27366148",
                "http://www.ncbi.nlm.nih.gov/pubmed/23324172",
                "http://www.ncbi.nlm.nih.gov/pubmed/18670612",
                "http://www.ncbi.nlm.nih.gov/pubmed/18510760",
                "http://www.ncbi.nlm.nih.gov/pubmed/10912681",
                "http://www.ncbi.nlm.nih.gov/pubmed/14962913",
                "http://www.ncbi.nlm.nih.gov/pubmed/18631390",
                "http://www.ncbi.nlm.nih.gov/pubmed/11292857",
                "http://www.ncbi.nlm.nih.gov/pubmed/11292858",
                "http://www.ncbi.nlm.nih.gov/pubmed/25223041"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148",
                    "text": "FullSSR is a new bioinformatic tool for microsatellite (SSR) loci detection and primer design using genomic data from NGS assay.",
                    "offsetInBeginSection": 150,
                    "offsetInEndSection": 278,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23324172",
                    "text": "We selected a set of 500 microsatellite loci identified in contigs with minimum 100X coverage for primer design and synthesis, and tested a subset of 269 primer pairs, 198 of which were polymorphic on 11 representative B. ruziziensis accessions.",
                    "offsetInBeginSection": 889,
                    "offsetInEndSection": 1134,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23324172",
                    "text": "Recently, next-generation sequencing technologies have been applied to generate sequence data for the identification of microsatellite regions and primer design.",
                    "offsetInBeginSection": 448,
                    "offsetInEndSection": 609,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18510760",
                    "text": "BatchPrimer3 v1.0 implements several types of primer designs including generic primers, SSR primers together with SSR detection, and SNP genotyping primers (including single-base extension primers, allele-specific primers, and tetra-primers for tetra-primer ARMS PCR), as well as DNA sequencing primers.",
                    "offsetInBeginSection": 929,
                    "offsetInEndSection": 1232,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14962913",
                    "text": "With the increase in the availability of DNA sequence information, an automated process to identify and design PCR primers for amplification of SSR loci would be a useful tool in plant breeding programs.",
                    "offsetInBeginSection": 275,
                    "offsetInEndSection": 478,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14962913",
                    "text": "We report an application that integrates SPUTNIK, an SSR repeat finder, with Primer3, a PCR primer design program, into one pipeline tool, SSR Primer.",
                    "offsetInBeginSection": 479,
                    "offsetInEndSection": 629,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18631390",
                    "text": "CONCLUSION The combined approach of identifying SSR-enriched fragments by FIASCO coupled with the primer design and in silico amplification using phpSSRMiner represents an efficient and low cost pipeline for the large-scale development of microsatellite markers in plants.The approach described here could be readily adapted and utilized in other non-related species with none or limited genomic resources.",
                    "offsetInBeginSection": 1548,
                    "offsetInEndSection": 1954,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11292857",
                    "text": "Alternatively, sequence tag primers can be used to directly amplify corresponding SSR loci from genomic DNA, thereby reducing the cost of developing a microsatellite marker to the synthesis of just one sequence-specific primer.",
                    "offsetInBeginSection": 1106,
                    "offsetInEndSection": 1333,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11292858",
                    "text": "A modified selectively amplified microsatellite polymorphic loci assay is used to generate multi-locus SSR fingerprints that provide a source of polymorphic DNA markers (SAMs) for use in genetic studies.",
                    "offsetInBeginSection": 165,
                    "offsetInEndSection": 368,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25223041",
                    "text": "In total, 1890 EST-SSR loci were identified, of which, 1296 SSR sequences could be used for primer design.",
                    "offsetInBeginSection": 199,
                    "offsetInEndSection": 305,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70e88699e2c3af2600000a",
            "body": "Describe mechanism of action of Nusinersen.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27939059",
                "http://www.ncbi.nlm.nih.gov/pubmed/28884620",
                "http://www.ncbi.nlm.nih.gov/pubmed/29091570",
                "http://www.ncbi.nlm.nih.gov/pubmed/28229309",
                "http://www.ncbi.nlm.nih.gov/pubmed/28485722",
                "http://www.ncbi.nlm.nih.gov/pubmed/26865511",
                "http://www.ncbi.nlm.nih.gov/pubmed/29105153",
                "http://www.ncbi.nlm.nih.gov/pubmed/28369979",
                "http://www.ncbi.nlm.nih.gov/pubmed/29130140",
                "http://www.ncbi.nlm.nih.gov/pubmed/28799578"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059",
                    "text": "INTERPRETATION Administration of multiple intrathecal doses of nusinersen showed acceptable safety and tolerability, pharmacology consistent with its intended mechanism of action, and encouraging clinical efficacy.",
                    "offsetInBeginSection": 2944,
                    "offsetInEndSection": 3158,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059",
                    "text": "METHODS This open-label, phase 2, escalating dose clinical study assessed the safety and tolerability, pharmacokinetics, and clinical efficacy of multiple intrathecal doses of nusinersen (6 mg and 12 mg dose equivalents) in patients with infantile-onset spinal muscular atrophy.",
                    "offsetInBeginSection": 348,
                    "offsetInEndSection": 626,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28884620",
                    "text": "Clinical use of nusinersen is also reviewed.",
                    "offsetInBeginSection": 750,
                    "offsetInEndSection": 794,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29091570",
                    "text": "METHODS We conducted a randomized, double-blind, sham-controlled, phase 3 efficacy and safety trial of nusinersen in infants with spinal muscular atrophy.",
                    "offsetInBeginSection": 339,
                    "offsetInEndSection": 493,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28485722",
                    "text": "Recent approval of nusinersen provides a much-needed boost for antisense technology that is just beginning to realize its potential.",
                    "offsetInBeginSection": 1124,
                    "offsetInEndSection": 1256,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28485722",
                    "text": "Here, we provide a historical account of events that led to the discovery of ISS-N1 and describe the impact of independent validations that raised the profile of ISS-N1 as one of the most potent antisense targets for the treatment of a genetic disease.",
                    "offsetInBeginSection": 871,
                    "offsetInEndSection": 1123,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26865511",
                    "text": "OBJECTIVE To examine safety, tolerability, pharmacokinetics, and preliminary clinical efficacy of intrathecal nusinersen (previously ISIS-SMNRx), an antisense oligonucleotide designed to alter splicing of SMN2 mRNA, in patients with childhood spinal muscular atrophy (SMA).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 273,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29105153",
                    "text": "We review the chemistry, pharmacology and mechanisms of action of ASOs, pre-clinical data and clinical trials in neuromuscular diseases and discuss some ethical, regulatory and policy considerations in the clinical development and use of ASOs.",
                    "offsetInBeginSection": 797,
                    "offsetInEndSection": 1040,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29130140",
                    "text": "OBJECTIVE This study describes the early results of technical success, complications and radiation dose of intrathecal delivery of nusinersen using cone-beam CT guidance with two-axis fluoroscopic navigational overlay.",
                    "offsetInBeginSection": 651,
                    "offsetInEndSection": 869,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29130140",
                    "text": "CONCLUSION Cone-beam CT guidance with two-axis navigational overlay is a safe, effective method for gaining transforaminal intrathecal access in children with spinal abnormalities and hardware precluding the use of standard techniques.",
                    "offsetInBeginSection": 1674,
                    "offsetInEndSection": 1909,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6fa9f7b750ff4455000061",
            "body": "Describe Click-PEGylation",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28366801",
                "http://www.ncbi.nlm.nih.gov/pubmed/18590303",
                "http://www.ncbi.nlm.nih.gov/pubmed/20024305",
                "http://www.ncbi.nlm.nih.gov/pubmed/23534985",
                "http://www.ncbi.nlm.nih.gov/pubmed/28116403",
                "http://www.ncbi.nlm.nih.gov/pubmed/25640893",
                "http://www.ncbi.nlm.nih.gov/pubmed/22275125",
                "http://www.ncbi.nlm.nih.gov/pubmed/24184633",
                "http://www.ncbi.nlm.nih.gov/pubmed/21438062",
                "http://www.ncbi.nlm.nih.gov/pubmed/17226981"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28366801",
                    "text": "To establish a more robust method for redox-selective PEGylation, we have utilised a Click chemistry approach, where free thiol groups are first labelled with a reagent modified to contain an alkyne moiety, which is subsequently Click-reacted with a PEG molecule containing a complementary azide function.",
                    "offsetInBeginSection": 1551,
                    "offsetInEndSection": 1856,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28366801",
                    "text": "Here we show how the Click-PEGylation technique can be used to interrogate the redox state of proteins.",
                    "offsetInBeginSection": 2068,
                    "offsetInEndSection": 2171,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18590303",
                    "text": "In this work, we investigate the PEGylation of porous silicon wafers using click chemistry.",
                    "offsetInBeginSection": 159,
                    "offsetInEndSection": 250,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20024305",
                    "text": "Copper-free, strain-promoted click reaction with azides showed excellent kinetics, and a functionalised aza-cyclooctyne was applied in fast and efficient PEGylation of enzymes.",
                    "offsetInBeginSection": 84,
                    "offsetInEndSection": 260,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23534985",
                    "text": "To study the potential of the tyrosine click reaction to introduce poly(ethylene glycol) chains onto proteins (PEGylation), we demonstrate that this novel reagent provides for the selective PEGylation of chymotrypsinogen, whereas traditional succinimide-based PEGylation targeting lysine residues provided a more diverse range of PEGylated products.",
                    "offsetInBeginSection": 954,
                    "offsetInEndSection": 1303,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23534985",
                    "text": "Finally, we applied the tyrosine click reaction to create a novel antibody-drug conjugate.",
                    "offsetInBeginSection": 1304,
                    "offsetInEndSection": 1394,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25640893",
                    "text": "Here, we demonstrate how these new catalysts can be used in a generally applicable procedure for fluorescent labeling, PEGylation, immobilization, and release of aldehyde- and ketone- functionalized proteins.",
                    "offsetInBeginSection": 170,
                    "offsetInEndSection": 378,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22275125",
                    "text": "Overall, the click reaction provided a convenient tool for the pegylation of BSA.",
                    "offsetInBeginSection": 986,
                    "offsetInEndSection": 1067,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24184633",
                    "text": "Fusion of the anti-EpCAM DARPin Ec1 to ETA\u2033 and expression in methionine-auxotrophic E. coli enabled introduction of the nonnatural amino acid azidohomoalanine (Aha) at position 1 for strain-promoted click PEGylation.",
                    "offsetInBeginSection": 458,
                    "offsetInEndSection": 677,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17226981",
                    "text": "Presented here is the synthesis of a polyester-drug graft copolymer conjugate, enabled by click cycloaddition of azide-functionalized camptothecin derivatives with alkyne-functionalized aliphatic polyesters.",
                    "offsetInBeginSection": 227,
                    "offsetInEndSection": 434,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70ea8299e2c3af2600000b",
            "body": "Does Evolocumab improve cognitive function?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28207168",
                "http://www.ncbi.nlm.nih.gov/pubmed/28813214",
                "http://www.ncbi.nlm.nih.gov/pubmed/28744103",
                "http://www.ncbi.nlm.nih.gov/pubmed/26868195",
                "http://www.ncbi.nlm.nih.gov/pubmed/28988500",
                "http://www.ncbi.nlm.nih.gov/pubmed/26414456",
                "http://www.ncbi.nlm.nih.gov/pubmed/29121222",
                "http://www.ncbi.nlm.nih.gov/pubmed/28683788",
                "http://www.ncbi.nlm.nih.gov/pubmed/27092712",
                "http://www.ncbi.nlm.nih.gov/pubmed/28812389"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28207168",
                    "text": "EBBINGHAUS will evaluate whether the addition of evolocumab to statin therapy affects cognitive function over time in patients with stable cardiovascular disease.",
                    "offsetInBeginSection": 1748,
                    "offsetInEndSection": 1910,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813214",
                    "text": "Conclusions In a randomized trial involving patients who received either evolocumab or placebo in addition to statin therapy, no significant between-group difference in cognitive function was observed over a median of 19 months.",
                    "offsetInBeginSection": 2301,
                    "offsetInEndSection": 2529,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813214",
                    "text": "Background Findings from clinical trials of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have led to concern that these drugs or the low levels of low-density lipoprotein (LDL) cholesterol that result from their use are associated with cognitive deficits.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 275,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28744103",
                    "text": "Appropriate candidates for evolocumab primarily are individuals at high cardiovascular risk, including those with familial hypercholesterolemia and/or established cardiovascular disease, who are already on statin therapy.",
                    "offsetInBeginSection": 769,
                    "offsetInEndSection": 990,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26868195",
                    "text": "INTERPRETATION Evolocumab markedly reduces atherogenic lipoproteins in patients with type 2 diabetes, an effect that is consistent across subgroups and similar to that seen in patients without type 2 diabetes.",
                    "offsetInBeginSection": 2339,
                    "offsetInEndSection": 2548,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28988500",
                    "text": "Evolocumab is an injectable, fully human monoclonal antibody and a member of the newest class of low density lipoprotein cholesterol (LDL-C) lowering agents called proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 229,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28988500",
                    "text": "This review will focus on the overall safety of evolocumab including cognitive impairment, very low LDL-C levels, new onset diabetes and glucose abnormalities, effect on vitamin E and steroid hormones, liver and muscle abnormalities, and immunogenicity and injection site reactions.",
                    "offsetInBeginSection": 624,
                    "offsetInEndSection": 906,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26414456",
                    "text": "EXPERT OPINION In OSLER and ODYSSEY LONG TERM, there were very few cardiovascular outcomes, but the trials do suggest that evolocumab and alirocumab may reduce these outcomes.",
                    "offsetInBeginSection": 549,
                    "offsetInEndSection": 724,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683788",
                    "text": "This suggests that evolocumab clinically improves the nephrotic condition.",
                    "offsetInBeginSection": 1032,
                    "offsetInEndSection": 1106,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27092712",
                    "text": "Randomized trials have shown marked reductions in low-density lipoprotein cholesterol (LDL-C), a risk factor for cardiovascular disease (CVD), when evolocumab is administered.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a75dff883b0d9ea66000003",
            "body": "Name curated data resources for ChIP-seq data",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27789702",
                "http://www.ncbi.nlm.nih.gov/pubmed/24253304",
                "http://www.ncbi.nlm.nih.gov/pubmed/19892823",
                "http://www.ncbi.nlm.nih.gov/pubmed/28529706",
                "http://www.ncbi.nlm.nih.gov/pubmed/22495751",
                "http://www.ncbi.nlm.nih.gov/pubmed/26969372",
                "http://www.ncbi.nlm.nih.gov/pubmed/29059324",
                "http://www.ncbi.nlm.nih.gov/pubmed/21113027",
                "http://www.ncbi.nlm.nih.gov/pubmed/22827163",
                "http://www.ncbi.nlm.nih.gov/pubmed/24335146"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27789702",
                    "text": "Although rapidly accumulating publicly available ChIP-seq, DNase-seq and ATAC-seq data are a valuable resource for the systematic investigation of gene regulation processes, a lack of standardized curation, quality control and analysis procedures have hindered extensive reuse of these data.",
                    "offsetInBeginSection": 236,
                    "offsetInEndSection": 527,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27789702",
                    "text": "To overcome this challenge, we built the Cistrome database, a collection of ChIP-seq and chromatin accessibility data (DNase-seq and ATAC-seq) published before January 1, 2016, including 13 366 human and 9953 mouse samples.",
                    "offsetInBeginSection": 528,
                    "offsetInEndSection": 751,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24253304",
                    "text": "Within this database, we collected all publicly available ChIP-Seq data on CRs in human and mouse and categorized the data into four cohorts: the reader, writer, eraser and remodeler cohorts, together with curated introductions and ChIP-Seq data analysis results.",
                    "offsetInBeginSection": 761,
                    "offsetInEndSection": 1024,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28529706",
                    "text": "Therefore, a relational database in which available ChIP-Seq datasets are curated is essential.",
                    "offsetInBeginSection": 438,
                    "offsetInEndSection": 533,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28529706",
                    "text": "Results: We present Expresso (database and webserver) as a tool for the collection and integration of available Arabidopsis ChIP-Seq peak data, which in turn can be linked to a user's gene expression data.",
                    "offsetInBeginSection": 534,
                    "offsetInEndSection": 739,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28529706",
                    "text": "Known target genes of transcription factors were identified by motif analysis of publicly available GEO ChIP-Seq data sets.",
                    "offsetInBeginSection": 740,
                    "offsetInEndSection": 863,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22495751",
                    "text": "We have created CistromeMap as a web server to provide a comprehensive knowledgebase of all of the publicly available ChIP-Seq and DNase-Seq data in mouse and human.",
                    "offsetInBeginSection": 118,
                    "offsetInEndSection": 283,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26969372",
                    "text": "We then utilized 61 RNA-seq and 32 ChIP-seq datasets to improve the annotation of the curated lncRNAs with regards to transcriptional direction, exon regions, classification, expression in the brain, possession of a poly(A) tail, and presence of conventional chromatin signatures.",
                    "offsetInBeginSection": 1033,
                    "offsetInEndSection": 1313,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29059324",
                    "text": "These include new genomes for both supported species (each with chromosome scale assemblies), new genome annotations, genome segmentation, dynamic and interactive visualization for RNA-Seq data, updated ChIP-Seq mapping, GO terms, protein interaction data, ORFeome support, and improved connectivity to other biomedical and bioinformatic resources.",
                    "offsetInBeginSection": 514,
                    "offsetInEndSection": 862,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24335146",
                    "text": "Here we provide a systematic motif analysis for 427 human ChIP-seq data sets using motifs curated from the literature and also discovered de novo using five established motif discovery tools.",
                    "offsetInBeginSection": 274,
                    "offsetInEndSection": 465,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a72284b2dc08e987e000001",
            "body": "Can radius fracture cause carpal tunnel syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29169594",
                "http://www.ncbi.nlm.nih.gov/pubmed/23026468",
                "http://www.ncbi.nlm.nih.gov/pubmed/21786553",
                "http://www.ncbi.nlm.nih.gov/pubmed/21505639",
                "http://www.ncbi.nlm.nih.gov/pubmed/26566562",
                "http://www.ncbi.nlm.nih.gov/pubmed/11514776",
                "http://www.ncbi.nlm.nih.gov/pubmed/20470591",
                "http://www.ncbi.nlm.nih.gov/pubmed/27454517",
                "http://www.ncbi.nlm.nih.gov/pubmed/7524581",
                "http://www.ncbi.nlm.nih.gov/pubmed/10207976"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169594",
                    "text": "Carpal tunnel syndrome (CTS) after distal radius fractures can present in 3 forms: acute, transient, and delayed.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169594",
                    "text": "Prophylactic carpal tunnel release in the absence of signs and symptoms of CTS after a distal radius fracture is not indicated.",
                    "offsetInBeginSection": 314,
                    "offsetInEndSection": 441,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026468",
                    "text": "Delayed carpal tunnel syndrome presenting after a distal radius fracture has healed is best managed in standard fashion.",
                    "offsetInBeginSection": 465,
                    "offsetInEndSection": 585,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21786553",
                    "text": "CONCLUSION Simultaneous anterior transverse carpal ligament resection can effectively prevent the delayed carpal tunnel syndrome occurrence for the distal radius fracture with open reduction by palm side.",
                    "offsetInBeginSection": 1211,
                    "offsetInEndSection": 1415,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21505639",
                    "text": "We report the incidence of late onset post-operative carpal tunnel syndrome (late carpal tunnel syndrome) and late median nerve neuropathy after volar plating of distal radius fracture by conducting a retrospective study on volar plating for distal radius fracture performed during 2002 to 2006.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 295,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26566562",
                    "text": "We report a case of acute rupture of the flexor pollicis longus and flexor carpi radialis tendons with acute carpal tunnel syndrome after a Gustilo-Anderson type II open distal radius fracture.",
                    "offsetInBeginSection": 141,
                    "offsetInEndSection": 334,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27454517",
                    "text": "Carpal tunnel syndrome is a common complication associated with distal radius fractures.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 88,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27454517",
                    "text": "Being well known and accepted techniques of carpal tunnel release, we believe that the techniques described in this paper provide a viable alternative for carpal tunnel release in the setting of distal radius fracture fixation; with the added advantages of the original minimally invasive techniques.",
                    "offsetInBeginSection": 628,
                    "offsetInEndSection": 928,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7524581",
                    "text": "Chronic pressure here may cause carpal tunnel syndrome.",
                    "offsetInBeginSection": 651,
                    "offsetInEndSection": 706,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10207976",
                    "text": "Carpal tunnel syndrome after fracture of the distal radius is a well known complication in adults, but in small children carpal tunnel syndrome is extremely rare.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a75f1f383b0d9ea66000006",
            "body": "Can Logic Alignment Free (LAF) be used for bacterial genomes classification?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26664519",
                "http://www.ncbi.nlm.nih.gov/pubmed/25573913",
                "http://www.ncbi.nlm.nih.gov/pubmed/22312592",
                "http://www.ncbi.nlm.nih.gov/pubmed/21161744",
                "http://www.ncbi.nlm.nih.gov/pubmed/25313296",
                "http://www.ncbi.nlm.nih.gov/pubmed/21906634",
                "http://www.ncbi.nlm.nih.gov/pubmed/22072304",
                "http://www.ncbi.nlm.nih.gov/pubmed/27409298",
                "http://www.ncbi.nlm.nih.gov/pubmed/25259891",
                "http://www.ncbi.nlm.nih.gov/pubmed/21496953"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519",
                    "text": "In this paper, we present Logic Alignment Free (LAF), a method that combines alignment-free techniques and rule-based classification algorithms in order to assign biological samples to their taxa.",
                    "offsetInBeginSection": 315,
                    "offsetInEndSection": 511,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519",
                    "text": "We apply LAF successfully to the classification of bacterial genomes to their corresponding taxonomy.",
                    "offsetInBeginSection": 690,
                    "offsetInEndSection": 791,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519",
                    "text": "Alignment-free algorithms can be used to estimate the similarity of biological sequences and hence are often applied to the phylogenetic reconstruction of genomes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25573913",
                    "text": "MOTIVATION Alignment-based sequence similarity searches, while accurate for some type of sequences, can produce incorrect results when used on more divergent but functionally related sequences that have undergone the sequence rearrangements observed in many bacterial and viral genomes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 286,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25573913",
                    "text": "Here, we propose a classification model that exploits the complementary nature of alignment-based and alignment-free similarity measures with the aim to improve the accuracy with which DNA and protein sequences are characterized.",
                    "offsetInBeginSection": 287,
                    "offsetInEndSection": 516,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22312592",
                    "text": "We have therefore developed an alignment-free algorithm for rapidly detecting horizontal gene transfer between closely related bacterial genomes.",
                    "offsetInBeginSection": 526,
                    "offsetInEndSection": 671,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22312592",
                    "text": "Our implementation of this algorithm is called alfy for \"ALignment Free local homologY\" and is freely available from http://guanine.evolbio.mpg.de/alfy/.",
                    "offsetInBeginSection": 672,
                    "offsetInEndSection": 825,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21161744",
                    "text": "CONCLUSIONS Both LAF and UVL reduce PJI.",
                    "offsetInBeginSection": 1394,
                    "offsetInEndSection": 1434,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25313296",
                    "text": "The workflow utilizes highly scalable parallel applications for classification and sequence alignment.",
                    "offsetInBeginSection": 951,
                    "offsetInEndSection": 1053,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21906634",
                    "text": "Notably, the trees derived from the alignment of other conserved COG genes divided the Bacillus and Corynebacterium genera into the same subgroups produced by the novel bacterial tree.",
                    "offsetInBeginSection": 465,
                    "offsetInEndSection": 649,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a722a052dc08e987e000002",
            "body": "Is Marfan syndrome associated with chordal rupture?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7790334",
                "http://www.ncbi.nlm.nih.gov/pubmed/10441700",
                "http://www.ncbi.nlm.nih.gov/pubmed/14658812",
                "http://www.ncbi.nlm.nih.gov/pubmed/18172522",
                "http://www.ncbi.nlm.nih.gov/pubmed/17317544",
                "http://www.ncbi.nlm.nih.gov/pubmed/1888465",
                "http://www.ncbi.nlm.nih.gov/pubmed/15755703",
                "http://www.ncbi.nlm.nih.gov/pubmed/776440",
                "http://www.ncbi.nlm.nih.gov/pubmed/2278175",
                "http://www.ncbi.nlm.nih.gov/pubmed/23700867"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7790334",
                    "text": "It is worthy to report this case because of rarities such as Marfan's syndrome accompanied by Prinzmetal's variant angina, perioperative coronary artery spasm in modified Bentall's operation, and perioperative chordal rupture of the mitral valve and progression of mitral valve regurgitation.",
                    "offsetInBeginSection": 659,
                    "offsetInEndSection": 951,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7790334",
                    "text": "In a modified Bentall's operation (button technique), perioperative severe coronary artery spasm occurred in spite of the preventive use of nitroglycerin infusion, which resulted in profound ventricular fibrillation and subsequent chordal rupture of the mitral valve with Sellers IV regurgitation.",
                    "offsetInBeginSection": 130,
                    "offsetInEndSection": 427,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10441700",
                    "text": "The neonatal Marfan syndrome is an autosomal dominantly inherited disease with an extremely poor prognosis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 107,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10441700",
                    "text": "This report gives a clinical and echocardiographic description of an infant with a mutation in exon 29 of the fibrillin-1 gene (FBN1), a region in which this severe form of Marfan syndrome seems to cluster.",
                    "offsetInBeginSection": 108,
                    "offsetInEndSection": 314,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14658812",
                    "text": "Three patients underwent mitral annuloplasty and chordal shortening.",
                    "offsetInBeginSection": 772,
                    "offsetInEndSection": 840,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14658812",
                    "text": "CONCLUSION This experience in mitral valve procedures indicated that the connective tissue defect might compromise the results of such surgery, but that mitral valve operations could be performed satisfactorily in young Marfan syndrome patients, despite complications of left ventricular dilatation.",
                    "offsetInBeginSection": 1109,
                    "offsetInEndSection": 1408,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18172522",
                    "text": "Repair of the mitral valve in children who have Marfan syndrome is especially difficult due to the presence of generalized connective tissue disorder, which may lead to future elongation and rupture of chordae tendineae that were unaffected at the time of mitral valve repair.",
                    "offsetInBeginSection": 205,
                    "offsetInEndSection": 481,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1888465",
                    "text": "Gargoylism promotes abnormal thickening of collagen fibers in the fibrosa via acid-mucopolysaccharide (aMPS) overproduction, but Marfan syndrome weakens the valves in spite of increased aMPS.",
                    "offsetInBeginSection": 345,
                    "offsetInEndSection": 536,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/776440",
                    "text": "Associated Cardiac Diseases, i.e., Marfan's syndrome, ostium secundum atrial septal defect and atherosclerotic coronary artery disease, are discussed, and a section on Treatment deals chiefly with prophylaxis for infective endocarditis and the management of arrhythmias and chest pain.",
                    "offsetInBeginSection": 1109,
                    "offsetInEndSection": 1394,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23700867",
                    "text": "Marfan syndrome is an autosomal dominant disorder of connective tissue with up to 25% of cases related to a spontaneous mutation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a75f2fc83b0d9ea66000007",
            "body": "What is TCGA2BED?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28049410"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "We also provide and maintain an automatically updated data repository with publicly available Copy Number Variation, DNA-methylation, DNA-seq, miRNA-seq, and RNA-seq (V1,V2) experimental data of TCGA converted into the BED format, and their associated clinical and biospecimen meta data in attribute-value text format.",
                    "offsetInBeginSection": 814,
                    "offsetInEndSection": 1132,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "RESULTS We propose TCGA2BED a software tool to search and retrieve TCGA data, and convert them in the structured BED format for their seamless use and integration.",
                    "offsetInBeginSection": 417,
                    "offsetInEndSection": 580,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "Furthermore, TCGA2BED extends TCGA data with information extracted from other genomic databases (i.e., NCBI Entrez Gene, HGNC, UCSC, and miRBase).",
                    "offsetInBeginSection": 667,
                    "offsetInEndSection": 813,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "CONCLUSIONS The availability of the valuable TCGA data in BED format reduces the time spent in taking advantage of them: it is possible to efficiently and effectively deal with huge amounts of cancer genomic data integratively, and to search, retrieve and extend them with additional information.",
                    "offsetInBeginSection": 1135,
                    "offsetInEndSection": 1431,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "In this work, we focus on The Cancer Genome Atlas, a comprehensive archive of tumoral data containing the results of high-throughout experiments, mainly Next Generation Sequencing, for more than 30 cancer types.",
                    "offsetInBeginSection": 203,
                    "offsetInEndSection": 414,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "BACKGROUND Data extraction and integration methods are becoming essential to effectively access and take advantage of the huge amounts of heterogeneous genomics and clinical data increasingly available.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 202,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "The BED format facilitates the investigators allowing several knowledge discovery analyses on all tumor types in TCGA with the final aim of understanding pathological mechanisms and aiding cancer treatments.",
                    "offsetInBeginSection": 1432,
                    "offsetInEndSection": 1639,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "Additionally, it supports the conversion in CSV, GTF, JSON, and XML standard formats.",
                    "offsetInBeginSection": 581,
                    "offsetInEndSection": 666,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a722ccd2dc08e987e000003",
            "body": "What is the mechanism of action of Tezepelumab?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28877011",
                "http://www.ncbi.nlm.nih.gov/pubmed/28583618",
                "http://www.ncbi.nlm.nih.gov/pubmed/28368013",
                "http://www.ncbi.nlm.nih.gov/pubmed/19967312",
                "http://www.ncbi.nlm.nih.gov/pubmed/12467887",
                "http://www.ncbi.nlm.nih.gov/pubmed/17361728",
                "http://www.ncbi.nlm.nih.gov/pubmed/6369884",
                "http://www.ncbi.nlm.nih.gov/pubmed/8054612",
                "http://www.ncbi.nlm.nih.gov/pubmed/12858935",
                "http://www.ncbi.nlm.nih.gov/pubmed/12690410"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12467887",
                    "text": "One of the mechanisms of action of CBZ and ZNS is inactivation of voltage-gated Na+ channel (VGSC).",
                    "offsetInBeginSection": 131,
                    "offsetInEndSection": 230,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12467887",
                    "text": "Our findings enhance our understanding of the mechanisms of action of CBZ and ZNS as AEDs, which possibly reduce P-type VSCCs/synaptobrevin-related exocytosis mechanisms during the depolarization stage, and simultaneously enhance N-type VSCCs/syntaxin-related exocytosis mechanisms at the resting stage.",
                    "offsetInBeginSection": 1381,
                    "offsetInEndSection": 1684,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12467887",
                    "text": "CBZ and ZNS increased Ca2+-evoked release, an action selectively inhibited by inhibitors of N-type VSCC and syntaxin.",
                    "offsetInBeginSection": 986,
                    "offsetInEndSection": 1103,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12467887",
                    "text": "CBZ and ZNS reduced K+-evoked release, an action predominantly inhibited by inhibitors of P-type VSCCs and synaptobrevin.",
                    "offsetInBeginSection": 1104,
                    "offsetInEndSection": 1225,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6369884",
                    "text": "The molecular mechanism of action is known for diuretic agents such as acetazolamide (carbonic anhydrase), theophylline (phosphodiesterase), digitalis glucosides (Na-K-ATPase), spironolactone (aldosterone antagonism) and dopamine (specific receptors?).",
                    "offsetInBeginSection": 224,
                    "offsetInEndSection": 476,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6369884",
                    "text": "The mechanism of action of diuretics can be established by studying the molecular mechanism of action, the site of action within the nephron, and the relationship between the pharmacokinetics of the diuretic and its effect.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 223,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6369884",
                    "text": "The main site of diuretic action is well established for the different groups of diuretics: carbonic anhydrase inhibitors act on the proximal tubulus, loop diuretics on the diluting segment, thiazides on the cortical diluting segment/distal tubulus, and potassium-sparing agents on distal tubulus/collecting ducts.",
                    "offsetInBeginSection": 851,
                    "offsetInEndSection": 1165,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8054612",
                    "text": "Activation of succinate oxidase pathway in that situation may be regarded as a immediate compensatory mechanism entering in action at limitation of NADH-oxidase pathway and promoting increase of tissue resistance at oxygen deficiency.",
                    "offsetInBeginSection": 299,
                    "offsetInEndSection": 533,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8054612",
                    "text": "The mechanism of antihypoxic action of succinate-containing derivative of 3-hydroxypiridine (mexidol) on hypoxic isolated contractive heart was investigated.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 157,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12690410",
                    "text": "Antiepileptic drugs (DAEs) act through different mechanisms of action: increase in central inhibition, inhibition of excitatorios mechanisms and modification of the excitability through their action on the ionic channels.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 221,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a75f5aa83b0d9ea66000008",
            "body": "Describe JACUSA",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28049429",
                "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                "http://www.ncbi.nlm.nih.gov/pubmed/15861591",
                "http://www.ncbi.nlm.nih.gov/pubmed/25709171",
                "http://www.ncbi.nlm.nih.gov/pubmed/8140769",
                "http://www.ncbi.nlm.nih.gov/pubmed/18428249",
                "http://www.ncbi.nlm.nih.gov/pubmed/28800283",
                "http://www.ncbi.nlm.nih.gov/pubmed/8933228",
                "http://www.ncbi.nlm.nih.gov/pubmed/23617612",
                "http://www.ncbi.nlm.nih.gov/pubmed/25543586"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429",
                    "text": "CONCLUSION Our software JACUSA detects single nucleotide variants by comparing data from next-generation sequencing experiments (RNA-DNA or RNA-RNA).",
                    "offsetInBeginSection": 1974,
                    "offsetInEndSection": 2123,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                    "text": "We describe first a field deployable mass spectrometer, based on an ion trap analyzer, and variants of that system.",
                    "offsetInBeginSection": 375,
                    "offsetInEndSection": 490,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                    "text": "We describe four sensing and characterization technologies recently developed at Los Alamos National Laboratory; a select set of mass spectral and optical techniques is emphasized.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                    "text": "We then describe a hand-held, battery-operated optical spectrometer, usable in either absorption, or fluorescence excitation mode.",
                    "offsetInBeginSection": 491,
                    "offsetInEndSection": 621,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15861591",
                    "text": "Experience of SA-RPE using the simplified technique described by Pogrel et al is describe.",
                    "offsetInBeginSection": 585,
                    "offsetInEndSection": 675,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25709171",
                    "text": "We describe a rare, newly described syndrome with features of overgrowth and vascular malformations.",
                    "offsetInBeginSection": 113,
                    "offsetInEndSection": 213,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8140769",
                    "text": "The authors describe another subtype of antigen HLA-B27, described as HLA-B27P3.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 80,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18428249",
                    "text": "Several support protocols describe methods for adenovirus growth and purification, biotinylation, inactivation with psoralen, and quantitation of the adenovirus particles.",
                    "offsetInBeginSection": 279,
                    "offsetInEndSection": 450,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8933228",
                    "text": "The aim of this study is to describe the essential characteristics of a family affected by the newly-described proximal myotonic myopathy (PROMM) The clinical, laboratory and genetic findings are described and compared with those reported in the literature, and the clinical spectrum of the manifestations that are similar to but distinct from myotonic dystrophy (MD) is also explored.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 385,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23617612",
                    "text": "PURPOSE To describe a case of unilateral intracranial arachnoid cyst in association with enophthalmos and epiphora on the same side.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a722d9f2dc08e987e000004",
            "body": "What is mechanism of action of Benralizumab?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27097165",
                "http://www.ncbi.nlm.nih.gov/pubmed/28530840",
                "http://www.ncbi.nlm.nih.gov/pubmed/23866823",
                "http://www.ncbi.nlm.nih.gov/pubmed/27119985",
                "http://www.ncbi.nlm.nih.gov/pubmed/29086236",
                "http://www.ncbi.nlm.nih.gov/pubmed/26205082",
                "http://www.ncbi.nlm.nih.gov/pubmed/28737051",
                "http://www.ncbi.nlm.nih.gov/pubmed/28919200",
                "http://www.ncbi.nlm.nih.gov/pubmed/22136436",
                "http://www.ncbi.nlm.nih.gov/pubmed/28109128"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27097165",
                    "text": "Benralizumab is an anti-interleukin-5 receptor \u03b1 monoclonal antibody that depletes blood and airway eosinophils.",
                    "offsetInBeginSection": 215,
                    "offsetInEndSection": 328,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27097165",
                    "text": "CONCLUSIONS Benralizumab reduced asthma exacerbation and improved lung function and asthma control in adults with uncontrolled eosinophilic asthma.",
                    "offsetInBeginSection": 1393,
                    "offsetInEndSection": 1540,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29086236",
                    "text": "Benralizumab is a monoclonal antibody that targets interleukin-5 receptor \u03b1 to deplete blood eosinophils and improve the clinical outcomes of allergic asthma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 159,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28737051",
                    "text": "Anti-IL-5-based therapies (mepolizumab and reslizumab are humanized monoclonal antibodies (hmAbs) that recognize free IL-5, benralizumab is a hmAb directed at the \u03b1 subunit of the IL-5R) target the IL-5-signaling in eosinophilic asthma.",
                    "offsetInBeginSection": 299,
                    "offsetInEndSection": 536,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28737051",
                    "text": "Other benefits of benralizumab are fast (within 24\u00a0h) depletion of peripheral blood eosinophils, potent suppressive activity of bone marrow eosinophils and eosinophil precursors, tissue eosinophil apoptosis regardless of the presence of eosinophil survival factors and even at low IL-5R densities.",
                    "offsetInBeginSection": 952,
                    "offsetInEndSection": 1250,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28919200",
                    "text": "BACKGROUND Benralizumab is an anti-eosinophilic, anti-interleukin-5 receptor \u03b1 monoclonal antibody that has been shown to significantly reduce asthma exacerbations and improve lung function for patients with severe, uncontrolled asthma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 237,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22136436",
                    "text": "As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma.",
                    "offsetInBeginSection": 102,
                    "offsetInEndSection": 249,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22136436",
                    "text": "INTRODUCTION Benralizumab is a monoclonal antibody that binds the \u03b1 subunit of the receptor to IL-5.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 101,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28109128",
                    "text": "Benralizumab is a humanized, afucosylated, anti-interleukin-5 receptor \u03b1, immunoglobulin G (IgG) 1 \u03ba monoclonal antibody.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 123,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28109128",
                    "text": "Stochastic simulations supported an every-8-week dosing schedule of benralizumab for a phase IIb study in patients with uncontrolled asthma.",
                    "offsetInBeginSection": 945,
                    "offsetInEndSection": 1085,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a75f6e083b0d9ea66000009",
            "body": "Which data simulator is available for CLIP-SEQ experiments?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26776207",
                "http://www.ncbi.nlm.nih.gov/pubmed/28254606",
                "http://www.ncbi.nlm.nih.gov/pubmed/21389147",
                "http://www.ncbi.nlm.nih.gov/pubmed/21037263",
                "http://www.ncbi.nlm.nih.gov/pubmed/25652745",
                "http://www.ncbi.nlm.nih.gov/pubmed/24451213",
                "http://www.ncbi.nlm.nih.gov/pubmed/28605404",
                "http://www.ncbi.nlm.nih.gov/pubmed/21994224",
                "http://www.ncbi.nlm.nih.gov/pubmed/26539468",
                "http://www.ncbi.nlm.nih.gov/pubmed/28336542"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207",
                    "text": "To this date, however, it has not been assessed which of the available tools are most appropriate for the analysis of CLIP-Seq data.",
                    "offsetInBeginSection": 325,
                    "offsetInEndSection": 457,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21037263",
                    "text": "In this study, we introduce a novel database, starBase (sRNA target Base), which we have developed to facilitate the comprehensive exploration of miRNA-target interaction maps from CLIP-Seq and Degradome-Seq data.",
                    "offsetInBeginSection": 421,
                    "offsetInEndSection": 634,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25652745",
                    "text": "DESCRIPTION Here, we constructed a database, CLIPdb, to describe RBP-RNA interactions based on 395 publicly available CLIP-seq data sets for 111 RBPs from four organisms: human, mouse, worm and yeast.",
                    "offsetInBeginSection": 426,
                    "offsetInEndSection": 626,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25652745",
                    "text": "We consistently annotated the CLIP-seq data sets and RBPs, and developed a user-friendly interface for rapid navigation of the CLIP-seq data.",
                    "offsetInBeginSection": 627,
                    "offsetInEndSection": 768,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25652745",
                    "text": "We applied a unified computational method to identify transcriptome-wide binding sites, making the binding sites directly comparable and the data available for integration across different CLIP-seq studies.",
                    "offsetInBeginSection": 769,
                    "offsetInEndSection": 975,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25652745",
                    "text": "CONCLUSION Manually curated metadata and uniformly identified binding sites of publicly available CLIP-seq data sets will be a foundation for further integrative and comparative analyses.",
                    "offsetInBeginSection": 1266,
                    "offsetInEndSection": 1453,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25652745",
                    "text": "Large amounts of crosslinking immunoprecipitation (CLIP)-seq data (including HITS-CLIP, PAR-CLIP, and iCLIP) have been recently produced to reveal transcriptome-wide binding sites of RBPs at the single-nucleotide level.",
                    "offsetInBeginSection": 204,
                    "offsetInEndSection": 423,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24451213",
                    "text": "Here, we present PIPE-CLIP, a Galaxy framework-based comprehensive online pipeline for reliable analysis of data generated by three types of CLIP-seq protocol: HITS-CLIP, PAR-CLIP and iCLIP.",
                    "offsetInBeginSection": 232,
                    "offsetInEndSection": 422,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21994224",
                    "text": "RESULTS We describe Pyicos, a powerful toolkit for the analysis of mapped reads from diverse HTS experiments: ChIP-Seq, either punctuated or broad signals, CLIP-Seq and RNA-Seq.",
                    "offsetInBeginSection": 355,
                    "offsetInEndSection": 532,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26539468",
                    "text": "Our findings can serve as a general guideline for CLIP experiments design and the comprehensive analysis of CLIP-Seq data.",
                    "offsetInBeginSection": 894,
                    "offsetInEndSection": 1016,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a72302b2dc08e987e000005",
            "body": "Treatment of which disease was studied in the Gore REDUCE Clinical Study?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29090661",
                "http://www.ncbi.nlm.nih.gov/pubmed/28222987",
                "http://www.ncbi.nlm.nih.gov/pubmed/10847965",
                "http://www.ncbi.nlm.nih.gov/pubmed/27872317",
                "http://www.ncbi.nlm.nih.gov/pubmed/26808286",
                "http://www.ncbi.nlm.nih.gov/pubmed/2940526",
                "http://www.ncbi.nlm.nih.gov/pubmed/10395270",
                "http://www.ncbi.nlm.nih.gov/pubmed/22288601",
                "http://www.ncbi.nlm.nih.gov/pubmed/18559363",
                "http://www.ncbi.nlm.nih.gov/pubmed/24721761"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29090661",
                    "text": "Aims The Gore REDUCE Clinical Study (REDUCE) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.",
                    "offsetInBeginSection": 194,
                    "offsetInEndSection": 507,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29090661",
                    "text": "The trial should determine whether patent foramen ovale closure with the Gore septal occluders is safe and more effective than medical therapy alone for the prevention of recurrent clinical ischemic stroke or new silent brain infarct; the neuroimaging data will provide an opportunity to further support the proof of concept.",
                    "offsetInBeginSection": 1629,
                    "offsetInEndSection": 1954,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987",
                    "text": "CONCLUSIONS Our multicenter experience with the GORE TIGRIS Vascular Stent demonstrates continued good results\u00a0at\u00a02\u00a0years for endovascular treatment of challenging obstructive superficial femoral artery and popliteal artery disease.",
                    "offsetInBeginSection": 1517,
                    "offsetInEndSection": 1752,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987",
                    "text": "This study therefore investigated the performance of the GORE TIGRIS Vascular Stent at three different centers in France in patients with symptomatic peripheral artery disease.",
                    "offsetInBeginSection": 251,
                    "offsetInEndSection": 427,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987",
                    "text": "METHODS This retrospective, single-arm, multicenter cohort study included 215 patients with peripheral artery disease (Rutherford-Becker category 2-6) who were treated with the GORE TIGRIS Vascular Stent, a dual-component stent consisting of a nitinol wire frame combined with a fluoropolymer-interconnecting structure.",
                    "offsetInBeginSection": 430,
                    "offsetInEndSection": 749,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987",
                    "text": "BACKGROUND Preliminary results in small single-center studies after stenting with the GORE TIGRIS Vascular Stent (W.\u00a0L.\u00a0Gore & Associates, Flagstaff, Ariz) show promising short-term primary patency rates, but larger, multicenter studies are needed.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 250,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27872317",
                    "text": "METHODS A prospective, single-center pilot study recruited 30 symptomatic patients (mean age 64 years; 18 men) to evaluate the safety and early efficacy of the new Gore balloon-expandable covered endoprosthesis for the treatment of de novo or restenotic common and/or external iliac artery lesions.",
                    "offsetInBeginSection": 115,
                    "offsetInEndSection": 413,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26808286",
                    "text": "BACKGROUND The aim of this study is to assess the safety and the short-term results of endovascular treatment of common iliac artery (CIA) aneurysms using the new GORE EXCLUDER iliac branch endoprosthesis (IBE) device.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 218,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22288601",
                    "text": "CONCLUSION Implanting a Gore Bio-A\u00ae Fistula Plug is a simple, minimally invasive, safe and potentially effective procedure to treat complex anal fistula.",
                    "offsetInBeginSection": 1258,
                    "offsetInEndSection": 1412,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22288601",
                    "text": "METHOD Eleven patients with a complex anal fistula underwent insertion of Gore Bio-A\u00ae Fistula Plugs.",
                    "offsetInBeginSection": 329,
                    "offsetInEndSection": 430,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a760e5583b0d9ea66000018",
            "body": "Which comparisons demonstrate the applicability of StereoGene in regulatory genomics?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29028265",
                "http://www.ncbi.nlm.nih.gov/pubmed/15814024",
                "http://www.ncbi.nlm.nih.gov/pubmed/23175757",
                "http://www.ncbi.nlm.nih.gov/pubmed/10207157",
                "http://www.ncbi.nlm.nih.gov/pubmed/14993210",
                "http://www.ncbi.nlm.nih.gov/pubmed/28155637",
                "http://www.ncbi.nlm.nih.gov/pubmed/17201929",
                "http://www.ncbi.nlm.nih.gov/pubmed/26388177",
                "http://www.ncbi.nlm.nih.gov/pubmed/16407459",
                "http://www.ncbi.nlm.nih.gov/pubmed/23440612"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265",
                    "text": "These analyses provide examples for the broad applicability of StereoGene for regulatory genomics.",
                    "offsetInBeginSection": 1473,
                    "offsetInEndSection": 1571,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265",
                    "text": "We apply our method to numerous comparisons of ChIP-Seq datasets from the Human Epigenome Atlas and FANTOM CAGE to demonstrate its wide applicability.",
                    "offsetInBeginSection": 1062,
                    "offsetInEndSection": 1212,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15814024",
                    "text": "This paper reviews methods of identifying conserved regulatory elements of developmental genes by comparative genomics, including new attempts to detect conserved features beyond simple sequence similarities.",
                    "offsetInBeginSection": 555,
                    "offsetInEndSection": 763,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23175757",
                    "text": "RESULTS We present a framework for reconstructing gene regulatory networks from genetical genomics data where genotype and phenotype correlation measures are used to derive an initial graph which is subsequently reduced by pruning strategies to minimize false positive predictions.",
                    "offsetInBeginSection": 557,
                    "offsetInEndSection": 838,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23175757",
                    "text": "However, although genetical genomics data contain rich information, a clear dissection of causes and effects as required for reconstructing gene regulatory networks is not easily possible.",
                    "offsetInBeginSection": 366,
                    "offsetInEndSection": 554,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10207157",
                    "text": "These results demonstrate the utility of genomic sequence comparisons of homologous genes in related species as an effective tool with which to dissect the functional information of complex genes.",
                    "offsetInBeginSection": 821,
                    "offsetInEndSection": 1017,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14993210",
                    "text": "CompareProspector outperformed many other computational motif-finding programs, demonstrating the power of comparative genomics-based biased sampling in eukaryotic regulatory element identification.",
                    "offsetInBeginSection": 1375,
                    "offsetInEndSection": 1573,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26388177",
                    "text": "CONCLUSIONS The proposed motif-based regulon inference approach can discover the organism-specific regulatory interactions on a single genome, which may be missed by current comparative genomics techniques due to their limitations.",
                    "offsetInBeginSection": 1488,
                    "offsetInEndSection": 1719,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23440612",
                    "text": "The sequencing of many vertebrate species over the last decade has opened up the possibility of using comparative genomics as a powerful tool to elucidate regulatory elements in the vertebrate genome.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 200,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23440612",
                    "text": "Its genome has been used in large-scale genome comparisons to locate vertebrate specific regulatory elements and also it has been an excellent model system to test out the predicted DNA sequences for their ability to drive reporter gene expression in vivo.",
                    "offsetInBeginSection": 258,
                    "offsetInEndSection": 514,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a72329e2dc08e987e000006",
            "body": "Falciform ligament sign is characteristic to which disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26577973",
                "http://www.ncbi.nlm.nih.gov/pubmed/23133059",
                "http://www.ncbi.nlm.nih.gov/pubmed/19716250",
                "http://www.ncbi.nlm.nih.gov/pubmed/2003436",
                "http://www.ncbi.nlm.nih.gov/pubmed/27938473",
                "http://www.ncbi.nlm.nih.gov/pubmed/3881894",
                "http://www.ncbi.nlm.nih.gov/pubmed/2910743",
                "http://www.ncbi.nlm.nih.gov/pubmed/10495995",
                "http://www.ncbi.nlm.nih.gov/pubmed/9744402",
                "http://www.ncbi.nlm.nih.gov/pubmed/17322659"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26577973",
                    "text": "Pathologies of the falciform ligament are extremely rare entities ranging from cyst and hematoma to abscess and gangrene.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 121,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133059",
                    "text": "Primary tumor of falciform ligament is exceedingly uncommon.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 60,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19716250",
                    "text": "RESULTS All specific air distributions were more frequently present in patients with gastroduodenal perforation than lower GI tract perforation, but only the falciform ligament sign was statistically significant (p<0.05).",
                    "offsetInBeginSection": 1158,
                    "offsetInEndSection": 1379,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2003436",
                    "text": "One or more of these signs were present in 26 cases (59%) of pneumoperitoneum, including the right-upper-quadrant gas sign in 18 cases (41%), Rigler's sign in 14 cases (32%), and the falciform ligament and football signs in one case each (2%).",
                    "offsetInBeginSection": 697,
                    "offsetInEndSection": 940,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27938473",
                    "text": "Mesenchymal stem cells (MSCs) were isolated from the liver falciform ligament and abdominal subcutaneous adipose tissue in patients undergoing partial hepatectomy for liver disease.",
                    "offsetInBeginSection": 270,
                    "offsetInEndSection": 451,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27938473",
                    "text": "Falciform ligaments in the liver are surrounded by adipose tissue.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 66,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3881894",
                    "text": "The demonstration of a vessel in the falciform ligament, traditionally presumed to be a reopened umbilical vein, is an important sonographic sign of portal hypertension.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 169,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2910743",
                    "text": "Cullen's sign can be seen to be secondary to the tracking of liberated pancreatic enzymes to the anterior abdominal wall from the inflamed gastrohepatic ligament and across the falciform ligament.",
                    "offsetInBeginSection": 721,
                    "offsetInEndSection": 917,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10495995",
                    "text": "Internal hernia through a defect in the falciform ligament is extremely rare, with six reported cases including our own in Japan.",
                    "offsetInBeginSection": 576,
                    "offsetInEndSection": 705,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17322659",
                    "text": "The patient with the falciform ligament disease represents the first reported case of primary torsion and infarction of the falciform ligament, and the patient with the transverse colon epiploica represents the first reported case of vibration-induced appendix epiploica torsion and infarction.",
                    "offsetInBeginSection": 445,
                    "offsetInEndSection": 739,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        }
    ]
}
